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Approximately 1 in 70 people in the UK will be diagnosed with pancreatic cancer during their 
lifetime and there are currently no effective drugs to treat the disease. Anti-austerity agents - 
compounds capable of removing a cancer cells’ ability to tolerate nutrient deprivation – provide 
one possibility for future chemotherapeutics in this area. (+)-Grandifloracin (GF) is one such agent 
and is, therefore, an exciting lead for anti-austerity drug discovery against PANC-1 cells. 
The initial aim of this project was to explore the potential of GF through the production of a range 
of structural analogues based upon variation of the ester R-group within the molecule. A series of 
analogues exploring electronic and steric parameters was designed and synthesised. This aim was 
further broadened through the design of amide and thioester containing R-groups. A selection of 
GF analogues was then assessed for their biological activity against PANC-1 cells with the most 
active compound, shown below, discovered to have increased its activity by an order of magnitude 






Figure A: Most active structural analogue of grandifloracin discovered during the course of this work 
Through the course of this work a number of unusual structural rearrangement products were also 
discovered. Some of which contained novel 3D architectures and were only accessed via novel 
synthetic methodologies also discovered during this project. The two most structurally unusual 






Figure B: Examples of unusual structural rearrangement products discovered during the course of this work  
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Chapter 1: Introduction 
1.0: Background to pancreatic cancer 
The pancreas is an important organ, essential for homeostasis of the body, which is located in the 
abdomen behind the stomach. It contains many ducts which combine to form the common bile 
duct which then empties into the small intestine. The pancreas operates as both an exocrine and 
endocrine gland. The Islets of Langerhans, regions of the pancreas containing specialised endocrine 
cells, secrete insulin and glucagon into the blood stream in order to maintain blood glucose levels. 
In contrast, the Acinar cells are responsible for secreting digestive enzymes such as amylase, trypsin 
and lipase. These enzymes form an integral part of the digestive system, metabolising fats, 
carbohydrates and proteins.  
 
 
Figure 1: The anatomy of the human pancreas. Figure reproduced from reference1 
 
Approximately 99% of pancreatic cancers are adenocarcinomas which are formed from the 
epithelial cells which line the exocrine ducts.2 The other 1% of tumours are formed from the 
specialised endocrine and exocrine cells themselves, as well as other rare causes such as the 





1.2: Incidence and survival rate 
Pancreatic cancer is the eleventh most common cancer in the UK with 9,921 people diagnosed with 
the disease in 2015, accounting for 3% of all cancer cases. Almost half of people diagnosed were 
over the age of 75, with the rate was slightly higher for females over males in the UK. Over the past 
40 years, the incidence of pancreatic cancer has peaked and troughed differently for males and 
females, however the rates for both sexes have increased by 15% since the early 1990s.4  
 
Even within the context of cancer, pancreatic cancer has a particularly bleak outlook. The latest 
data released from Cancer Research UK in 2016 showed that only 21% of patients diagnosed with 
the disease would survive over a year and the survival rate dropped to only 1% of patients surviving 
over 10 years, i.e. long term survival with the cancer in remission. The main reason for such a low 
survival rate is often attributed to late diagnosis. Once a patient has been seen in a primary care 
setting, referred to a specialist and then diagnosed, the cancer is often too advanced for surgical 
resection and has often metastasised. Most patients diagnosed with pancreatic cancer are told that 
they have less than a year to live and the survival rate has not improved since the 1970s.5 
 
1.3: Risk factors 
The causes of pancreatic cancer are not fully understood, however there are several known risk 
factors which increase a person’s likelihood of developing the disease. The majority (>50%) of 
patients diagnosed with pancreatic cancer are over the age of 75 and the risk of pancreatic cancer 
increases with age.6 As with most cancers, a major risk factor in the development of the disease is 
smoking or the use of smokeless tobacco. A study conducted by Parkin et al. found that 
approximately 29% of incidences of pancreatic cancer were caused by consuming tobacco, 
regardless of form. The direct link between smoking and pancreatic cancer is unknown, however it 
is believed that the nitrosamines found in tobacco are involved in the promotion of the disease.7,8  
 
Patients with long-term inflammation of the pancreas, or chronic pancreatitis, often caused by long 
term consumption of alcohol, are also at an increased risk of the cancer. A family history of 
pancreatitis, caused by a gene mutation inherited from one parent, accounts for 1% of pancreatic 
cancers and increases a person’s risk of pancreatic cancer 50 fold.7 A study published by Luo et al. 
in 2007 demonstrated a link between a Helicobacter pylori infection, linked to the development of 
stomach ulcers, and pancreatic cancer. Patients who presented with a stomach ulcer, and were not 
operated upon, were 20% more likely to develop pancreatic cancer than those who underwent 
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surgical resection. An exact cause again cannot be apportioned; however, it is believed that the 
production of nitrosamines by the bacteria play a major role.9  
 
Diabetes and pancreatic cancer have been shown to possess a cause and effect relationship with 
80% of people diagnosed with pancreatic cancer also having diabetes. It has been shown that 
pancreatic cancer can cause diabetes due to the malignancy spreading throughout the organ and 
affecting both the islet and beta cells which are responsible for producing insulin. Anti-diabetic 
medication has also demonstrated a role in increasing a patient’s risk of pancreatic cancer. The 
stimulation of the islet and beta cells, often over a prolonged period of time, by the drugs has been 
shown to augment a person’s risk of the disease.10 
 
Long term infection with hepatitis B and/or C also increases a person’s risk of pancreatic cancer.11 
Diet and weight also play a part in increasing a person’s chance of developing the disease. A study 
in 2012 found that having a Body Mass Index of over 35 increased the relative risk by about 50%.12 
Larsson and Wolk also demonstrated using meta-analysis that consuming an increased amount of 
red meat, ca. 120 g per day, also led to an increased risk of developing pancreatic cancer within 
their cohort. Interestingly this was only shown in men, with an increased consumption of red or 
processed meat having no impact on women’s risk.13 
 
1.4: Current treatment options 
The most effective current treatment for pancreatic cancer is a surgical procedure called a 
pancreaticoduodenectomy, or Whipple, which is performed to remove cancerous tumours from 
the head of the pancreas. However, according to research published in 2007, approximately two 
thirds of patients are diagnosed with late stage disease and therefore are not eligible for the only 
potentially curative treatment option available for this disease.14 Furthermore, according to recent 
guidance issued by The National Institute for Health and Care Excellence (NICE), the body 
responsible for issuing policy and guidance to healthcare professionals in the UK, only after all 
possible avenues for surgical intervention have been exhausted should combination chemotherapy 
or alternative chemical agents be used due to their limited effectiveness.15  
 
There are, however a number of chemical agents currently on the market which are either 





1.5: Current chemotherapy options 
1.5.1: Gemcitabine 
There are currently no effective drug therapies available for the treatment of pancreatic cancer 
which offer meaningful increases in survival rate. This helps to explain the poor prognosis rates 
described above. The current recommended adjuvant chemotherapy in the UK is gemcitabine, also 
known as Gemzar (1), which was developed by Eli Lilly and Company, however generic versions are 








                                                                                             




Figure 2: Structure of gemcitabine (1) and deoxycytidine (2) 
 
Gemcitabine, 2’, 2’-difluoro-2’-deoxycytidine, is a nucleoside analogue of deoxycytidine (2) in which 
the hydrogen atoms of the 2’-carbon have been replaced by fluorine atoms. Gemcitabine acts as a 
prodrug and is metabolised to a corresponding 5’-diphosphate and triphosphate by deoxycytidine 
kinase.18 These metabolites are pharmacologically active through their ability to inhibit cellular 
processes and induce cell apoptosis. The 5’-diphosphate metabolite inhibits ribonucleotide 
reductase, which is the enzyme responsible for producing deoxyribonucleotides, which are required 
for DNA synthesis and repair. The 5’-triphosphate metabolite competes with the naturally occurring 
deoxycytidine 5-triphosphate for incorporation into the DNA.19  
 
The results of the first clinical trials involving gemcitabine for the treatment of pancreatic cancer 
were published in the late nineties and did show a marginal improvement through the 
administration of gemcitabine over the traditional 5-fluorouracil (3). The randomised trial published 
in 1997 which compared the use of gemcitabine to traditional chemotherapies at the time showed 
an increase in median survival rate of 1.24 months for the group given gemcitabine compared to 
the group administered 5-fluorouracil and the 12-month survival rate did increase by 16% for the 
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gemcitabine group. Survival rates have barely changed since the introduction of gemcitabine back 




5-Fluorouracil (3) has been a stalwart of cancer therapeutics since its design and synthesis by Dr 
Charles Heidelberger in 1957.21 It still forms a mainstay of modern chemotherapy; in fact it was 
listed in the World Health Organisations “List of Essential Medicines” in 2013.22 5-Fluorouracil is an 
alternative, and more traditional, choice of chemotherapeutic to gemcitabine (1) against pancreatic 
cancer. 5-Fluorouracil is a pyrimidine analogue which inhibits the enzyme thymidylate synthase. 
This blocks the synthesis of the nucleoside base thymidine, which is required for DNA synthesis. 
Thymidylate synthase acts by methylating deoxyuridine monophosphate to form thymidine 
monophosphate. By inhibiting this enzyme, 5-fluorouracil is able to limit the supply of thymidine 
monophosphate, which in turn limits, and ultimately stops, the growth of cells. This effect is felt 
more keenly in the rapidly multiplying cancer cells and therefore its effect will be seen in these cells 
prior to homeostatic cells, thus it acting as an anti-cancer therapeutic.23 
 





                                                                                                                           
                                          
 
                           
                       Figure 3: Structure of 5-fluorouracil                Figure 4: Structure of capecitabine 
 
Capecitabine (4), marketed by Roche as Xeloda, is a prodrug of 5-fluorouracil and is metabolised 
upon administration to 5-fluorouracil. Its mechanism of action is identical to that of the parent drug 
however its formulation enables oral administration. This greatly improves patient satisfaction with 
the drug as this removes the need for hospital visits and central venous access, which can lead to 
thrombosis and infection. Capecitabine also removes intestinal exposure to the drug as it is almost 




5-Fluorouracil, however, causes acute side effects, as well as poorly predicted drug toxicity levels. 
Severe diarrhoea is the main side effect, as well as neutropenia and thrombocytopenia. The severity 
of the side effects can often cause patients to withdraw from treatment and drug resistance is 
becoming an ever increasing problem.25 Again the clinical trial data show only a minimal 
improvement to survival through the administration of 5-fluorouracil. Data published in the British 
Journal of Cancer in 2009 assessed the benefit of 5-fluorouracil, administered with folinic acid, 
versus no treatment. The authors showed that the drug regime increased median survival by 6.4 
months and the 2-year survival rate by 12%. Although offering some short term benefit, this 
treatment still offers a bleak long term outlook.26 
 
1.5.3: FOLFIRINOX 
FOLFIRINOX is a combination therapy first introduced in 2010 that contains 5-fluorouracil (3), 











Figure 5: Component drugs of FOLFIRINOX 
The constituents contribute the following therapeutic benefits; 5-Fluorouracil (3), as described 
above, is a pyrimidine analogue which disrupts the synthesis of DNA; leucovorin (5) is a vitamin B 
analogue which modulates the side effects of 5-fluorouracil; irinotecan (6), is a topoisomerase 
inhibitor which stops DNA from uncoiling and duplicating; oxaliplatin (7) is a platinum-based 





FOLFIRINOX has shown to increase the median progression free survival rate of metastatic 
pancreatic cancer from 6.8 months to 11.1 months, however the side effects are much greater with 
24.7% of patients displaying high-grade neutropenia. The side effects of this treatment are so 




Nab-paclitaxel, or nanoparticle albumin-bound paclitaxel, is an adjuvant therapy given in 
combination with gemcitabine for advanced metastatic pancreatic cancer. Paclitaxel is bound to 
albumin as the delivery vehicle which helps it to migrate through blood vessel walls utilising 
glycoprotein 60-mediated endothelial cell transcytosis and accumulation in the area of tumour by 
albumin binding to SPARC (secreted protein, acidic and rich in cysteine). It also acts as a mitotic 
inhibitor drug. Paclitaxel’s main activity is to promote microtubule production and then render 
them inert to depolymerisation.29 
 
The National Institute for Care and Health Excellence, or NICE, however, released guidance in 2014 
which recommended that nab-paclitaxel given with gemcitabine should be removed from the NHS 
formulary due to its limited benefits and prohibitively high cost.30 The results of a clinical trial which 
were published in 2013 did demonstrate that nab-paclitaxel administered with gemcitabine did 
improve patient survival rates. The benefit was minimal though, with the median overall survival 
and progression free survival rate increasing by only 1.8 months compared with gemcitabine 
monotherapy.31  
 
Overall, these results help to illustrate the current level of success in relation to chemotherapeutic 
treatment of pancreatic cancer. Given the very elevated levels of costs associated with nab-
paclitaxel, and an increase of survival rate of only 1.8 months, it is easy to understand why NICE has 
deemed the drug regime not acceptable for the NHS. Pancreatic cancer, as demonstrated above, is 
one of the most aggressive and difficult cancer types to treat. This is in part due to the often late 
diagnosis of the disease, which results in the tumour being well established, and having also 
metastasised to other areas of the body. The cause of pancreatic cancer is also still not well 
understood, in fact the primary cause is still unknown, and therefore it is difficult to predict patients 






Figure 6: Effect of paclitaxel on microtubule production: Cells entering mitosis in the presence of 
concentrations of paclitaxel form abnormal spindles that contain additional spindle poles. Rather than 
mounting a long-term mitotic arrest, these cells enter anaphase and divide their chromosomes in multiple 
directions. However, a portion of the cytokinetic furrows often fail, and two or three daughter cells are usually 
produced. Chromosome segregation is randomized due to multipolar division followed by partial cytokinesis 
failure. The resultant daughter cells are aneuploid, and a portion of these die (red X), presumably due to loss 
of one or more essential chromosomes. Figure reproduced from reference 32. 
 
1.5.5: Novel treatments in clinical trials 
Over the past decade there have been a number of new compounds which have been developed 
for the treatment of pancreatic cancer and have entered into clinical trials. These novel compounds 
have been benchmarked against the current standard chemotherapeutic, gemcitabine, however, 
most have not shown superior activity to the current treatment regimes. 
 
A randomized phase III study published in 2006 compared the effect of adding exatecan mesylate 
(8) to gemcitabine on survival rates in patients with untreated advanced pancreatic cancer. 
Exatecan mesylate is a synthetic analogue of camptothecin from the plant Camptotheca acuminata. 
Its cytotoxic properties come from its ability to inhibit the catalytic activity of the nuclear enzyme 
Topo I which is responsible for gene transcription and DNA replication. Exatecan was developed in 










Figure 7: Structure of exatecan mesylate33 
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The trial recruited 349 patients, with roughly half receiving the novel treatment regime. 
Unfortunately, the trial concluded that exatecan plus gemcitabine did not impart greater survival 
rates compared to gemcitabine alone. The cohort receiving the novel regime also displayed much 
higher levels of toxicities compared with the gemcitabine alone group.34 
 
Another Phase III clinical trial published in 2010 examined the effect of adding an alternative 
adjuvant to gemcitabine in order to increase its anti-tumour activity. This time, the study compared 
the effect of the addition of cetuximab, a monoclonal antibody which targets epidermal growth 
factor receptor, to gemcitabine on median survival rate when compared to the current treatment 
regime. Early clinical evidence has emerged on the potential role of the epidermal growth factor 
receptor signalling pathway in pancreatic cancer development and metastasis. In order to explore 
this theory, a clinical study was conducted utilising cetuximab. In the trial involving 745 people, it 
was concluded that the addition of the monoclonal antibody targeting epidermal growth factor 
receptor did not improve median survival rate compared with patients treated with gemcitabine 
alone.35  
 
Acelarin (9), also known as NUC-1031, is currently being assessed through the ACELARATE trial 
which is being run through various sites in the United Kingdom. It is very similar in its action to that 
of the current recommended drug for patients with metastatic pancreatic adenocarcinoma, 
gemcitabine. It was developed due to problems with resistance to gemcitabine which limits its 
efficacy. As such, acelarin has been designed to address the problems with resistance and to 
increase the intracellular levels of the active agent. In a recent phase I clinical trial, acelarin was 
shown to have activity against a range of metastatic cancers, including pancreatic. It is currently 
undergoing a phase III study, ACELARATE, which hopes to demonstrate the agents superiority in 










Figure 8: Structure of acelarin 
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Although different chemotherapeutics and drug regimens have been introduced over the past two 
decades, as this section shows, they have only managed to impart small improvements to 
progression free survival and overall median survival rates. The overall median survival rate has not 
changed greatly since the introduction of 5-fluorouracil for the treatment of pancreatic cancer in 
the 1990s. The 10-year survival rate still stands at only 1%.5 This clearly demonstrates a significant 
need for an effective, targeted treatment against this disease which imparts a meaningful increase 
to median survival rates and progression free survival. 
 
2.0: Austerity 
One of the other factors which lends this cancer type an advantage is its particular ability to survive 
under what are termed “austere” conditions. The rapid growth of the tumour leads to the 
production of ineffective vasculature; with leaky, twisted and ineffective vessels present. This, in 











Figure 9: The difference between healthy and ineffective vasculature. Figure reproduced from reference 38. 
 
This has been demonstrated through angiographic, sonographic and tomographic studies of 
pancreatic tumours.39-41 These harsh conditions would imply that a toxic environment would be 
induced within the tumour which would limit the cells’ ability to survive and divide. Many cellular 
responses occur as a result of such conditions. Metabolic stress induced through hypoglycaemia 
causes genetic mutations and cellular functions to become impaired.42 Hypoxia causes 
angiogenesis, or the production of blood vessels, within the tissues and also induces hypoxia-
inducible factor-1 (HIF-1). This causes a large number of genes to become activated which increases 




In spite of the potential for angiogenesis to alleviate some of the tumour’s metabolic and oxidative 
stresses, pancreatic tumour microenvironments remain hypoxic and lacking in nutrients. Under 
these conditions, the cancerous cells not only survive, but they also thrive. This does, however, 
provide a potential mechanism to exploit for the purpose of a targeted therapeutic. 
 
3.0: Anti-austerity strategy 
In 2000, Izuishi et al. published a study which examined the effect of austere conditions on cellular 
and genetic processes, and which introduced a new potential target for chemotherapeutics. They 
designed an assay to explore the effects of nutrient deprivation on certain cell lines and also to 
understand the mechanisms by which these cells can survive under these conditions. They cultured 
liver, pancreatic and gastric cancer cell lines, as well as normal human fibroblasts, in a medium 
which was lacking serum, glucose and amino acids. They found that the normal human fibroblasts 
all died within 24 hours, however, they found that the liver and gastric cancer cell lines survived 
longer, up to 36 hours, and the pancreatic cancer cells lines survived significantly longer with 
greater than 50% of the cells surviving after 48 hours.45  
 
Figure 10: Effect of each nutrient deprivation on cell 
survival in the PANC-1 cell line. Cells were seeded at a 
density of 1.5 × 105 cells/well in six-well plates and 
incubated in completely fresh medium for 20 h. The 
cells were washed with PBS, and the medium was then 
changed to a medium without the nutrient factors. 
Medium was deprived of each nutrient and prepared 
by adding 1 mg/ml D-glucose, amino acid solution, or 
10% of dialyzed foetal bovine serum to the basal 
medium, which contained only electrolytes and 
vitamins, according to DMEM recipes. Cell survival in 
the presence (A) and absence (B) of serum is shown. 
Cell numbers at the start of starvation were considered 
to be 100%. Combinations of nutrients were as follows: 
○, glucose and amino acids; •, glucose; □, amino acids; 











Once the longevity of these cell lines had been established, the authors set about to discover the 
processes which underpinned this ability. Previous studies had shown that Akt, also known as 
protein kinase B (PKB), is over-expressed in pancreatic cancer cell lines.46 In order to establish this 
link, Izuishi et al. transfected antisense RNA expression vectors into PANC-1 cells. By doing so, they 
blocked the expression of the genes encoding for Akt 1-3 and therefore stopped production of the 
protein kinase. Through this work, they were able to demonstrate that the antisense RNA 
expression vector for Akt1 and Akt2 significantly diminished tolerance of cells to nutrient-deprived 
media, therefore showing that Akt1 and 2 were necessary for survival, however Akt3 had little 
effect. These results confirmed that Akt/PKB was involved in the cells’ ability to survive nutrient 
deprived conditions and therefore allowed researchers to focus their attention on molecules which 
could potentially disrupt this mechanism, and hence this produces a novel anti-austerity strategy.45  
 
4.0 Anti-austerity agents 
The search for compounds which are able to disrupt this mechanism began in earnest with several 
groups around the globe focusing on this task. A simple yet effective assay has been developed by 
Esumi et al. which allows for the testing of compounds without previous knowledge of their protein 
targets. The assay prescribes the culturing of two sets of the same pancreatic cancer cell line, PANC-
1, in two different media; one in nutrient-rich medium and the other in medium lacking amino 
acids, serum and amino acids. The cells are then both treated with test compounds and left to 
incubate for 24 hours. Cell viability is then quantified via the use of a dye-based colorimetric assay. 
The results allow researchers to identify easily agents which not only act against PANC-1 cells but 
also specifically under nutrient-deprived conditions.47 The figure below demonstrates the results of 
















Figure 11: The effect of insulin (5 μg/ml), troglitazone (20 μm), wortmannin (100 nm), and LY294002 (50 μm) 
on PANC-1 cell survival in low-nutrient medium. The 10% diluted DMEM was prepared by diluting DMEM 
containing 10% FCS with basal medium. After 24 h in low-nutrient medium, cell survival was estimated by the 
trypan blue staining method in triplicate. The number of cells at the beginning of starvation was 100%. Figure 
reproduced from reference 45. 
 
This assay has enabled the simple detection of compounds which act to remove a cell’s ability to 
survive under nutrient deprivation. This has led to the emergence of a new class of potential cancer 
therapeutics, known as anti-austerity compounds. The subsequent section will highlight a number 
of the most potent anti-austerity agents, some of which have reached in vivo studies, and therefore 
demonstrate the potential which these compounds hold. Anti-austerity compounds can be split 
into two main areas of classification based on the nature of their origin: synthetic small molecules 
and natural products.  
 
There are a number of methods which can be employed to quantify the level of biological activity 
of anti-austerity agents. The three most common, and the only ones referred to within this thesis, 
are PC50, IC50 and LC50. A PC50 value is the concentration at which 50% of pancreatic cancer cells die 
preferentially in nutrient-deprived media, compared to those cultured in nutrient sufficient 
media.48 An IC50 value, or half maximal inhibitory concentration, is more broadly defined as the 
concentration of a substance that is required for 50% inhibition of a biological process in vitro.49 
Finally, an LC50 value is the concentration of a substance which kills 50% of the test subjects, in this 






4.1: Pyrvinium pamoate 
Esumi et al. demonstrated the potential anti-austerity properties of pyrvinium pamoate (10) as part 
of a larger piece of work looking at the topic of cellular austerity.51 Pyrvinium pamoate is an 
anthelminthic which is used to treat parasitic infections. Their rationale for focusing on 
anthelminthics was that pathogenic parasites are often able to metabolise anaerobically and 
therefore may have similar targets to austerity-tolerant cancer cell lines.  
 
They demonstrated that pyrvinium pamoate was able to inhibit strongly the growth of PANC-1 cells, 
as well as, two other pancreatic cancer cell lines and one colon cancer cell line. The necrotic cell 
death was also only induced in nutrient-depleted medium and not in nutrient-sufficient medium. 
Esumi et al. were also able to show that the toxicity was only present when glucose was removed 
from the medium irrespective of the presence of serum or amino acids. This indicates that the 
glucose metabolic pathway holds the key to the cancer cell lines’ ability to survive under conditions 
of nutrient stress. They also discovered, through analysis of the PKB/Akt pathway, that 














Figure 15: Structure of pyrvinium pamoate 
 
Esumi et al. then went on to test pyrvinium pamoate against PANC-1 cells in vivo using nude mice. 
Due to previously reported low intestinal bioavailability, they first administered pyrvinium pamoate 
subcutaneously which strongly inhibited PANC-1 tumour formation via necrosis. They then went on 
to administer the drug orally which again showed strong inhibition of tumour formation. This set of 
experiments was then repeated on SCID mice which were severely deficient in B and T lymphocytes. 
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The results were again positive, moreover, they were also able to demonstrate that 










Figure 16: Antitumour activity of 10 as measured by effect on transplanted PANC-1 cell tumours in nude mice. 
Six days after transplantation of the tumour cells, animals were divided into two groups, and treatment 6 
days/week was started 2 weeks after transplantation. 10 (- - -) or vehicle (----) was force-fed intrasurgically. 
Tumours were measured every week, and tumour volume was calculated. Each point is a mean and SD of 
data from 10 mice. Figure reproduced from reference 51. 
 
 
4.2: 2-Pyridine thiosemicarbazones  
A piece of work led by Shakya et al. was conducted in order to explore the possibility of using 2-
pyridine thiosemicarbazones as a potential treatment for pancreatic cancer. Thiosemicarbazones 
have long been of interest to medicinal chemists due to the plethora of reported biological 
activities, such as antitumour.52 Furthermore, Triapine (3-aminopyridine-2-carboxaldehyde 
thiosemicarbazone) has recently been shown in a phase II clinical trial to have antitumour activity 
on metastatic squamous cell carcinoma of the head and neck53. Triapine exerts its antitumour 
properties by inhibiting ribonucleotide reductase, an enzyme which converts ribonucleotides into 
deoxyribonucleotides. This was of interest with respect to pancreatic cancer as ribonuclease 
reductase is often overexpressed in this type of cancer.54 
 
As such, Awale et al. designed and synthesised a series of structural variants of 2-pyridine 
thiosemicarbazones and tested them against PANC-1 human pancreatic cancer cells which had 
been cultured under austere conditions. Interestingly, they found that all 12 compounds displayed 
preferential cytotoxicity against PANC-1 cells with the most potent (11), shown in figure 17, having 











Figure 17: Structure of most active 2-pyridineformamide thiosemicarbazone analogue55 
 
4.3: Kigamicin D 
Kigamicin D (12) is a natural product produced by an acinomycete which was the first naturally 
derived compound to be reported for its ability to inhibit the ability of pancreatic cancer cells 
(PANC-1) to survive under nutrient deprived conditions. In 2004 Lu et al. published a data set which 
demonstrated the ability of Kigamicin D to preferentially inhibit PANC-1 cells under nutrient 
deprived conditions, specifically glucose deprivation. The compound completely killed PANC-1 cells 
through necrosis after 6 hours at a concentration of 1 µg mL-1 in nutrient depleted media, however 
it had no effect on PANC-1 cells which were cultured on nutrient-sufficient media. Lu et al. were 
also able to show that its mechanism of action was through the inhibition of phosphorylation of 











Figure 18: Structure of kigamicin D 
 
Due to the encouraging results shown in vitro, Lu et al. went on to administer kigamicin D to nude 
mice. Positive results were again displayed with subcutaneous administration reducing tumour size 





Following the publication of kigamicin D’s encouraging results, Shipman, Whatmore and co-workers 
investigated the tetrahydroxanthone nucleus, which is at the core of all the kigamicins, by 
synthesising structural analogues. They utilised a dibromide starting material (13) which was then 
subjected to palladium-catalysed cyclisations in the presence of PhB(OH)2 which produced the 
kigamicin C analogue (15) in 78% yield. Through the use of time-course GC-MS they were able to 
deduce that the reaction progressed through the intermediate (14) via C-O and C-C sequential bond 
construction rapidly and then further conversion to compound 15 was observed through Miyaura-















Scheme 1: Synthesis of kigamicin C analogue57 
 
Biological testing of the analogue 15 against PANC-1 tumour cells found that it inhibited PANC-1 
cells survival at greater than 10 times lower concentrations in nutrient-deprived compared to 
nutrient-sufficient conditions. It also demonstrated greater selectivity for the cancer cells compared 
to kigamicin C, however was appreciably less active than the natural product.57 
 
4.4: Arctigenin 
Arctigenin (17) was one of the first natural product to be investigated and the results published by 
Awale and Esumi in 2006. Using the wealth of indigenous knowledge of traditional Japanese Kampo 
medicine practitioners, Awale et al. screened 500 medicinal plants for their preferential toxicity to 
pancreatic cancer cell lines under nutrient deprived conditions. It was found that an extract from 
Arctium lappa, or greater burdock, figure 19, displayed complete preferential toxicity against 




Upon further purification and separation, it was found that the active component of the extract 
was (–)-arctigenin.58 (−)-Arctigenin was added to nutrient deprived cells at a concentration of 1 µg 
mL-1 and complete cytotoxicity was observed within 12 hours. Through further testing, the group 
were also able to demonstrate that the PKB/Akt pathway was, once again, the target for the 
compound and that, through inhibiting phosphorylation, it removed the cells’ ability to survive 
under such conditions.  
 
Like pyrvinium pamoate, arctigenin was also shown only to 
elicit a pharmacological response in the cells which were 
subjected to nutrient starvation, in particular glucose 
deprivation, and not in cells which had a ready supply of 
nutrients. It again showed activity against four pancreatic 
cancer cell lines, as well as, one colon cancer cell line, plus it 
demonstrated good activity in vivo. Arctigenin was administered          Figure 19: Arctium lappa59         
to nude mice via intraperitoneal injection and was shown to retard the growth of PANC-1 tumours. 
The growth rate of the tumour was significantly less than that of the control group with the mean 
tumour doubling time 23 days for the control group and 49 days for the arctigenin-administered 
group. No overall weight loss or adverse side effects were also observed making arctigenin’s 
preclinical safety profile encouraging.58 
 
The results of a phase I clinical trial involving (–)-arctigenin have recently been published with 
promising observations. The phase I trial has examined the effect of (–)-arctigenin on advanced 
pancreatic cancer which was refractory to gemcitabine. It was dosed in the form of GBS-01 which 
was an extract from the plant Arctium lappa Linné rich in arctigenin. GBS-01 is registered in the 
Japanese pharmacopoeia and, therefore, Ikeda et al. were permitted to proceed straight to clinical 
trials without the need for preclinical evaluations. Esumi et al. have reported that no serious side 
effects on bone marrow, liver or kidney function were observed and it was efficiently absorbed, as 
well as rapidly conjugated to glucuronic acid. It was also shown that arctigenin had a small effect 
on tumour progression and disease stability with a median progression-free survival of 1.05 months 
and an overall median survival rate of 5.68 months. As a result, (–)-arctigenin has now passed into 




Interestingly, it was also found that the extract of Arctium lappa contained another compound, 
arctiin (16), which was found to be a pro-drug for arctigenin due to it being metabolised by intestinal 












Figure 20: Structure of arctiin (16) and (–)-arctigenin (17) 
 
The group have taken this work one step further by synthesising analogues of (–)-arctigenin and 
testing the resultant compounds both in vitro and in vivo. They focused on substituting the four 
oxygen containing groups attached to both phenyl rings whilst leaving the lactone ring system itself 
intact. They tested all 15 synthesised analogues against PANC-1 tumour cells, which had been 
cultured in either nutrient-deprived or nutrient-sufficient media, and found 18, 19 and 20 to have 













Figure 21: Structural analogues of (–)-arctigenin61 
 
They then took forward 20 and tested it this time in vivo against nude mice inoculated with CAPAN-
1 cells, another pancreatic cell line. Upon administration of either 20, (–)-arctigenin or a control 
20 
 
vehicle, the authors found that both 20 and (–)-arctigenin significantly reduced tumour growth 
compared to the control compound, as well as, that of mean wet weight and size of excised 
tumours. They do not provide any conclusive comparisons between 20 and (–)-arctigenin, so it is 
difficult to judge the efficacy of the new analogue, however it did perform as well as the parent 
compound.61 
  
From the powdered roots of Wikstroemia indica, Awale et al. were able to isolate a number of 
compounds, chief among them (+)- and (–)-arctigenin. This allowed an interesting comparison of 
activity levels based upon stereochemistry. The group discovered that, unlike the previously 
isolated (–)-arctigenin, the (+)-enantiomer displayed no preferential cytotoxicity towards PANC-1 
pancreatic cancer cells. Thus, confirming that the (2R,3R)-absolute configuration was essential for 
activity.62 
 
Dibwe et al. have also isolated a structurally very similar molecule, (–)-buplerol, from the root of 
Aflamomum melegueta, a plant which has long been used in Congolese traditional medicine. They 
tested the isolated compound for its in vitro activity against PANC-1 cells and a potent PC50 value of 
8.42 µM was recorded. The compound was also found to promote cell death via apoptosis, a 
preferable mode of cell death.63 
 
(–)-Arctigenin, and its related structural compounds, provide a promising glimpse into the 
possibilities which naturally-derived anti-austerity agents could provide. Since the initial discovery 
of (−)-arctigenin and kigamicin D, there have been dozens of other compounds which have been 




In the previous examples listed above, the majority of compounds have induced cell death via 
necrosis. Cell death can occur via various pathways, however the main three are apoptosis, 
autophagy and necrosis. Apoptosis and autophagy are processes of natural cell death whereby the 
cell is programmed to shut down its biological activity in a controlled manner. In necrosis, the 
process of cell death is induced via an external process and therefore is not controlled via the 
normal biological processes. As such, this form of cell death is almost always detrimental to the 




With this information in mind, it is always going to be preferable for a cancer chemotherapeutic to 
induce cell death via the two programmed cell death processes rather than necrosis. An extract of 
the flower Kayeaassamica, native to Myanmar, has yielded a variety of coumarin-based 
compounds, nine of which have been found to be novel, which crucially induce cell death via 















Figure 22: Morphological change of human pancreatic cancer PANC-1 cells under nutrient-deprived medium 
after 24 h exposure with 1 μM of 2 (Kayeassamin D), 3 (Kayeassamin E) or 5 (Kayeassamin G) Figure 
reproduced from reference 65. 
 
Win et al. have investigated this extract and found 5 compounds named Kayeassamins (21 a, b, d, 
e & g), table 1, which all exhibited a PC100 value of 1 µM towards PANC-1 cells under nutrient 
deprived conditions.  They were also able to show that apoptosis-like changes were seen within the 



















General structure of kayeassamin 
 

















Table 1: Structures of the most potent kayeassamins65 
 
The group were also able to carry out some structure-activity relationship studies on the molecules. 
According to Win et al. they found that structures with an isoprenyl or geranyl substituent at C-8 
and a hydroxypropyl substituent at C-4 produced the most potent response. Furthermore, they 
found that the presence of an oxobutyl or a 3-methyl-1-oxobutyl group at C-6 was also favoured 
over other moieties. Interchange of isoprenyl and any acyl groups of C-6 and C-8 also led to a 
dramatic reduction in activity, as well as replacement of the hydroxypropyl at C-4 with a phenyl 
group. The addition of another ring to the core structure also led to a reduction in activity.65 
 
Another group, Jun et al., have also synthesised a series of non-natural analogues based upon 
substitution of the coumarin core with isoprenylated ethers constructed of varying chain lengths. 
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The coumarin moiety itself has gained much interest in relation to medical applications due to its 
low toxicity, presence within many natural products and the ease with which modifications can be 
made. As table 2 shows, LC50 values decreased with increasing chain length indicating that 






Coumarin general structure 



























They also found that substitution at the 6- position on the coumarin scaffold furnished analogues 
with the greatest potency, compared to modifications at the 3- and 7- positions indicating that the 
increase in activity is regiospecific. The analogue with the greatest cytotoxicity was found to contain 
a farnesylated ether at the 6- position which produced a LC50 value of 4µM. 
 
Interestingly, Jun et al. also found that unsubstituted hydroxyl coumarins had no appreciably 
cytotoxicity and the presence of isolated isoprenyl alcohols actually increased PANC-1 cell 
viability.66 
 
4.6: Naphthylisoquinoline alkaloids from Ancistrocladus species 
Continuing with the theme of compounds extracted from plant-based 
sources, the next example to be covered is a range of compounds 
recently isolated from a Congolese liana. Ancistrocladus likoko J. 
Léonard (Ancistrocladaceae) is an indigenous liana, or woody vine, 
mainly found in watery areas in the north-central part of the 
Democratic Republic of Congo. Ancistrocladus liana are particularly of 
note pytochemically due to their production of structurally unique     Figure 23: Ancistrocladus likoko67                                                                                                    
naphthylisoquinoline alkaloids. Such alkaloids have been shown to display medicinal properties 
such as antiplasmodial, antitrypanosomal, antileishmanial, antileukemic and anti-HIV. Given the 
raft of previously discovered medicinal properties, Fayez et al. set out to explore the anticancer 
potential of this plant.                                                         
 
To begin, the group extracted the powdered, dried twig material of Ancistrocladus likoko with a 
mixture of chloroform and methanol. They then performed successive silica gel chromatography 
separations and finally reverse-phase HPLC by which means they isolated nine new compounds and 
six previously known metabolites. Interestingly, three of the new compounds, ancistrolikokines E, 
E2 and F (23-25) are the first examples of monomeric naphthyldihydroisoquinolines with R-













Figure 24: Structure of ancistrolikokines E, E2 & F displaying unique R configuration at C-367 
 
They then tested all of the isolated compounds, both novel and known, against PANC-1 cells which 
had been cultured under austere conditions. They discovered that all of the 
naphthyldihydroisoquinoline alkaloids exhibited moderate to high levels of anti-austerity activity 
with PC50 values in the micromolar range. The most active compound, however, was 











 Figure 25: Structure of Ancistrolikokine H267                                        Figure 26: Preferential cytotoxic activity of  
ancistrolikokine H2 (26) against the PANC-1  
human pancreatic cancer cell line in  
nutrient-deprived medium (NDM) and  
Dulbecco's modified Eagle's medium (DMEM). 
Figure reproduced from reference 67. 
 
The same group have also explored another genus of Ancistrocladus, A. ileboensis, for any potential 
compounds which may possess anti-austerity activity. Initially, the group took ground and air-dried 
root material and extracted it with a mixture of methanol and chloroform. They then subjected the 
crude extract to preparative scale HPLC in order to isolate the 3 constituents. Again, they were all 
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naphthylisoquinoline alkaloids, and the major component was identified as the previously known 
compound jozimine A2 (29). The further two alkaloids isolated were, however, novel and a detailed 
piece of work was conducted in order to elucidate their structures. They were finally identified and 














         Figure 27: Structure of                                       Figure 28: Structure of                        Figure 29: Structure of                  
                jozilebomine A68                                                   jozilebomine B68                                      jozimine A268 
 
They then tested all three of the extracted compounds against PANC-1 pancreatic cancer cells which 
had been cultured under conditions of nutrient stress. They found that all three compounds 
displayed potent anti-austerity activity towards the cancer cells with PC50 values ranging from 2.24 
to 0.1 µM. The most active, which superseded even the activity of the positive control, arctigenin, 
was the previously known compound jozimine A2 (29), with a PC50 value of 0.1 µM. 
 
They then went on to examine further the biological effects of all three compounds on pancreatic 
cancer cells via staining with ethidium bromide and acridine orange. They discovered that 
treatment with 5 µM of either jozilebomine A, B or jozimine A2 led to catastrophic cellular changes 
within the cancer cells, leading to membrane rupture and breakdown of cellular organelles leading 




Figure 30: Morphological changes of PANC-
1 cells induced by (B) jozilebomine A (27), 
(C) jozilebomine B (28), and (D) jozimine A2 
(29) in comparison to untreated cells (A): 
PANC-1 cells were treated with 5 μM of the 
dimer jozilebomine A, jozilebomine B or 
jozimine A2 in 12-well plates and incubated 
for 24 h. Cells were stained with ethidium 
bromide (EB) and acridine orange (AO). The 
cells were photographed under 
fluorescence (red and green) and phase 
contrast (grey) modes using an EVOS FL 
digital inverted microscope. Figure 







Even more recently, Lombe et al. have published yet more work surrounding compounds isolated 
from an Ancistrocladus liana, however this time from a potentially new species or subspecies of the 
plant. They discovered this potentially new liana outside the village of Bonsolerive in the 
Democratic Republic of Congo. It possesses very striking, large leaves and hooked inflorescences 
which have never been witnessed in Ancistrocladus previously. Phytochemical analysis of its leaves 
confirmed substantial differences between this plant and other genuine samples of known 
Ancistrocladus species.69  
 
They ground and air-dried the leaves, as before, and performed an extraction using methanol and 
dichloromethane. They then purified the crude extract using a cation-exchange column, to remove 
any non-basic metabolites, followed by preparative HPLC. Following this process, they isolated four 
previously known naphthylisoquinoline alkaloid metabolites from other Ancistrocladus species and 
five novel compounds, subsequently named Michellamines A6, A7 & B4 and Ancistrobonsolines A1 
& A2. 
 
Following successful isolation and purification, the group conducted an extensive piece of work in 
order to elucidate the structure of the novel compounds. Once satisfied that they had the correct 
structures for the compounds, they then tested all the compounds, both known and novel, against 
PANC-1 cells in order to assess their anti-austerity activity. They discovered that all the compounds 
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tested exhibited cytotoxic properties, however, the most potent compounds were found to be 
ancistrobonsolines A1 (30) and A2 (31) with PC50 values of 7.5 and 12.1 µM respectively.  
 
 
                      




                Figure 31: Structure of ancistrobonsolines A169         Figure 32: Structure of ancistrobonsolines A269 
In order to understand this observed biological activity further, the group, once again, performed 
an ethidium bromide-acridine orange double-staining fluorescence assay. Upon dosing PANC-1 cells 
under nutrient-deprivation with 12.5 µM of ancistrobonsolines A1 and A2, they observed dramatic 
morphological changes to the cells and breakdown of the intracellular organelles, leading to total 
cell death, as shown in the figure below.69  
Figure 33: Morphological changes of PANC-1 human pancreatic cancer cells induced by the new compounds 
ancistrobonsolines A1 (30, columns B & C) and A2 (31, columns D & E) in comparison to the untreated ones 
(control). Figure reproduced from reference 69. 
 
As this section demonstrates, compounds isolated from natural sources have yielded promising 
drug candidates in the fight against pancreatic cancer. The above details the main discoveries made 
within the last decade, however a few other compounds have also been isolated with much lower 
activity levels and therefore have not been covered here.  A few anti-austerity agents have also, 
crucially, been shown to induce apoptotic cell death, as opposed to the detrimental necrotic 
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pathway, as well as shown promise in animal models. The next step in taking these compounds 
forward is to find viable synthetic routes and to undertake analogue synthesis programmes, where 
necessary. Extracting such products from natural sources alone is both economically and 
environmentally unviable on a commercial scale. Many of these compounds have been discovered 
from rare or inaccessible sources and exploitation of this natural resource in order to produce 
pharmaceuticals on a global scale would destroy habitats and ultimately render the natural sources 
extinct, as well as being prohibitively expensive. In contrast, the natural product (+)-grandifloracin 
is, however, a molecule which has been discovered from a natural source and has been successfully 
synthesised, enantioselectively, from commercially available starting materials. It is also the 
primary focus molecule for the original research described in this thesis. 
 
5.0: (+)-Grandifloracin 
(+)-Grandifloracin (GF) (53), is an anti-austerity agent first isolated by Awale et al. from the plant 
Uvaria dac, figure 34, which is a woody tree native to southeast Asian countries.47 Awale et al. 
isolated the compound as part of their continuing effort to identify cancer chemotherapeutics 
which preferentially inhibit cancerous cells under nutrient deprived conditions. From a 
dichloromethane extract of the plant, Awale et al. successfully isolated 10 novel compounds, 
among them seven new cyclohexane derivatives named uvaridacanes A and B, uvaridacols A-D and 
uvaridapoxide A, as well as grandifloracin.70   
 
The opposite enantiomer, (−)-grandifloracin, has, interestingly, also been isolated from Uvaria 
grandiflora by Liao and co-workers in 1997.71 Following the initial discovery, it has also been isolated 
from Uvaria rufa72 and Uvaria calamistrata.73 
                                                                      
Grandifloracin, an amorphous white solid, has been the compound which 
this project has focused on, in particular through the design and synthesis 
of structural analogues. This molecule was chosen due to the previous work 
the Lewis group had conducted on this compound; publishing an 
asymmetric synthesis of the compound in 2012,74 detailed later in this 
section, and the production of a number of analogues. This combined with 
its previously elucidated biological activity as shown by Awale et al., led to 
the design of this project. GF was subjected to Esumi’s anti-austerity assay, 
along with the other isolated compounds, and was found to display         Figure 34: Uvaria grandiflora75                  
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the most potent preferential cytotoxic activity against a range of cancer cell lines, however most 
notably against PANC-1 cells in nutrient-deprived media (NDM) with a PC50 of 14.5 µM.47 The PANC-
1 cells were tested under various nutrient conditions whereby serum, amino acids or glucose were 
removed. It was found that GF was most potent when glucose or serum was removed which 
reduced the cell survival to just 2%, as shown in figure 35 below.70        
       
 
Figure 35: Effect of (+)-grandifloracin on PANC-1 cell survival after 24 hours in NDM and normal medium 
(DMEM). (A) Effect of (+)-grandifloracin concentration on cell survival in NDM and DMEM. (B) Effects of 
medium components, i.e., glucose, amino acids, and serum. Figure reproduced from reference 70. 
 
Although the mechanism of action of GF is still being elucidated, a study was able to show that GF 
induces autophagic cell death due to the upregulation of the microtubule-associated protein 1 light 
chain 3, a marker of autophagic cell death, however there was no evidence of the expression of 
capase-3 and Bcl-2 apoptosis marker proteins. GF was also shown to inhibit completely Akt 
phosphorylation at serine 473, as well as, mTOR phosphorylation at serine 2448 after 6 hours in 
nutrient-deprived conditions which is detailed in the western blot analysis in figure 36 below. Akt 
is a protein kinase activated in most tumours and is responsible for a variety of cellular functions. 
Akt is activated downstream by mTOR and, therefore, as GF has been shown to inhibit the activation 






Figure 36: Effect of GF against Akt and mTOR. Figure reproduced from reference 70 
 
5.1: Syntheses of grandifloracin 
5.1.1: SIBX-mediated racemic synthesis 
The first racemic synthesis of grandifloracin was reported by Lebrasseur et al. in 2007 as part of 
their ongoing work exploring the use of stabilised 2-iodoxybenzoic acid or SIBX, the non-explosive 
variant of the λ5-iodane 2-iodoxybenzoic acid (IBX). SIBX typically consists of 49% IBX, 22% benzoic 
acid and 29% isophthalic acid, although individual formulations can vary. Hypervalent iodine 
reagents, such as SIBX, offer the opportunity to carry out an hydroxylative dearomatization process 
on 2-alkylphenols in order to convert them into their corresponding orthoquinols or Diels−Alder 
cyclodimerisation products.  
 
In reference to the synthesis of racemic grandifloracin specifically, as shown in scheme 2, they were 
able to demonstrate the ability of SIBX to oxidise the phenol motif of 2-hydroxybenzyl benzoate 
into its corresponding ketone, hence creating an orthoquinol, which then underwent a Diels–Alder 
[4+2] cycloaddition reaction with itself to furnish GF. Although the yields were promising, 30% post 
purification, this synthetic method did not afford any enantioselectivity and therefore would not 
be able to produce enantiopure (+)-grandifloracin as isolated from Uvaria grandiflora, however it 





















Scheme 2: Racemic synthesis of grandifloracin76 
 
5.1.2: Sodium periodate-mediated racemic synthesis 
During the course of this project, a group led by Professor Stoltz in California published an 
alternative racemic synthesis of grandifloracin. The key Diels−Alder cyclodimerisation step was 
preserved, as well as the use of an iodine based oxidant, however this time the process was 
mediated by sodium periodate. The premise for the development of this alternative synthesis was 
to enable a greater scope of diversification of the grandifloracin core which would be useful in 
producing a medicinal chemistry screening library or to understand any potential structure-activity 
relationships, whilst also increasing atom efficiency.77  
 
Bergner et al., therefore, developed a synthesis which enabled the diversification of the core motif 
to be conducted after the key oxidative cyclodimerisation. This would allow a far greater scope of 
functional groups to be incorporated into the molecule as they no longer had to tolerate the 
oxidative conditions of the cyclodimerisation step. It would also avoid the use of protecting groups 
which decreases atom efficiency and necessitates extra reaction steps within the overall synthesis. 
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Scheme 3: Sodium periodate-mediated synthesis of (±)-grandifloracin77 
 
In comparison to the Lebrasseur at al. synthesis detailed earlier, this alternative synthesis 
undertakes the Diels−Alder dimerisation process at the beginning of the synthesis to produce an 
interesting (bis)epoxide containing compound (39). The epoxides can then be easily hydrolysed 
open in order to generate the reactive tetra-ol containing intermediate. This can then be reacted 
with a range of electrophiles, which can regioselectively react with the primary alcohols, to produce 
a variety of (±)-grandifloracin analogues.  
 
Following the success of this novel synthetic route, Bergner et al. proceeded to demonstrate the 
utility of this method by producing a series of GF analogues which will be discussed in detail within 






5.2: Asymmetric synthesis of (+)-grandifloracin 
Lewis were the first group to publish an asymmetric synthesis of (+)-grandifloracin utilising a 
microbial dihydroxylation product as the starting material. Biocatalysis is becoming an ever more 
important methodology through which chemical transformations are performed. Not only does it 
fulfil green criteria, but microorganisms are also able to perform transformations which are simply 
not possible through traditional catalytic means. One such previously inaccessible compound has 
been exploited by Lewis in their synthesis of (+)-GF. Enzymatic dihydroxylation of aromatic 
substrates usually results in hydroxylation ortho, meta to the existing substituent, e.g. compound 
87 to compound 88, however it was found that R. Eutropha B9 was able to metabolise benzoate to 














Figure 37: Dihydroxylation by R. Eutropha B974 
 
This ipso, ortho diol (44) was the key starting material in the synthesis of (+)-GF. By accessing this 
starting material with pre-installed stereochemistry relating to the hydroxyl groups, Lewis et al. 
were able to design an alternative route to (+)-GF which resulted in the desired enantiomer. The 
ipso, ortho diol is however relatively unstable, especially at high temperatures or extremes of pH, 
causing it to undergo facile dehydration and rearomatisation back to the aromatic 
monohydroxylated compound. In order to stop this from happening, Lewis protected the diol as a 
tricarbonyliron(0) complex. This protected the substrate from rearomatisation whilst other 
transformations were performed on the rest of the molecule, as shown in scheme 4 below. 
 
It was found that protection of the secondary alcohol was also necessary in order to stop 
benzoylation of both alcohols which added extra steps. The other basic transformations, however, 
are similar to those employed by Lebrasseur et al. and the same Diels–Alder dimerisation is key to 
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this synthetic pathway as well.76 By devising this route, Palframan et al. have enabled an effective 
synthesis of the enantiopure product, (+)-grandifloracin, which, combined with the biological data, 


































6.0: Grandifloracin structural analogues 
Following their successful publication of the asymmetric synthesis of (+)-grandifloracin, Ali Khan et 
al. went on to synthesise several enantiopure analogues utilising the core grandifloracin motif and 
tested them against PANC-1 cells in both nutrient-sufficient and -deprived conditions. As scheme 6 
shows below, they synthesised two compounds containing para-substituted benzoyl ester groups, 
one bearing a 4-chloro- group (54) and another bearing a 4-methoxy group (55). They then tested 
these analogues against PANC-1 cells and found both to be more potent than the parent (+)-
grandifloracin, (60) producing an IC50 value of 77 µM and (61) producing an IC50 value of 52 µM 
compared to the IC50 value for the parent compound, (+)-grandifloracin, of >500 µM in conditions 
containing 0.5% serum.79 It is this increase in activity of the two analogues synthesised which led us 


























They also hydrogenated (+)-grandifloracin utilising hydrogen and 
palladium on carbon to produce a saturated analogue of the 
parent compound, (62). This hydrogenated analogue was then 
tested against PANC-1 cells under both nutrient-sufficient and 
nutrient-deprived conditions and was found to again be more 
potent than (+)-grandifloracin under conditions containing 0.5% 
serum producing an IC50 value of 86 µM. This was a surprising                        Figure 38: Structure of                                                                                                                                           
result as it was previously hypothesised that the enone motif may                 hydrogenated (+)-GF79 
have acted as a Michael acceptor within the cell. Further modelling revealed that, in spite of altering 
the hybridisation of several carbons, due to the rigid ring structure, the overall conformation of the 
molecule was not altered to any great extent which could help to explain the unexpected result.79 
                                                                                                                                                   
In addition to the asymmetric analogues which Lewis et al. synthesised, the group led by Professor 
Stoltz have also published a series of racemic structural analogues, however have yet to publish any 
biological data relating to these compounds. Their small structural library was synthesised in order 
to test the robustness of their new method for the synthesis of racemic grandifloracin, as detailed 
above. Their method was to produce the tetra-ol intermediate (40), as shown overleaf, and then 
derivatize this utilising a variety of acyl chlorides. Using this method, they introduced a methyl 
substituent to the phenyl ring in the para, meta and ortho positions, which was well tolerated with 
their new synthetic method, giving roughly similar yields to the parent compound. Then they 
replaced the phenyl ring with both a cyclohexane and a cyclopropane ring which, interestingly, gave 
slightly increased yields. They finally introduced both an electron donating para-methoxy- group 
and an electron withdrawing para-cyano group onto the phenyl ring.  The electron-donating group 
significantly increased the reaction yield whilst the electron-withdrawing group substantially 


















R-group (a-g) Yield (%) 
2-Me-C6H4 48 
3-Me- C6H4 51 
4-Me- C6H4 55 
4-OMe- C6H4 69 






Table 3: Synthesis of racemic grandifloracin analogues with reaction yields77 
 
7.0: Oxidative dearomatisation reactions 
The key to all three of the published synthetic methods to grandifloracin is the [4+2] Diels–Alder 
dimerisation process. This is enabled through the oxidation of the phenolic alcohol to its 
corresponding ketone, dearomatising the phenyl ring and producing an orthoquinol, which contains 
the essential diene motif. This then allows the dimerisation to take place through a Diels–Alder 
cycloaddition reaction.  
 
Phenols are generally considered to be mildly electron-rich aromatic nucleophiles which are 
capable of undergoing either, a one-electron oxidation into delocalized phenoxy radical species, or 
a two-electron oxidation into cationic electrophiles of the phenoxenium type.80 As shown above 
through the previous work of Palframan et al.,74 the reactive orthoquinol, a non-aromatic 
cyclohexadienone, can undergo cycloaddition and nucleophilic addition processes, providing they 




As detailed on page 32, the oxidant employed by Lebrasseur et al. was stabilised 2-iodoxybenzoic 
acid or SIBX. SIBX is a hypervalent iodine(V) reagent which was developed by Ozanne et al. in 2003 
as a safe alternative to other iodine(V) reagents, such as 2-iodoxybenzoic acid (IBX) and Dess–
Martin periodinane.81 Although such reagents provide an environmentally friendly alternative to 
other heavy metal based oxidants, their industrial applications are limited due to hypervalent iodine 
reagents’ propensity for violent decomposition if exposed to elevated temperatures or impact. SIBX 
was, therefore, developed as a safe alternative, which kept the oxidative ability of iodine(V), but 
reduced the risk of explosion. It is a white solid which contains a mixture of benzoic acid (22 %), 
isophthalic acid (29 %) and o-iodoxybenzoic acid (49 %).81 According to Quideau et al., the exact 
mechanistic implications of hypervalent iodine reagents in phenolic dearomatisation are still not 
well understood, with many hypothetical representations based on either ionic associative or 
dissociative, ligand coupling or radical reaction paths. In a recent review article, they provide the 

















Scheme 6: Various mechanistic postulations on the involvement of hypervalent iodine species in phenol 
dearomatisation. Figure reproduced from reference 80 
 
Based on this information, the following potential dissociative mechanism for the oxidation of the 




















Scheme 7: IBX oxidation mechanism 
In this case, the oxidation of the phenolic starting material by o-iodoxybenzoic acid results in the 
production of a very reactive dieneone intermediate (67) which rapidly undergoes an 
intermolecular Diels−Alder dimerisation process with another identical molecule to produce the 
desired grandifloracin dimer, as shown in scheme 8 below. The regio- and stereochemical 
implications of this process are plentiful, but despite this plethora of mechanistic nuances, the 







Scheme 8: [4+2] Diels−Alder dimerisation process 
 
Many natural products are found to contain either an orthoquinol moiety, either within the 
molecule, or are formed from an orthoquinol intermediate, as with grandifloracin. As such, 
oxidative phenolic dearomatisation reactions, performed using SIBX, have found great utility in 
natural product synthesis,82 some examples of which are detailed in figure 39 below.  
 
















Figure 39: Structures of humulone (68), aquaticol (69) and bisorbicillinol (70) 76 
 
Naturally occurring orthoquinols are rarely isolated due to their high reactivity and ability to readily 
undergo cyclodimerisation reactions. There are, however, examples of where the steric properties 
of the molecule block the dimerisation process and they remain as monomers, such as humulone 
(68). In most other circumstances the cyclodimerisation process occurs which results in products 
such as aquaticol (69) and bisorbicillinol (70) as detailed below.76 
 
The next section will now briefly discuss the role of oxidative dearomatisation reactions in the 
production of natural products, in particular focusing on the three natural products introduced 
above; humulone; aquaticol and bisorbicillinol. 
 
7.1: Humulone 
Humulone (68) is an α-acid which is a naturally occurring product of hops. It was first isolated in 
1904 as a pale yellow, bitter tasting enolic acid. Humulone forms the major component of the bitter 
acids present in hops which are responsible for the taste and stability of beer. It is biosynthesised 
by the hop plant, Humulus lupulus, from isovaleryl-CoA, malonyl-CoA and dimethylallyl 
pyrophosphate precursor molecules. It is an unusual example of an isolable orthoquinol motif 
which is prevented from dimerising due to the steric bulk surrounding the potentially reactive 











Figure 40: Structure of humulone (110) with unusual isolated orthoquinol motif highlighted 
 
7.2: Aquaticol 
Aquaticol (69) is a naturally occurring product from Veronica anagallis-aquatica, which is a plant 
often used in traditional Chinese medicine. Retrosynthetic analysis carried out by Gagnepain et al. 
found that it was biosynthesised via a [4+2] Diels–Alder cyclodimerisation process similar to that 
employed by Uvaria grandiflora in the biosynthesis of grandifloracin. As shown in scheme 9 below, 
aquaticol is dimerised from the (6R,7S)-orthoquinol intermediate (71), which is itself derived from 











Scheme 9: Retrosynthetic pathway of aquaticol84 
 
In many of the studied orthoquinol dimerisations, the cycloaddition always occurs with endo 
selectivity, with the dieneophile present in the monomer always reacting through its Δ-4,5 bond, 
which displays remarkable regioselectivity.  
 
It was also found through investigations into the biosynthetic pathway of aquaticol, that the two 
monomers approach each other with the two hydroxyl groups facing towards each other, which, in 
other situations, would not occur due to steric clash. Gagnepain et al. suggest that this selectivity 
is imparted due to an endo- configuration allowing more successful overlap of the p-orbitals of the 
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carbons of the orthoquinol intermediates. The exclusivity of the Δ-4,5 bond formed, they suggest, is 
due to the loss of the enone conjugation energy, which would occur if the alternative bond was 
involved instead, imparting a high level of regioselectivity.85 
 
7.3: Bisorbicillinol 
Bisorbicillinol (70) is a natural product which was isolated from the fungal species Trichoderma sp. 
USF-2690, which became of interest due to its anti-oxidant properties. It was found by Nicolaou et 
al. that bisorbicillinol and many other related compounds were formed from a common precursor, 
sorbicillin (75). As scheme 10 shows, the proposed retrosynthetic analysis employs another regio- 








Scheme 10: Retrosynthetic pathway of bisorbicillinol (70)86 
 
Unlike Gagnepain et al., Nicolaou et al. utilised lead(IV) acetate as the oxidant to convert one of the 
tertiary, phenolic hydroxyl groups into its corresponding ketone and thus producing either the 
diene (73) or dienophile (74). These then go on to undergo the Diels–Alder cyclodimerisation 
reaction producing the desired bisorbicillinol. By minimising the equivalents of oxidant present, and 
utilising the naturally occurring hydrogen bond present between the existing carbonyl and adjacent 
hydroxyl group, they were able to exert regiocontrol in their oxidation. This is another example of 
how Nature, and consequently synthetic chemists, has employed the use of oxidative phenolic 





There are many other examples of natural and synthetic strategies which employ the same basic 
principles that are utilised by Uvaria grandiflora, and the subsequent synthetic chemists, in the 
synthesis of (+)-grandifloracin. This section helps to highlight the utility and versatility of oxidative 
phenolic dimerisation in the production of natural products and gives credence to the use of such 
a process in the synthesis of (+)-grandifloracin. 
 
As this introduction highlights, there is a real need for alternative, effective treatments against 
pancreatic cancer. The current chemotherapeutics on the market do not add meaningful extension 
to life and often cause severe side effects. Anti-austerity agents, as reviewed earlier in this section, 
are an emerging area of research, which offer an exciting new avenue for drug development in this 
field. (+)-Grandifloracin, an anti-austerity agent, has emerged as a potential drug candidate due to 
its impressive biological activity and published asymmetric synthesis. This, combined with the 
earlier work conducted on analogue synthesis, led to the design of this project, which will build 
upon the previously published work carried out on (+)-grandifloracin. This will be conducted 
through the design and synthesis of a structurally diverse analogue library, based upon the (+)-
grandifloracin scaffold, biological testing of the aforementioned compounds and then further 
refinement and development of the compounds. The ultimate aim of the project will be to make a 
meaningful impact on the area of pancreatic cancer treatment through the early stage 


















Chapter 2: (+)-Grandifloracin analogues 
1.0: Ester analogue synthesis 
The initial aim of this project was to synthesise a series of analogues based upon the (+)-
grandifloracin (GF) scaffold and the first part of this section will cover the results made in this area. 
At the outset of this research, it was decided to focus our attention on synthesising a series of 
analogues which only differed by the structure of their ester containing R- groups, as shown in 






Figure 41: (+)-Grandifloracin with the R-groups highlighted in red 
 
 
Figure 42: Ester-containing R-group analogues synthesised 
The proposed series would leave the “core” grandifloracin scaffold unaffected, however it would 
alter the physical and electronic properties of the R-groups. We hypothesised that the ester groups 
which tether these R-groups to the core motif are hydrolysed by intra-cellular enzymes, such as 






Scheme 11: Hypothesised in vivo metabolism of GF to active “tetra-ol” compound 
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A series of analogues was therefore proposed which would alter either the electronic properties of 
the attached benzoyl group, and therefore the rate of hydrolysis, or the physical properties of the 
same group, by substituting the aromatic ring for another structure. Once tested using Esumi’s anti-
austerity assay,45 these compounds would then provide some indication about our pro-drug 
hypothesis and therefore the direction of further analogue design.  
This alteration of the electronic properties of the ester would have an impact on the compounds 
log P value, or lipophilicity. As the log P value increases, so does the lipophilicity of the compound, 
and, therefore, its propensity to cross the phospholipid bilayer into the cell. If the hydrolysis process 
was to happen via intra-cellular enzymes as hypothesised, then an increased rate of membrane 
diffusion would lead to an increase in activity. Conversely, as the log P decreases, so does its 
lipophilicity. This could imply that it would be more favourable for the compound to remain within 
the aqueous extra-cellular environment, rather than cross the cell membrane, and, therefore, the 





Figure 43: Effect of functional groups on logP values 
This, however, could be further complicated by the mechanism through which the compound is 
entering the cell. It could be, as described above, a matter of simple diffusion across the 
phospholipid bi-layer into the cell, in which case lipophilicity would play a key role, or alternatively, 
some active transport process may be employed. Passive transportation utilises the concentration 
gradient, and the consequent gain in entropy after diffusion has occurred, to drive transportation.87 
In contrast, active transport relies upon cellular energy and transmembrane proteins in order to 
achieve this movement, often enabling disfavoured movement across membranes.88 If the 
structure of the ester was altered to such an extent that the lipophilicity became dramatically 
reduced, then the compound could still enter into the cell via an active process using intra-cellular 
ATP or an electrochemical gradient. These are all consideration which must be borne in mind when 
designing analogues and analysing their subsequent data. 
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A racemic approach would be adopted in the synthesis of analogues. Although an asymmetric 
synthesis of (+)-grandifloracin had been devised previously in the group74, due to the brevity of the 
racemic synthesis, it was decided to synthesise all first-generation analogues as racemates and then 
resynthesise the most active compounds asymmetrically. There were two examples in the literature 
of synthetic strategies devised by separate groups in order to synthesise grandifloracin racemically. 
The first synthesis was reported by Lebrasseur et al. in 2007 which utilised the hypervalent iodine 
reagent “stabilised 2-iodoxybenzoic acid” or SIBX.81 This synthesis was developed as part of a larger 
piece of work being carried out by the group into oxidative de-aromatisation/dimerization cascade 
reactions.76 The initial synthesis of GF was conducted via this method as shown in scheme 12. 
Although this method did provide a satisfactory route to the parent (±)-grandifloracin, synthesis of 
analogues proved challenging due to the difficult separation of the isomeric mixture of products 
produced. The [4+2] Diels−Alder dimerisation process is also an inherently low yielding 
transformation and therefore the mixture of low yields and challenging purifications lead us to 



















Scheme 12: Racemic synthesis of grandifloracin utilising SIBX76 
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Although low yielding, the Diels−Alder dimerisation process, reported by Gangepain et al., is 
surprisingly selective. If we consider all the possible mechanisms by which this process could 
proceed, it is remarkable that such a proportion of the desired product is produced. For example, 
either of the two carbon-carbon double bonds within the monomer could act as the dienophile, 
which could then approach either above or below the diene. This would result in either an exo or 
endo product forming. These alternative products are shown in scheme 13 below. This can then be 
further complicated by the introduction of a racemic monomer, as is the case with the SIBX 
oxidation of salicyl alcohol. For example, if the monomer was a single enantiomer, then one can 
imagine a situation where the (S)-dienophile reacts with the (S)-diene to produce a single isomeric 
product and vice versa if the R-enantiomer were used. If we then introduce racemates, then we 
have the possibility of the (S)-dienophile reacting with the (R)-diene or the (R)-dienophile reacting 















Scheme 13: Potential isomeric products produced during Diels−Alder dimerisation process  
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Dimerisation cascade reactions, of which the Diels−Alder process falls within, are plentiful in Nature 
and often produce very specific products due to stereospecific processes occurring in vivo. The 
cycloadditions of a variety of natural products involving orthoquinol monomers were studied and 
they were all found to occur with endo selectivity, with the dienophile always reacting through the 
same carbon-carbon double bond of the monomer.84,85 The monomers were also found to approach 
each other with two hydroxyl groups facing each other, in spite of the obvious steric clash. In order 
to understand this process further, Quideau et al. submitted the cyclodimerisation process involved 
in the formation of aquaticol to computational analysis. They discovered that the selectivity was 
due to Cieplak hyperconjugation. In the transition states studied, the group found that the Δ-4,5 
bond of one monomer approached anti to the σc,c bond of an allylic substituent on the other 
monomer. This approach could allow for Cieplak hyperconjugation because the σc,c bond orbital of 
the allylic substituent was suitably aligned with the σ* orbital of a C-C bond within the other 
monomer. The computational models showed that the dihedral angles of the two bonds closely 





Figure 44: Structure of the studied transition state, which leads to (+)‐aquaticol (111), with dihedral angles 
and interatomic distances (Å), and schematic view of “Cieplak–Fallis” interactions (in kcal mol−1). Figure 
reproduced from reference 84 
 
Although other factors were studied, such as electrostatic and steric effects, the conclusion of the 
study was that hyperconjugation appears to be the determining factors in the selectivity of these 
cyclodimerisations. A similar process could, therefore, be occurring within the formation of 
grandifloracin which could explain the selectivity experienced.84,85  
A search through the literature yielded a second example of a synthesis of grandifloracin, also 
racemically, however this time via a multistep process utilising an alternative iodine-based oxidant, 




Scheme 14: Synthesis of (±)-grandifloracin (36) utilising sodium periodate77 
Whilst the work described in this chapter was in progress, the Stoltz group published an efficient 
synthesis of grandifloracin and various structural analogues synthesised via this method77. 
Therefore, we explored this route and we were able to adapt successfully the synthesis in order to 
access our target compounds. The method, as shown in scheme 14, utilised the same starting 
material, however, used sodium periodate to produce a dimerisation product containing the core 
grandifloracin motif, the (bis)epoxide intermediate (39). This procedure had previously been 
reported by Adler et al.89 The (bis)epoxide intermediate (39) could then be manipulated to produce 
the desired product in a good yield as shown above.  
 
1.1: para-Trifluoromethylbenzoyl-GF (79) 
We took this method forward and synthesised compound 79 successfully as demonstrated in 
scheme 15. Analogue 79 was chosen due to the additional –CF3 group on the benzoyl ester 
imparting greater lipophilicity to the molecule, as well as additional steric bulk. Through biological 
testing, this could highlight how the differing physicochemical properties might affect the potency 
of the analogue and whether affecting the polarity of the benzoyl group would influence the 













Scheme 15: Our synthesis of compound (±)-79 utilising SIBX 
Salicyl alcohol (32) was reacted with sodium periodate in water and kept at ca. 4 oC.  After which 
time, the product was filtered off and required no further purification at this stage. The simplicity 
of this first step relies upon the differing solubilities of the starting material and product in water; 
the salicyl alcohol being soluble in water and the (bis)epoxide not so.  
The (bis)epoxide compound was then stirred in water at 60 oC for 2 days and the epoxides were 
hydrolysed to produce tetra-ol compound (40). This was carried forward without any purification 
because of the high polarity of the molecule which made it difficult to purify via column 
chromatography. Due to the resulting intermediate containing both primary and tertiary alcohols, 
exploitation of the difference in reactivity between the primary and tertiary alcohols afforded 
selectivity for the former. The tetra-ol was treated with 4-trifluoromethylbenzoyl chloride and 
pyridine in dichloromethane initially at 0 oC for 1 hour and then at room temperature (ca. 20 oC) for 
a further 4 hours. After purification via column chromatography, the target compound was 
produced in high purity, however only in 10% yield. As with all of the ester-based analogues, the 
remaining mass was attributed to a small amount of starting material, however the large majority 
of undesired material was a mixture of isomeric products of the aryl ester. 
It should be noted that synthesis of this analogue was attempted initially via the Quideau method; 
however, as shown below, we were unable to progress the synthesis further than the initial mono-
esterified compound. This was due to a complex mixture of isomeric products being formed which 




Scheme 16: Attempted synthesis of analogue (±)-79 using SIBX 
 
1.2: para-Fluorobenzoyl-GF (85) 
Following the successful synthesis of our first analogue, we turned our attention to the next 
compound. The addition of the single fluorine atom at the 4 position of the benzoyl ester in 
analogue 85 was chosen as it will modulate the polarity of the molecule and the electronic 
properties of the ester bond motif. Introduction of fluorine into a molecule will generally increase 
lipophilicity and, therefore, membrane permeability.90 This could lead to an increased intracellular 
concentration of the compound, which would then be available to intracellular enzymes. Should 
the pro-drug hypothesis be correct, we would then see an increase in activity. This potential 
increase in activity could also be further augmented by the electron-withdrawing effect of the 
fluorine atom at the 4 position of the benzoyl ester. This could render the ester carbonyl carbon 
more δ positive and therefore more attractive to nucleophilic attack. Both effects should have a 
positive impact on the activity of the compound, should the tetra-ol (40) be the pharmacologically 
active moiety. 
As with the previous analogue, we initially attempted to synthesise compound 85 via the Quideau 
method, i.e. utilising SIBX, as shown in scheme 17, however, again, major problems were 




Scheme 17: Attempted synthesis of analogue (±)-85 using SIBX 
Following this unsuccessful attempt, we again turned our attention to the Stoltz method utilising 
sodium periodate. Using the reaction scheme shown below, we were able to successfully synthesise 







Scheme 18: Successful synthesis of analogue (±)-85 utilising NaIO4 
This synthesis again began through the production of tetra-ol (40) utilising the same method as 
previously. Following the low yield of the previous analogue synthesis, we decided to add a 
nucleophilic catalyst to the reaction mixture, 4-(dimethylamino)pyridine or DMAP, in order to 
address this issue. This time we treated the crude tetra-ol containing intermediate with 4-
fluorobenzoyl chloride in the presence of DMAP and triethylamine in dichloromethane at room 
temperature for 24 hours. Utilising this new procedure, we were able to produce the desired 




1.3: 3,4,5-Trimethoxybenzoyl-GF (86) 
We now turned our attention to the synthesis of analogue 86. The 3,4,5-trimethoxy benzoyl ester 
derivative was chosen due to it inducing the opposite effect to that of the previous analogue, 85. 
Methyl ethers are readily metabolised in vivo which would render the molecule much more polar, 
and therefore water soluble, which increases its rate of excretion from the body.91 This again could 
shed light on the molecule’s biological half-life and also to what extent altering the metabolic half-
life has on potency. The 3,4,5-trimethoxy group would also have an electron donating effect which 
would produce a much more electron rich aromatic ring. 
 
Due to the potential that the 3,4,5-trimethoxybenzoyl group would not withstand the oxidative 
conditions of the Quideau method, we decided solely to attempt to synthesise this compound via 







Scheme 19: Successful synthesis of analogue (±)-86 via the modified Stoltz method 
We reacted the tetra-ol intermediate (40) with 3,4,5-trimethoxybenzoyl chloride in the presence of 
the nucleophilic catalyst DMAP and triethylamine in dichloromethane at room temperature for 24 
hours. Despite the addition of the catalyst, we were only ever able to achieve a yield of 12%, 
however, through use of both column chromatography and subsequent recrystallization, we were 
able to achieve high levels of purity. The decreased yield could be attributed to the alteration of 
the electronic properties of the benzoyl group caused by the addition of the electron-donating 
effects of the methoxy- groups. 
Steric parameters would also be investigated with a 2,2-dimethylpropanoate and a 
cyclopentylcarboxylate ester containing analogue. The rationale behind the synthesis of these 
compounds was twofold. Firstly, they either increase or decrease the steric bulk in relation to the 
original phenyl ring and by doing so could give us an indication about whether the R-groups are 
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participating in an interaction between the compound and the active site. Secondly, as they are 
both saturated moieties, they also remove any possible π-π interactions which, again, may be 
relevant within the active site.  
 
1.4: 2,2-dimethylpropanoate-GF (87)  
The synthesis of the 2,2-dimethylpropanoate containing molecule proceeded smoothly and we 







Scheme 20: Successful synthetic route to compound (±)-87 
Without the use of the nucleophilic catalyst DMAP, the yield of this reaction was very low, however 
through its use we managed to increase the yield to an acceptable level and produce the desired 
compound in a high level of purity. 
 
1.5: Cyclopentylcarboxylate-GF (88) 
The cyclopentylcarboxylate ester derivative served as more of a challenge and the purification in 
particular proved difficult. However, use of the modified Stoltz method we were able to synthesise 
successfully the desired analogue in 10% yield. This low yield is mainly down to the multiple 
purification processes which were required in order to ensure an acceptable level of purity for 






Scheme 21: Synthesis of analogue (±)-88 
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The crude tetra-ol was treated with cyclopentanecarbonyl chloride in the presence of DMAP and a 
base, trimethylamine, in dichloromethane. The reaction was allowed to stir at room temperature 
for 16 hours before purification via column chromatography and subsequent recrystallization. This 
produced the desired compound in an acceptable level of purity for biological evaluation, however 
in a less than optimal yield. 
 
1.6: Nicotinoylester-GF (89) 
Next we turned our attention to the synthesis of a nicotinoylester-containing analogue of GF, 
however, for the first time, we experienced complications. The rationale behind synthesising this 
analogue was that it offered an opportunity to introduce a pyridyl nitrogen atom into the molecule. 
Pyridyl nitrogens are often found within drug molecules as they are weakly basic and, thus at 
physiological pH, they are partly protonated and partly neutral. This provides two benefits related 
to drug activity; the protonated form is more water soluble, and therefore aids motility and 
absorption, whereas the neutral form aids membrane transport. The addition of the pyridyl 
nitrogen also incorporates an additional hydrogen bond acceptor into the molecule whilst having a 
minimal impact on the overall molecular weight. Furthermore, the addition of a heterocycle into 
the compound could also modulate the polar surface area of the molecule, normally increasing 
polarity.92 
The synthesis began with the treatment of crude tetra-ol (40) with nicotinoyl chloride hydrochloride 
and pyridine in dichloromethane at room temperature for 18 hours. Following work-up and 
purification via column chromatography, we discovered that only the two separate mono-
substituted products had been produced, i.e. a nicotinoyl group had been added to one primary 
alcohol in one compound and the other for the subsequent product, and none of the desired di-
substituted compound had been produced. The major product of both mono-substituted 






Scheme 22: Synthesis of (±)-89 utilising NaIO4 
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Figure 45: HMBC spectrum of compound (±)-89 displaying the vicinal di-ol signals 
Although we were unable to obtain an x-ray crystal structure, the identity of the major product was 
elucidated using 2D NMR spectral data. As shown above, through HMBC data, it was possible to 
identify the –CH2 group adjacent to the ester moiety. The protons of the AB system at 
approximately 4.43 ppm represent the methylene group adjacent to the ester moiety due to its 
strong interaction with the ester carbonyl carbon at 165.0 ppm. The identity of the quaternary 
centre to which it is attached can then be elucidated by looking at another HMBC interaction of the 
same methylene group. There are two easily identifiable functional groups adjacent to both 
quaternary centres. One has a ketone and the other has an enone motif adjacent. Utilising the 
differences in chemical shifts between the two moieties, the HMBC spectrum above shows an 
interaction between the protons of the methylene group at 4.40 ppm and the enone carbon at 
165.0 ppm. The protons of the other methylene group, approximately 3.03 ppm, display no 
interaction with the ester carbonyl carbon and a very weak HMBC interaction with the ketone 
carbon at 204.2 ppm. We can, therefore, assign the structure of the major regioisomer as 
compound 89. 
It was always our aim to produce the di-substituted product, i.e. a nicotinoyl group attached to both 
primary alcohols, however, this proved extremely difficult and after multiple attempts only the 
mono-substituted products were ever isolated. It could be hypothesised that following initial mono-
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ester formation a structural conformation made it energetically unfavourable for the second 
addition to take place. Alternatively, once the initial addition had occurred, a hydrogen bond could 
be formed between the nitrogen of the newly formed nicotinoyl group and the remaining primary 
alcohol of the molecule rendering the second addition energetically unfavourable. Nevertheless, 
the mono-substituted product was produced in good yield and provided an important addition to 
our growing analogue library.  
Through the work described above, we were able to successfully synthesise a range of structural 
analogues of grandifloracin containing a variety of ester based R-groups. The analogues explore 
electronic and steric parameters and, through biological testing, were expected to provide 
information on the compound’s mechanism of action and metabolism. 
 
2.0: Amide analogues of GF 
Following the successful synthesis of a range of ester R-group analogues, we decided to turn our 
attention to some new chemistry in the production of amide R-group containing analogues. The 
next section of this chapter will describe the steps taken and the chemistries employed in the 
synthesis of such compounds. 
By introducing an amide functional group into the core grandifloracin motif this would add an 
additional hydrogen bond donor and would also be more resistant to hydrolysis, in comparison to 
the ester moiety. This could aid in the elucidation of our pro-drug hypothesis as, if hydrolysis to the 
tetra-ol (40) was required for biological activity, then a moiety more resistant to hydrolysis should 
display a decrease in activity accordingly. 
 
 2.1: (Bis)amido-GF analogue (93) synthesis via 2-(aminomethyl)phenol 
We commenced this section of work by simply substituting salicyl alcohol for the amino equivalent, 
2-(aminomethyl)phenol (91). Initially we attempted to synthesise the mono-substituted product by 
exploiting the difference in reactivity between the primary amine and the phenolic hydroxyl group. 
The amine should be more reactive than the phenolic hydroxyl group and, therefore, by controlling 
the equivalents of benzoyl chloride used, we hoped to achieve clean mono-benzoylation. This was 
found not to be the case and therefore, it was decided to force the reaction to the di-acylated 
product through the use of two equivalents of benzoyl chloride. This successfully produced the di-
substituted product in 75% yield following column chromatography. We then hydrolysed the more 
labile ester through the use of potassium hydroxide and ethanol. This was again successfully 
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achieved in a 97% yield following purification via column chromatography. The identity of this 
compound was confirmed both via the usual spectroscopic techniques, such as NMR spectroscopy, 






Figure 46: ORTEP representation of the structure of 90, as determined by x-ray crystallography. Ellipsoids are 
at 50% probability; H atoms are shown as spheres of arbitrary radius, plus line representation. 
Following confirmation that the desired monomer had been synthesised, we exposed N-(2-
hydroxybenzyl)benzamide (90) to the hypervalent iodine containing oxidant SIBX as per the 
previously described Lebrasseur method.76 This, unfortunately produced a mixture of products 
which contained both unreacted starting material (90) and a small amount of an alternative product 
of oxidation (94). We believe that rather than oxidising the phenolic hydroxyl group to the desired 
ketone, thus producing the reactive dienone motif required for the Diels−Alder process, it instead 





Scheme 23: Initial unsuccessful synthesis of racemic (bis)amido-GF (93) 
Following purification, the proton and carbon NMR spectra showed a mixture of compounds which 
sadly persisted, however we were able to attribute peaks to each potential product. The key 
indicators to justify the proposed structure were that one compound showed an absence of any 
hydroxyl or amide protons, however all the signals for the other required protons. We could, 
therefore, tentatively assign the identity of this compound as the undesired heterocyclic compound 
shown in scheme 23. The other compound, we postulate, could be unreacted starting material due 
to the presence of hydroxyl and amide protons.  
We were unable to gain a crystal structure of either compounds, and it was difficult to differentiate 
definitively between the two potential compounds, however this hypothesis was the most 
reasonable conclusion we could draw from the spectroscopic data available. 
 
2.2: (Bis)amino-GF (97) synthesis utilising phthalimide 
In light of this outcome, we set about to protect the third valency on the nitrogen by employing a 
phthalimide group as a protecting group. We could then expose the monomer to the oxidant, 
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hopefully achieve the dimerisation process, and then remove the phthalimide groups in order to 
unmask the desired amines. 
We were able to install successfully the phthalimide group onto the 2-(aminomethyl)phenol (91) 
through the use of N-hydroxyphthalimide in phosphate buffer solution in 35% yield, using the 
procedure previously reported by Rai et al.93 We then proceeded to expose the 2-(2-
hydroxybenzyl)isoindoline-1,3-dione intermediate (95) to SIBX and produced, what appeared to be, 
the desired product, however, despite our best efforts at purification, we were never able to 
remove the undesired isomeric products. It was, therefore, decided to telescope the product 
through without purification. Unfortunately, it proved to be impossible to remove the phthalimide 
groups whilst leaving the rest of the molecule unaffected. We employed the well-precedented 
removal technique for phthalimide groups, hydrazine, however, after multiple attempts, it 










Scheme 24: Synthesis of racemic phthalimide-protected GF (138) 
This could be attributed to hydrazine’s increased nucleophilicity due to the alpha effect. One of the 
classes of substrate most affected by this increased reactivity are activated double bonds and 
therefore it is quite conceivable that the hydrazine could also be attacking the enone as well as its 





2.3: Ritter amidation chemistry 
Our next attempt at the synthesis of an amide containing R-group analogue of GF was to explore 






Scheme 25: Modification of Ritter amidation using acetonitrile and (bis)epoxide 
Ritter and Minieri showed that nitriles can act as nucleophiles and attack alkenes to produce the 
corresponding amide via hydrolysis.95,96 By extension of this idea, we reasoned that acetonitrile 
could possibly attack the epoxides present on our (bis)epoxide intermediate (39) in the presence of 
a Lewis acid and produce the desired acetamide containing product, following hydrolysis. There 
were a number of related examples of such a reaction within the literature, however none using 
the exact substrate we were proposing.97-99 This provided both credence and a starting point from 









Scheme 26: Mechanistic rationale for proposed opening of epoxides with nitriles 
The (bis)epoxide (39) in acetonitrile was treated with added boron trifluoride diethyl etherate and 
then stirred at 80 oC for 20 hours. Our initial reaction yielded a very small amount of what appeared 
to be the desired product as well as a variety of other undesired by-products. We then set about to 
repeat the process to gain more material however this time we were unable to reproduce the result 
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we had previously achieved. After many repeats of the same reaction conditions without success, 






Scheme 27: Alternative Ritter amidation conditions 
We substituted acetonitrile for a more structurally complex nitrile, 2-fluorobenzonitrile, utilised 
dichloromethane as our solvent and added trifluoroethanol as an additive which had been shown 
to increase the yield of Ritter reactions.100 The major product from this reaction displayed unusual 
signals in the proton NMR spectrum and did not resemble the signals normally attributed to GF, or 
analogues thereof. We set about to elucidate the structure of this compound through the use of 
NMR-based methods, as well as x-ray crystallography, and finally through the use of NMR structure 
elucidation software. After unsuccessful attempts to elucidate the structure based on NMR 
spectroscopic data, the x-ray single crystal structure was obtained which showed a completely 





Scheme 28: Product of adapted Ritter amidation procedure 
Once the identity of the unexpected rearrangement product had been identified, it was decided to 
alter the Lewis acid in order to observe the effect. We therefore substituted boron trifluoride 
diethyl etherate for bismuth triflate. Upon work up and purification it was discovered that another 
rearrangement product had been produced in a 38% yield, with a structure different to that of the 
compound produced by boron trifluoride diethyl etherate. The structure was again confirmed via 
X-ray single crystallography and through the use of NMR structure elucidation software. Following 
further experimentation with this Lewis acid, it was found that this compound was reproducibly 
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produced only when one equivalent of Lewis acid was used. If sub-stoichiometric levels were used, 





Scheme 29: Alternative Ritter amidation conditions using bismuth triflate 
The findings above prompted an extensive study into the formation of these by-products, the 
results of which are described in the next chapter. Despite these exciting discoveries, we still had 
not been able to successfully synthesise an amide containing R-group GF analogue, which was the 
aim of this section of work. 
 
2.4: (Bis)azido-GF (149) 
As a result of the failure of the Ritter-type approach, we set about thinking of alternative groups 
which would enable us to incorporate the nitrogen into the molecule at an early stage and could 
then be manipulated into the functional group we required. A key requirement for enabling this 
strategy however would be that the nitrogen-containing moiety could withstand oxidising 
conditions or would not be oxidised itself. After searching the literature, we decided to attempt the 
use of azides. These represented a nitrogen containing moiety which was not oxidisable itself and, 
therefore, would hopefully survive the reaction conditions intact. 
We successfully synthesised the desired azide equivalent of salicyl alcohol, 2-(azidomethyl)phenol 
(106), using a previously reported procedure.101 This synthetic method allowed the one-pot 
conversion of salicyl alcohol to 2-(azidomethyl)phenol in a modified Appel reaction. Reaction of the 
starting material with sodium azide and triphenylphosphine in a mixture of carbon tetrachloride 
and N,N-dimethylformamide (1:3) at 90 oC for 18 hours gave, after column chromatography, a 
yellow oil in 56% yield.  
With the desired intermediate in hand, we turned our attention to the synthesis of the (bis)azido-
GF analogue (107) which would form an intermediate in the synthesis of our ultimate target, a 
(bis)amido-GF analogue (109). As the azide is non-oxidisable, we were able to take the 2-
(azidomethyl)phenol and treat it with SIBX in THF at room temperature for 16 hours. This 
underwent the aforementioned Diels−Alder dimerisation process and, following work-up and 
purification via column chromatography, we were able to synthesise the target compound in 12% 
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yield. The remainder of the mass balance was formed from a small amount of recovered starting 











Scheme 30: Synthesis of nitrogen-containing racemic GF analogue 
The isolation of this compound was a significant breakthrough within the project as it finally 
represented the successful incorporation of a nitrogen containing functional group into the R-
group. Unfortunately, due to time restrictions we were unable to proceed with this synthesis any 
further, however it could feasibly be conceived that the following would convert the synthesised 
(bis)azido-GF (107) analogue into the target (bis)amido-GF analogue (109). 
In 1919, Staudinger and Meyer reported the first method for the conversion of an azide to a 
phosphazo-containing compounds utilising tertiary phosphines.102 The phosphazo can then be 
simply converted into an amine via hydrolysis with water.103 By adaptation of this method, we could 
foresee the conversion of the (bis)azido-GF analogue into a (bis)amino-GF analogue as shown in 
scheme 30.  
With the (bis)amino-GF analogue in hand, we would expect smooth conversion from the primary 
amine to the desired amide through the use of benzoyl chloride and a suitable base. This would 
then produce the desired target compound of a (bis)amido-GF analogue, also shown in scheme 30.  
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With both a range of ester-based R-group analogues and a nitrogen containing R-group analogue, 
we moved our focus towards the synthesis of a thioester-containing analogue.  
 
3.0: Thioester synthesis 
3.1: Thioacetate-GF (111) 
Initial attempts were made through the use of thioacetic acid. Our idea was to open the 
(bis)epoxide containing intermediate utilising a sulfur-based nucleophile. This, however, proved 
challenging due to the “soft” nature of sulfur as a nucleophile, which readily added to the β-position 
of the enone motif in a Michael process and gave a mixture of bis- and tris- adducts. Therefore, we 
sought to force the production of the tri-substituted product through the use of three equivalents 
of thioacetic acid in the presence of a suitable base, trimethylamine, in dichloromethane. We did 
not isolate the product of the reaction, however, and went straight on to react the intermediate 
with the non-nucleophilic, strong base DBU with the hope that it would effect a retro-Michael 
elimination of the thioacetate group attached and reinstall the enone motif. Unfortunately, this did 





Scheme 31: Attempted synthesis of a racemic thioacetate containing GF analogue 
 
3.2: Benzoyl thioester-GF (112) 
We then repeated this process using thiobenzoic acid, in order to see if this would improve the 
selectivity of the nucleophile and also to investigate whether altering the nucleophilic species might 
result in the production of the desired compound. We therefore reacted the (bis)epoxide 
containing intermediate (39) with thiobenzoic acid and triethylamine in dichloromethane at room 
temperature for 18 hours. Crude proton NMR showed the potential presence of the desired product 
however the compound seemingly did not survive the acidic environment of column 









Scheme 32: Attempted synthesis of a racemic thioester analogue of GF using thiobenzoic acid 
The result of this reaction illustrates the problems we continued to experience during this section 
of work. That is to say, the inherent lability or reactivity of these compounds, which is the reason 
we wanted to synthesise them in the first place, led to problems with stability and therefore 
isolation. Evidence for the desired compounds was often observed within a crude NMR however 
many of the compounds either did not survive purification or simply decomposed upon storage. 
Despite this, we persevered and attempted to synthesise sulfur based compounds via a variety of 
methods. 
 
3.3: (Bis)thiirane synthesis 
We briefly attempted to convert the readily available (bis)epoxide containing intermediate into a 
(bis)thiirane containing compound utilising thiourea and 4Å molecular sieves via a slightly modified 
version of a previously published synthesis.104 Despite our best efforts, all we were able to recover 





Scheme 33: Attempted synthesis of a (bis)thiirane containing compound 
 
3.4: (Bis)cyclic sulfate-GF (114) 
Next, we turned our attention to the synthesis of a cyclic sulfate-containing compound, as it was 
thought that these could readily be opened using a sulfur-based nucleophile in order to produce 
the target compound. We, therefore, proceeded to treat the crude tetra-ol (40) with sulfuryl 
chloride in the presence of a hindered base, N,N-diisopropylethylamine,105 in dichloromethane at -
20 oC for 1 hour. This, again, did not produce the desired compound however resulted in the 
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Scheme 34: Attempted synthesis of a racemic cyclic sulfate containing compound 
In light of this result, we considered that sulfuryl chloride may not have been an appropriate 
reagent in order to carry out the desired transformation. Sulfuryl chloride can be considered as an 
electrophilic source of chlorine and therefore one could easily conceive many possible side 
reactions which could occur with the tetra-ol containing intermediate and such a compound. This 
could explain the multitude of compounds produced and the unsuccessful result.106 
 
3.5: (Bis)cyclic sulfite-GF (115) 
We devised an alternative synthetic strategy which involved the use of thionyl chloride. The 
premise was the same as that with sulfuryl chloride however this time the aim was to produce a 
cyclic sulfite-containing molecule and not a cyclic sulfate. The cyclic sulfite could then be oxidised 
to a cyclic sulfate should that be required at a later date. We therefore treated the tetra-ol 
containing intermediate (40) with thionyl chloride, in the presence of triethylamine, in 
dichloromethane at 0 oC for 1.5 hours. The crude NMR spectrum showed the presence of a 
diastereoisomeric mixture of the desired products due to the fact that two new stereocentres (at 
the two sulfur(IV) centres) had been introduced in an uncontrolled fashion. It was then decided to 
proceed without any purification due to the previously experienced instability of the sulfur-
containing compounds on silica gel. We then went on to treat the (bis)cyclic sulfite-containing 
molecule with sodium thiophenolate in N,N-dimethylformamide at room temperature for 20 hours. 
This unfortunately, again, produced a mixture of products which necessitated purification. This was 
attempted via column chromatography which caused degradation of the molecule(s). We were, 











Scheme 35: Attempted synthesis of a racemic thioester-based analogue via a (bis)cyclic sulfite intermediate 
 
3.6: (Bis)cyclic sulfate-GF (117) synthesis utilising 1,1’-sulfonyl diimidazole 
We attempted one final synthesis to produce a cyclic sulfur-containing intermediate which could 
hopefully be either isolated or used without purification. This time we decided to experiment with 
the use of 1,1’-sulfonyl diimidazole as an agent to install a cyclic sulfate moiety within the molecule. 
Due to the sulfur now being in a higher oxidation state (VI), and not stereogenic, this would remove 
the production of diastereoisomers and therefore the compound might not require purification. 
Analysis of the crude reaction mixture did not, however, show any changes to the starting material, 






Scheme 36: Synthesis of a racemic (bis)cyclic sulfate-containing compound via 1,1’-sulfonyl diimidazole 
 
3.7: (Bis)cyclic carbonate-GF 
It was at this point that we turned our attention away from the production of cyclic sulfur-
containing compounds and towards the generation of a cyclic carbonate instead. To do this, we 
substituted the above reagent, 1,1’-sulfonyl diimidazole, for a carbon-based alternative, 1,1’-
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carbonyl diimidazole (CDI).  We treated the tetra-ol containing intermediate with 1,1’-carbonyl 
diimidazole in dichloromethane at 0 oC and then allowed the reaction mixture to warm to room 






Scheme 37: Unexpected synthesis of an unusual rearrangement product 
After much investigation via various spectroscopic techniques, we were able to elucidate the above 
structure, which was able to be purified via column chromatography and appears to be stable for 
extended periods of time under normal lab conditions. It appears that the reaction proceeded as 
expected on the A ring, which liberated two molecules of imidazole. This then enabled an oxa-
Michael addition of the remaining primary alcohol onto the enone, under the aforementioned basic 
conditions, in order to produce a bridged ether species on the B ring. This compound not only 
possesses an unusual architecture; it also potentially presents an opportunity to functionalise one 
of the reactive vicinal-diol sites of the molecule in isolation to the other. This would produce 
differentially functionalised analogues of GF which, due to the inherent nature of the Diels−Alder 
dimerisation process, has until now not been feasible. This molecule will be discussed further in in 
chapter 4. 
Despite our best efforts in this area, we were never able to synthesise the desired sulfur-containing 










Chapter 3: Biological data 
Following the successful synthesis of a series of analogues, we combined these with another 
collection of analogues synthesised by a previous member of the Lewis group and we identified a 
collaborator who would be willing to carry out some biological evaluation of our compounds. Prof. 
Suresh Awale of Toyama University, Japan, who originally isolated grandifloracin, specialised in the 
evaluation of anti-austerity compounds against pancreatic cancer cell lines and therefore we were 
very grateful to be able to collaborate with an expert in this field. 
All the analogues synthesised were designed as anti-austerity agents and therefore their efficacy 
would need to be ascertained in a very specific manner. Izuishi et al. developed an assay which 
enabled the quantification of a chemical agent’s effectiveness to remove a cancer cell’s ability to 
survive under austere conditions.45 In other words, the assay measured the efficacy of the 
compound to kill the cancer cells under austere conditions.  
The basic premise of the assay is as follows; human pancreatic cancer cells were seeded into 96-
well plates and incubated in Dulbecco’s Modified Eagle’s Medium, i.e. under nutrient-rich 
conditions, at 37 oC for 24 hours. After which time, the cells were washed with phosphate-buffered 
saline solution and the medium was replaced with nutrient-deprived medium, i.e. lacking in serum, 
amino acid and glucose. The cells were then immediately dosed with serially diluted concentrations 
of the test samples. The cells were again allowed to incubated for 24 hours and after which time 
they were washed with further phosphate buffer solution and a cell counting kit solution was 
added. The plate was incubated for a further 2 hours and then the absorbance of the wells at 450 
nm was measured. The viable cell number was then determined using a previously developed 
calibration curve.107 This assay had been used previously to measure the activity of (+)-
grandifloracin and it returned a PC50 value of 14.5 µM.70 
 
1.1: Inactive analogues 
Out of the 21 compounds sent for testing, 10 of them returned very low activity levels and therefore 











Figure 47: log concentration Vs cell survival plots of inactive compounds 
 
1.2: Analogues with equivalent or greater activity than (+)-grandifloracin 
The other 11 compounds which were sent for evaluation showed more promise and two particular 
molecules returned as markedly active, in fact an order of magnitude more active than the parent 















Figure 48: log concentration Vs cell survival plots of active compounds 
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The biological testing identified 5 compounds which had greater activity than the parent 
compound, (+)-grandifloracin, which had a PC50 14.5 µM. The table below details these compounds: 





















Table 4: PC50 and cLogP values of 5 most active analogues 
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Using the activities of these compounds, there are a few initial conclusions which we can draw in 
reference to structure-activity relationship. The most surprising result was that the most active 
compound did not contain an R-group ester motif, only a benzyl ether, and therefore we can 
conclude that the ester moiety is not required for biological activity. This also calls into question 
our initial prodrug hypothesis as rapid, enzymatic hydrolysis is unlikely to take place on the ether 
containing group. The introduction of a p-fluoro- or p-trifluoromethyl- group onto the benzyl ester 
R-group appears to increase activity and, in the case of the p-fluoro-, it does so significantly. The 
removal of the alkenes from within the molecule also appears to have a beneficial effect on activity 
which is most surprising when you consider that the reactive enone motif is now no longer present. 
In light of these findings we set about designing a second generation of analogues which would test 
the aforementioned statements and also, hopefully, increase activity yet further. 
 
2.0: Second-generation analogue design and synthesis 
Following the successful biological evaluation of the first generation of GF analogues, we set about 
designing a series of second-generation compounds which would hopefully build upon the success 
of the former and also further confirm our structure-activity relationship conclusions. The two most 
active compounds from the first set of analogues were the fluorinated benzyl ether-containing 






Figure 49: Two most active GF analogues sent for biological evaluation 
This suggests that the benzyl ether R-group may impart an increased biological activity, however 
the substitution of the hydroxyl groups for fluorine atoms may be a deleterious addition. The 
fluorine atoms were incorporated into the molecule as a function of the synthesis and not 
necessarily as a desired addition. The fluorine substitution for hydroxyl groups are believed to be a 
deleterious addition due the effect displayed on biological activity against PANC-1 cells cultured 
under nutrient deprivation when incorporated into the parent (+)-grandifloracin, as shown from 
our recent biological evaluation work detailed above. The parent compound, (53), has a PC50 value 
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of 14.5 µM, whereas the substitution of hydroxyl groups for fluorine atoms renders the compound 






                        PC50 value = 14.5 µM                                                         PC50 value = 89.9 µM 
Figure 50: Biological activity of fluorinated GF analogues against PANC-1 cells cultured under nutrient 
deprived conditions 
We therefore wanted to produce a compound very similar to the first generation molecule however 
this time the fluorine atoms would be substituted back to the traditional hydroxyl groups (122). We 
also wanted to combine the modifications from both of the most active compounds and produce a 
p-fluorobenzyl ether-containing GF compound (123) which would hopefully improve the activity of 
the unsubstituted benzyl ether analogue. We would also re-synthesise the most active compound 
from the previous round of testing, compound 120, and re-test it to verify the results. This, 











          Figure 5: Second generation analogues 
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2.1: Re-synthesis of fluorinated benzyl ether-GF analogue (120) 
We initially focused our attention on re-synthesising the fluorinated benzyl ether analogue (120) 
which had previously been made by another group member. We employed a previously published 
method by Phipps and Toste. which could possibly allow the asymmetric synthesis of the desired 
compound however the exact transformation had not been shown within the previous work.  This 









Scheme 38: Proposed synthesis of compound 120 
Before we could attempt the dimerisation step utilising Toste’s adapted methodology and catalyst, 
we needed to synthesise 2-((benzyloxy)methyl)phenol (125). We again turned to the literature and 
were rewarded with a previously published methodology.109 We treated benzaldehyde dimethyl 
acetal with salicyl alcohol in the presence of a strong acid in acetonitrile at room temperature for 3 
hours. Following column chromatography, we were able to isolate the desired product in 65% yield. 
We then attempted a regioselective reductive opening of the acetal using borane. This step proved 
particularly challenging logistically and required the process to be conducted under strict anhydrous 
and anaerobic conditions. After many attempts to perfect the transformation, we were finally 
rewarded with the synthesis of the desired compound. We treated the acetal containing 
intermediate with borane trimethylamine complex and aluminium chloride in THF at 0 oC for 18 
hours. Following work-up and purification, this produced the desired compound (125) in 25% yield.  
We then took 125 forward and reacted it with SelectFluor, sodium carbonate and (R)-TCYP in 
toluene at room temperature for 72 hours. Unfortunately, following purification via column 
chromatography it was discovered that no dimerisation had occurred and we were only able to 
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isolate unreacted starting material quantitatively. Upon deeper inspection of the aforementioned 
published methodology, it was discovered that a longer synthesis may be required utilising 
protecting groups, which was described in relation to a synthesis of a fluorinated GF analogue, and 
is detailed below. This method has not been attempted due to a lack of time and funding, however 













Scheme 39: Alternative proposed synthesis to fluorinated-GF analogue 120 
 
2.2: Benzyl ether-GF analogue (122) 
We then turned our attention to the synthesis of compound (122), which is very similar to the 
previously described analogue, however the fluorine atoms have been replaced with hydroxyl 
groups. Thus rendering it more representative of the parent molecule. Our attempts in this area 
focused on the benzylation of the tetra-ol containing intermediate (40) via various methods. The 
first attempt was under basic conditions using sodium hydride and benzyl bromide, however we 
believe that the strong base used under these conditions caused undesirable side reactions and 









Scheme 40: Unsuccessful synthesis of compound 122 using sodium hydride and benzyl bromide 
After much literature searching, it was discovered that there were several alternative methods 
which could be employed in order to circumnavigate the issue surrounding the use of strong bases. 
The only method we attempted was through the use of benzyl trichloroacetimidate, which was 
adapted from previously published work.110 We treated the tetra-ol containing intermediate (40) 
with benzyl trichloroacetimidate, in the presence of triflic acid, in dichloromethane at room 
temperature for 18 hours. Upon work-up and interrogation via crude NMR, it was discovered that 
only starting material and reactant were present and there was no sign of the desired product 
having being produced. Due to time restrictions we only attempted this method once and therefore 







Scheme 41: Attempted benzylation of primary alcohol using benzyl trichloroacetimidate 
Alternatively, methods using other mild benzylating agents such as 2-benzyloxy-1-
methylpyridinium triflate could be employed.111 Furthermore, less harsh bases have been shown to 
be effective in benzylation of alcohols, such as silver(I) oxide, and they have also been shown to 







2.3: para-fluorobenzyl ether-GF analogue (123) 
Finally, we also started the synthesis of compound 123, the p-fluorobenzyl ether GF analogue, 
however we were unable to finish the synthesis due, again, to time and funding restrictions. We 
started the process with the synthesis of 5-fluoro-2-(hydroxymethyl)phenol (131) from 4-fluoro-2-
hydroxybenzoic acid (129). We achieved this by treating 4-fluoro-2-hydroxybenzoic acid with 
methanol and concentrated sulfuric acid at reflux (ca. 70 oC) for 16 hours. Upon work-up it was 
discovered that no purification was necessary and the desired compound, methyl 4-fluoro-2-
hydroxybenzoate (130), had been produced in 60% yield. We, therefore, we moved straight on to 
the reduction of methyl 4-fluoro-2-hydroxybenzoate using lithium aluminium hydride in THF. The 
reaction was stirred at room temperature overnight and, following work-up, it was discovered that, 
due to very high purity, no further purification would be necessary and the desired compound had 
been produced in 93% yield. 
 
 
Scheme 42: Synthesis of 5-fluoro-2-(hydroxymethyl)phenol 
With the 4-fluorosalicyl alcohol (131) in hand, we moved our attention to the acetal forming step. 
As with the non-fluorinated substrate, we treated 5-fluoro-2-(hydroxymethyl)phenol (131) with 
benzaldehyde dimethyl acetal in the presence of p-toluene sulfonic acid in acetonitrile at room 
temperature for 14 hours. Upon work-up and purification via column chromatography, it was 
discovered that the desired product had not been produced and only benzaldehyde and a small 
amount of unreacted 5-fluoro-2-(hydroxymethyl)phenol (131) was recovered from the column. 
This, perhaps, suggests that the para-fluoro group affected the ability to form the acetal. As stated 
previously, this reaction was only attempted once due to time pressures so through optimisation 










Scheme 43: Attempted synthesis of compound 132 
Although we were not able to complete the synthesis of the desired second generation analogue 
molecules, progress has been made in this area and many of the key intermediates or reactions 




















Chapter 4: Unusual rearrangement products 
Throughout the course of this project, we have not only been successful in the synthesis of a range 
of grandifloracin analogues, however we have also discovered interesting compounds or reactions 
along the way. This section will describe the results achieved in this area and the processes 
employed to elucidate their identities. 
 
1.0: Base-induced re-aromatisation products 
1.1: DBU induced re-aromatisation 
In the early stages of this project it became clear that the grandifloracin core scaffold was capable 
of undergoing a series of rearrangement processes to form a variety of architectures. One of the 
first examples of this happening was when we attempted to open the (bis)epoxide containing 
intermediate (39) with benzyl alcohol in the presence of DBU in THF. Instead of producing the 
expected addition product, the reaction, in fact, resulted in a base induced re-aromatisation 
process and the production of an unusual by-product in 51% yield. The only other compound to be 






Scheme 44: Synthesis of unexpected re-aromatisation product 
A very similar compound to the one discovered above had also been reported by Bergner et al. in 
their recent work describing an alternative synthetic method of (±)-grandifloracin (36), shown 
below in scheme 45, however their compound (134) was produced from the tetra-ol intermediate 
and therefore contained a di-ol on both rings and not the epoxide as above.77 Another example of 
re-aromatisation of the cyclohexanone ring of the (bis)epoxide was also shown by Adler et al., 








Scheme 45: Base induced re-aromatisation product reported by Bergner et al.77 
We were able to identify compound 133 initially via NMR spectroscopy, however we were also able 








Figure 52: ORTEP representation of the structure of 133, as determined by x-ray crystallography. Ellipsoids 
are at 50% probability; H atoms are shown as spheres of arbitrary radius, plus line representation 
Utilising all the NMR data available to us, we were able to assign the NMR spectra successfully. The 
single carbonyl within the molecule, C1, was easily assigned at δ 199.2 ppm due to its characteristic 
chemical shift and small, quaternary peak. The methylene protons of the epoxide ring, H15, were 
also easy to assign due to their distinctive AB system pattern and also their HMBC interaction to 
the carbonyl, C1. They were assigned at δ 2.97 and 3.03 ppm. From their HSQC interaction, we were 
able to assign the carbon to which they were attached, C15, at δ 53.4 ppm.  
The alkenic protons, H12.13, were then assigned as the multiplet peak at δ 6.77 ppm. Their complex 
splitting pattern arising from the interaction with each other and also the methine protons, H3 and 




The two aromatic protons, H9,10, appeared as a set of doublets at δ 6.71 and 7.16 ppm due to their 
interactions with each other only. These were the only aromatic protons in the molecule and, 
therefore, assignment based on chemical shift could be obtained.  
The other distinctive AB system pattern arose due to the methylene group at H17 and was assigned 
at δ 4.75 and 4.82 ppm. These peaks displayed a double doublet splitting pattern due to interaction 
with each other and also the primary hydroxyl proton, H18. Again, utilising the HSQC interactions 
we were able to identify the carbon to which the protons were attached at δ 57.5 ppm.  
The phenolic proton was assigned at δ 7.83 ppm due to its downfield position and singlet splitting 
pattern. The primary hydroxyl group proton, H18, whose interaction with the methylene protons, 
H17, caused a splitting pattern of a triplet to be observed, was assigned at δ 3.39 ppm. A COSY 






Figure 53: Compound 133 with atom labels displayed 
Following the discovery of this compound, we repeated the reaction in the absence of benzyl 
alcohol to test that it was the activity of the base, DBU, causing the re-aromatisation or whether 
there was any involvement by the benzyl alcohol. As expected, in the absence of the alcohol, the 
reaction proceeded as before and produced the same re-aromatised product in 50% yield. This was 
the only compound to be identified via TLC following work-up and the only compound to be isolated 
from the column. This implies that any other products must have been lost to the aqueous phase 
during work-up of the reaction. 
The next question then posed by this discovery is the mechanism of formation. One can postulate 











Scheme 46: Potential mechanism of formation for compound 133 
1.2: Sodium methoxide-induced re-aromatisation 
Following the discovery of this base-induced elimination reaction, we investigated other bases and 
reacted the (bis)epoxide intermediate (39), this time, with sodium methoxide in methanol. To our 
surprise this reaction produced another variant of the re-aromatised product which was structurally 
distinct to the previously discovered compound in 45% yield. The remainder of the mass balance 






Scheme 47: Discovery of compound 135 via base-induced elimination using NaOMe 
This reaction was repeated and, again, produced the same compound in an analogous yield thus 
proving reproducibility of this particular process. As with the previous re-aromatisation product, 
we elucidated the structure of this compound using traditional spectroscopic techniques however 
this time we were unable to gain an x-ray single crystal structure.  
The NMR data for this compound were very similar to that of compound 133, therefore we will not 
discuss assignment in detail. However, the –CH2OH group has now been replaced by an additional 
aromatic proton, which can be observed as a doublet at δ 6.67 ppm. Plus, the phenolic proton at δ 
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7.15 ppm now also appears as a doublet due to an interaction with the new proton, confirmed by 
COSY NMR data. 
As with the previous re-aromatisation product, we have postulated a potential mechanism of 
formation for this product which could follow the same initial base induced β-elimination process. 

















Scheme 48: Postulated mechanism of formation for compound 135 
These two products pose an interesting question in relation to mechanism of formation. It would 
appear that both re-aromatisation products are the result of a base-induced elimination process, 
however the question then becomes why the use of DBU should result in one product whilst sodium 
methoxide should result in a structurally distinct product. One difference between the two bases 
are the pKa values of their respective conjugate acids; methanol has a pKa value of 15.5 and the 
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conjugate acid of DBU has a pKa value of 13.9 in DMSO.113,114 These values imply that methanol is a 
weaker acid than that of the protonated amine species of DBU, however, conversely, this means 
that methoxide is a stronger base than DBU. Does this difference in basicity imply that methoxide 
is able to induce the elimination of formaldehyde, via a base-induced process, whereas DBU is an 
insufficiently strong enough base to carry out this process?  
The effect of solvent should also be considered. The sodium methoxide reaction is conducted in 
methanol which is a polar, protic solvent, whereby the DBU reaction is carried out in THF, a polar, 
aprotic solvent. Is it, therefore, the ability of the solvent to donate a proton into the reaction 
mixture which enables the further displacement of the formaldehyde. Another possibility is that 
methanol is better able to solvate and stabilise the intermediate molecules or transition states, 
thereby lowering the energy barrier and enabling the further reaction to occur.  
It would be necessary to carry out mechanistic investigations to test these theories, however it does 
provide an interesting discussion point as to the reason behind the different products formed. One 
final point to note is that in either reaction, no trace of the alternative re-aromatised product was 
detected, nor isolated, which implies that the DBU reaction stops at compound 133 whereas 
sodium methoxide causes the complete conversion to compound 135. 
 
2.0: Oxa-Michael addition product (118) 
Our next unusual product was discovered, again serendipitously, whilst attempting to synthesise a 
different target molecule. We were experimenting with the possibility of creating cyclic carbonates 
from the tetra-ol containing intermediate. This was with the view of opening these moieties with a 
nucleophile in order to add previously unobtainable functionality into the molecule, namely sulfur. 
It was discovered, however, that when we treated the tetra-ol intermediate with the 1,1’-carbonyl 
diimidazole in dichloromethane at room temperature overnight that a novel compound was 











Scheme 49: Reaction of tetra-ol with 1,1’-carbonyl diimidazole 
 
It appeared that the di-ol of the A ring behaves as expected and becomes cyclised into the desired 
cyclic carbonate moiety however this process liberates two molecules of imidazole, a base. This 
then appears to enable an oxa-Michael addition of the primary hydroxyl group onto the β position 
of the enone creating an ether containing bridge on the B ring. The formation of this compound 
was unexpected and therefore elucidating its identity was, again, a challenge. We could see from 
the 1H and 13C NMR spectra that the molecule contained a single cyclic carbonate and that the 
enone motif had been removed. We also observed that it still contained two alkenic protons, as 
well as, two ketone carbonyl environments. We could therefore tentatively assign a rough structure 
however we were able to gain an x-ray single crystal structure of the compound which 








Figure 54: ORTEP representation of the structure of 118, as determined by x-ray crystallography. Ellipsoids 
are at 50% probability; H atoms are shown as spheres of arbitrary radius, plus line representation 
Upon confirmation of the structure via x-ray crystallography, we were then better able to assign 
the proton and carbon NMR spectra utilising 2D techniques, such as HMBC, HSQC and COSY.  
Assignment of the carbonyl carbons proved the simplest. The carbonate carbonyl, C17, was assigned 
at δ 154.9 ppm due to its chemical shift value being much further upfield than the other two 
carbonyl peaks. It also demonstrated an HMBC interaction with the methylene group of the cyclic 
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carbonate, H15. The enone carbonyl carbon, C6, was assigned at δ 202.4 ppm as it too displayed an 
HMBC interaction with H15, the methylene of the cyclic carbonate. Whereas C20 showed no such 
interaction, however it did interact with H11, the methylene adjacent to it, and therefore it was 
assigned at δ 210.3 ppm.  
Utilising this methodology, we could, therefore, assign the respective methylene groups. They all 
displayed the distinctive AB splitting pattern and, as such, they were easily distinguishable from the 
other protons. The protons at H15 were assigned at δ 4.12 and 4.19 ppm. This was due to their 
chemical shift value being much further downfield compared to the other AB systems caused by 
their close proximity to electronegative atoms. They also displayed HMBC interactions with C17 and 
C6 as described previously. C15 was assigned at δ 71.5 ppm due to an HSQC interaction with the 
previously assigned protons. The protons at H11 were assigned at δ 2.50 and 2.71 ppm due to their 
strong interaction with C20, whereas the protons at H9 were assigned at δ 3.56 and 3.80 ppm due 
to their distinctive AB splitting pattern and their chemical shift. C11 was assigned at δ 43.7 ppm and 
C9 was assigned at δ 70.7 ppm again utilising HSQC interactions. 
The alkenic protons were also easily distinguishable due to their characteristic chemical shifts and 
splitting patterns. We were able to assign each proton depending, again, on HMBC interactions. 
The proton at H3 displayed an interaction with C6 and was therefore assigned at δ 6.26. Conversely, 
the proton at H5 showed no interaction with any carbonyl carbons and therefore could be assigned 
at δ 6.05 ppm. Based on these assignments, and utilising HSQC NMR data, we assigned the alkenic 
carbons as follows: C3 at δ 132.2 ppm and C5 at δ 131.8 ppm. 
H12 was assigned at δ 3.03 ppm due to an HMBC interaction with the carbonyl carbon C20 and C12 
was assigned at δ 41.7 ppm due to an HSQC interaction. The quaternary carbon C8 was assigned at 
δ 74.8 ppm due to an HMBC interaction with H9. The other quaternary carbon C1 was assigned at δ 
80.4 ppm due to an HMBC interaction with H15. H2 could then be assigned at δ 3.54 ppm due to an 
HMBC interaction with the previously assigned C1, as well as a COSY interaction with H5, and 
therefore C2 could be assigned at δ 41.7 ppm due to an HSQC interaction. H7 was then assigned at 
δ 4.21 ppm due to a COSY interaction with H2 and its downfield chemical shift indicative of it being 
adjacent to a hydroxyl group. C7 was then assigned at δ 70.7 ppm due to an HSQC interaction. H4 
was assigned at δ 3.44 ppm due to a COSY interaction with H3 and therefore C4 was assigned at δ 
48.9 ppm due to an HSQC interaction. Finally, H10 was assigned at δ 3.01 ppm due to a COSY 









Figure 55: Compound 118 displayed with atom labels 
Following successful identification and assignment, we repeated this reaction several times and we 
were able to produce the re-arrangement product reproducibly in 45% yield. It is interesting to note 
that when we reacted the tetra-ol (40) with imidazole, in place of 1,1’-carbonyl diimidazole, we did 
not observe any reaction with the tetra-ol and we were only able to recover unreacted starting 
material and imidazole. A possible explanation could be that 1,1’-carbonyl diimidazole produces an 
imidazoline anion during the ring closing reaction, rather than imidazole itself, which is much more 






Scheme 50: Unsuccessful reaction of tetra-ol with imidazole 
We also went on to react the tetra-ol (40) with triethylamine and DBU in order to induce the oxa-
Michael addition however each time we were unable to observe the desired bridged ether-
containing compound. This could be the result of the desired product being very water soluble and 
therefore being lost to the aqueous phase during work-up or that it is not produced under simple 
basic conditions. It may require the conformational change that the cyclic carbonate confers upon 
the molecule in order for the second bridge to be formed. We did not conduct any formal 
mechanistic investigations upon this molecule and therefore these theories are only postulations. 
 
2.1: Diversification of (+)-grandifloracin 
Despite compound 118 appearing to be produced only under specific conditions using 1,1’-carbonyl 
diimidazole, it does offer an exciting possibility to produce differentiated analogues of GF. Up until 
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this point, all the analogues had been produced through a Diels-Alder dimerisation process and 
therefore any functionality which was present on the A ring was also present on the B ring (i.e. both 
side chains were equivalent). This unusual molecule now offered the possibility of functionalising 
each ring independently and therefore producing a range of more extensively differentiated GF 
analogues. It is conceivable that the cyclic carbonate moiety could be treated with a primary amine 
to produce a carbamate containing moiety upon the A ring, for example.115 In the absence of the 
enone motif, single addition of the nucleophile could be achieved and the risk of nucleophilic 
addition at the enone β-position would been removed. It would then be plausible to carry out a 
retro-oxa-Michael reaction through the use of a base, such as DBU, in order to re-install the di-ol 
motif upon the B ring. The primary alcohol would then be available to react with an electrophile, 














Scheme 51: Potential inequivalent functionalisation of GF 
Due to time restrictions, we were unable to carry out any of the aforementioned transformations 
in practice. However, this potential synthetic strategy would produce an analogue of (±)-
grandifloracin which contained differing functionalities on either ring which has been, up until this 
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point, not possible. The effect of having two different functionalities within the molecule on 
biological activity has not yet been elucidated however presents an exciting opportunity for 
discovery. 
 
3.0: The discovery of a novel polycyclic product 
The next unexpected molecule was discovered as a result of our exploration of Ritter-type 
amidation chemistry. In an attempt to produce an amide-containing analogue of GF, we planned to 
carry out a Ritter amidation-type process on the (bis)epoxide containing intermediate. That is to 
say, we planned to open the epoxides using acetonitrile in the presence of a Lewis acid and then, 
following hydrolysis, produce the corresponding acetamide. After one initial successful reaction 
which produced a very small amount of the desired acetamide-containing product, we were unable 
to reproduce the initial result. We then set about modifying the reaction conditions through 
experimentation with different solvents, additives and nitriles however to no avail. It became 
apparent fairly early on in this process, however, that another compound was consistently 
produced but its NMR spectra did not contain any of the characteristic peaks associated with the 
GF scaffold. This compound was, therefore, initially overlooked until it was realised how 






Scheme 52: Irreproducible Ritter-type amidation reaction 
 
3.1: Structural elucidation 
We initially started the structural elucidation process via traditional means. The 1H and 13C NMR 
spectra, as well as COSY, NOESY, HSQC and HMBC spectra, gave very few clues as to the overall 
structure of the compound as the spectra were very unlike anything encountered on this project 
before. It was clear, however, that the molecule contained 4 alkenic protons, 2 of which were 
probably part of a conjugated enone system, and two carbonyl groups. The IR spectrum gave no 
further information on functional groups present within the molecule and the mass spectrum 
returned a peak with the same mass as that of the starting material. Thus, it appeared to be a 
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structural isomer of the (bis)epoxide compound. As we were unable to progress further with the 
structural elucidation at this point, we turned to our NMR specialists within the department who 
recommended the use of an NMR structure elucidation software called “ACD/Structure Elucidator” 
which had been recently released by ACD labs. 
After analysis of the spectra by the software, a series of potential structures were generated; 
however, the compound with the least difference between the predicted and actual chemical shifts 
was chosen and therefore the gross structure was tentatively assigned (the software package does 
not attempt to deduce relative stereochemistry, only skeletal connectivity). Due to the obscure 
nature of the compound’s architecture and completely novel core ring system, we had no other 
similar compounds from the literature with which to compare our spectroscopic data and so the 






Scheme 53: Synthesis of compound 104 using acetonitrile and boron trifluoride diethyl etherate 
Subsequently, however, we were able to grow crystals of the compound and, after x-ray diffraction 
analysis, the crystal structure exactly resembled that of the predicted structure by the NMR 
structure elucidation software. Furthermore, the x-ray structure revealed the relative 








Figure 56: ORTEP representation of the structure of 104, as determined by x-ray crystallography. Ellipsoids 
are at 50% probability; H atoms are shown as spheres of arbitrary radius, plus line representation of structure. 
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Following the confirmation of the structure, we were, once again, able to assign more accurately 
the NMR spectra. Utilising all the experiments available to us, including 2D spectra, we were able 
to assign the compound as follows.  
The initial assignments were made to the two carbonyl carbons within the molecule, forming the 
two enone motifs. These carbons were identified due to their characteristic chemical shift and their 
decreased size, due to their quaternary nature. The two carbonyl carbons were therefore assigned 
at δ 202.5 and 192.0 ppm. Absolute assignment of each signal was possible due to HMBC 
interactions of the carbonyl carbon to the adjacent protons of the alkene. The exocyclic methylene 
protons have distinctive small coupling constants of ca. 1 Hz. As such, the exocyclic methylene 
protons, H15, were assigned at δ 5.61 and 6.19 ppm. A strong HMBC interaction with the carbonyl 
carbon at δ 202.5 ppm could be observed and therefore this signal was assigned as C1. The 
remaining carbonyl signal, δ 192.0 ppm, was assigned as C9 due to its HMBC interaction with the 
other alkenic signal, H11, at δ 7.08 ppm. The remaining alkenic signal at δ 6.02 ppm could therefore 
be assigned as H10. 
From HSQC interactions with the alkenic protons, we could also assign the alkene carbons. C15 was 
assigned at δ 121.4 ppm due to its strong interactions with the protons at H15. C2 was assigned at δ 
143.9 ppm due to it being the only alkenic single displaying no HSQC interactions, as well as being 
much smaller than the other peaks, due to it being a quaternary carbon. Protons H10,11, assigned at 
δ 7.08 and 6.02 ppm, enabled identification of the final two alkenic carbons through HSQC 
interactions. C10,11 were, therefore, assigned at δ 126.4 and 150.4 ppm respectively. 
We were also able to assign confidently the protons at position 13 due to their distinctive AB system 
pattern. Both protons present at this position appear as doublets as they are diastereotopic and 
hence inequivalent, however they also display “roofing” to each other due to second-order effects. 
These protons were, therefore, assigned at δ 4.03 and 4.08 ppm. Again using HSQC data, we were 
also able to assign C13 at δ 72.7 ppm. 
Due to an HMBC interaction between C15 and H3, we could assign this proton at δ 3.42 ppm. The 
carbon, C3, to which H3 was attached was then identified at δ 52.0 ppm due to an HSQC interaction. 
A further HMBC interaction between C9 and H6 allowed its assignment at δ 2.82 ppm, with C6 being 
assigned at δ 31.5 ppm due to an HSQC interaction. H5 was assigned due to a NOESY interaction 
with H13 at δ 2.65 ppm. This then allowed the assignment of C5 at δ 41.2 ppm due to an HSQC 
interaction with H5. H4 could then be assigned at δ 4.36 ppm due to a COSY interaction with the 
previously assigned proton H5. C4 was then assigned at δ 81.8 ppm due to an HSQC interaction with 
H4. A COSY interaction between the previously assigned H3 and H16 allowed its assignment at δ 4.57 
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ppm. C16 could then be assigned at δ 69.2 ppm due to an HSQC interaction. Finally, H7 was assigned 
at δ 2.61 ppm through a COSY interaction with H16 and C7 was assigned at δ 45.6 ppm due to an 





Figure 57: Compound 104 with atom labels 
 
3.2: Reaction optimisation 
Remarkably, this simple two-step process produced a novel hexacyclic compound, with a 3D 
architecture that had not been reported in the literature before, from cheap, humble salicyl alcohol. 
We set about performing a series of reactions in order to test its reproducibility, as well as, with the 
aim of increasing the yield. Initially, we set about sequentially removing reactants from the reaction 
mixture in order to elucidate which compounds were necessary for the transformation and what 








BF3.OEt2 (1.2 eq.), trifluoroethanol (1.2 eq.) 11% 
BF3.OEt2 (1.2 eq.) 14% 
Scheme 54: Initial optimisation of the synthesis of compound 104 
This series of reactions concluded that neither the additive trifluoroethanol, nor the nitrile, 
acetonitrile, was necessary for the production of compound 104. It was also found that by removing 
these reactants it had a very limited effect on yield, in fact, the yields produced remained fairly 
constant throughout this process. Even though they were less than optimal yields, it was 
98 
 
encouraging to discover that compound 104 was reproducibly formed and was stable to column 
chromatography, as well as, storage at room temperature. 
Once reproducibility has been established, the next stage of the process was to optimise the 
reaction conditions with the view of increasing the yield. A Master’s project student, Harry Hatton, 
was supervised by myself and we undertook the task of carrying out an optimisation programme 
examining reaction time, temperature and solvent.  
Firstly, we re-examined the use of additives and found concurrent results with what we had found 
previously. The best yield, 17%, was obtained from the use of no additives. 
Additive Yield 




Table 5: The effect of differing additives on the yield of compound 146. All other reaction conditions remain 
unchanged. 
 
The student then examined the effect of reaction time on the yield of compound 104 produced and 
discovered that the yield generally increased with time however plateaued at around 20 hours with 
further time adding no benefit to yield. The maximum yield obtained remained, however, at 17%. 
Reaction time Yield 
45 mins 8.5% 
1 hour 7.5% 
5 hours 10.0% 
18 hours 17.0% 
48 hours 16.0% 
 
Table 6: The effect of differing reaction time on the yield of compound 104. All other reaction conditions 
remain unchanged. 
 
We then examined the effect of differing reaction time on the yield of compound 104, however, 
this time, with the reaction carried out at room temperature. This showed a slightly different trend 
with the yield increasing up until 96 hours however this could possibly be due to the rate of reaction 




Temperature Reaction time Yield 
Room temp. 2 hours 4.5% 
Room temp. 24 hours 5.2% 
Room temp. 96 hours 13.2% 
 
Table 7: The effect of differing reaction time on the yield of compound 104 at room temperature. All other 
reaction conditions remain unchanged. 
 
The next parameter in the reaction we altered was solvent. The student set up a series of parallel 
reactions each under the same reaction conditions, however utilising differing solvents. It was 
found that none of the alternative solvents tested improved the yield already achieved with dry 
dichloromethane but it was also discovered that no product was produced in either THF or toluene. 
 
Temperature Solvent Yield 
Room temp. THF 0% 
Room temp. Toluene 0% 
Room temp. CHCl3 7.50% 
Room temp. CH2Cl2 (Wet) 12.40% 
 
Table 8: The effect of differing reaction solvent on the yield of compound 104 at room temperature. All other 
reaction conditions remain unchanged. 
 
 
Yet another series of reactions was set up to examine the effect of altering the acid used in the 
reaction on yield of compound 104 produced. Surprisingly, it was found that no other Lewis nor 
Brønsted acid tested produced compound 104 in any quantity.  
Temperature Lewis/Brønsted Acid Yield 
Room temp. AlCl3 0% 
Room temp. Cu(BF4)2 0% 
Room temp. TiCl4 0% 
Room temp. pTSA 0% 
 
Table 9: The effect of differing acid on the yield of compound 104 at room temperature. All other reaction 
conditions remain unchanged. 
 
Finally, the effect of reducing the equivalents of Lewis acid added to catalytic amounts was 
examined and it was found that, by reducing the equivalent of BF3.OEt2 to 0.2 from 1.2, the yield 
dropped to less than 1%. Implying that the BF3.OEt2 is required in stoichiometric quantities.  
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Lewis Acid Equivalents Yield 
BF3.OEt2 0.2 <1% 
BF3.OEt2 1.2 5.2% 
 
Table 10: The effect of differing equivalents of acid used on the yield of compound 104 at room temperature. 
All other reaction conditions remain unchanged. 
 
It was therefore concluded that, after an extensive optimisation programme examining all the key 
parameters of the reaction, no alteration increased the yield to greater than that achieved under 
the original reaction conditions. This was a disappointing result however it was encouraging to see 
that compound 104 was produced in increasing regularity under differing reaction conditions and 
by a different experimentalist. 
 
3.3: Structural analogue synthesis 
Following this result, we turned our attention to furthering our understanding of the reaction 
mechanism in a hope that it might shed some light on how to increase the yield further. Again, in 
conjunction with Master’s students Jonathon Wood and Ryan Stendall, we set about to design and 
synthesise a range of structural analogues of compound 104 which would hopefully give some 
indication as to its mechanism of formation.  The basic premise of this piece of work was that 
methylated variants of the salicyl alcohol (32), and therefore (bis)epoxide intermediate (39), would 
be synthesised which would then be used to create methylated versions of compound 104. By 
varying the position of the methyl group, it was hoped that we could establish which positions on 
the molecule were involved in the rearrangement process. If by replacing a proton with a methyl 
group, this halted or reduced the rate of reaction, then we could tentatively conclude that the 
proton at that position was necessary for the reaction to occur or that the increased steric bulk 
interfered with the reaction mechanism. 
The first task in this process was to synthesise a series of methylated salicyl alcohols as they were 
not routinely commercially available. Depending on which functional group was present on the 
methylated phenol, we carried out simple transformations in order to synthesise the desired 
compounds.  
Commencing with the synthesis of 2-(hydroxymethyl)-3-methylphenol (141), we methylated the 
commercially available 2-hydroxy-6-methylbenzoic acid (139) using methanol and concentrated 
sulfuric acid. This successfully produced methyl 2-hydroxy-6-methylbenzoate (140) in 47% yield. 
Following work-up and isolation of the product, it was deemed of high enough purity that no further 
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purification would be necessary. We therefore reduced the methyl 2-hydroxy-6-methylbenzoate 
using lithium aluminium hydride in anhydrous THF which successfully produced the desired 





Scheme 55: Synthesis of 2-(hydroxymethyl)-3-methylphenol (141) from 2-hydroxy-6-methylbenzoic acid 
(139) 
The next salicyl alcohol which we synthesised was 2-(hydroxymethyl)-4-methylphenol (143). This 
was a simpler process as we were able to purchase the corresponding aldehyde, 2-hydroxy-5-
methylbenzaldehyde (142), and therefore we only had to carry out a simple reduction using sodium 





Scheme 56: Synthesis of 2-(hydroxymethyl)-4-methylphenol (143) from 2-hydroxy-5-methylbenzaldehyde 
(142) 
 
Continuing the theme, we next synthesised 2-(hydroxymethyl)-5-methylphenol (146) in a two-step 
process similar to that for a previous methylated salicyl alcohol. We therefore methylated the 
commercially available 2-hydroxy-4-methylbenzoic acid (144) again utilising methanol and 
concentrated sulfuric acid to produce methyl 2-hydroxy-4-methylbenzoate (145) in 41% yield. Upon 
work-up and interrogation by NMR, it was decided that no further purification would be necessary 
due to the high levels of purity. We therefore reduced the ester with lithium aluminium hydride to 
produce 2-(hydroxymethyl)-5-methylphenol (146), following purification via column 







Scheme 57: Synthesis of 2-(hydroxymethyl)-5-methylphenol (146) from 2-hydroxy-4-methylbenzoic acid 
(144) 
 
The final methylated salicyl alcohol was synthesised via an identical two-step process to the 
previous molecule however the reduction step was carried out using lithium borohydride and not 
lithium aluminium hydride as before. This produced the desired 2-(hydroxymethyl)-6-methylphenol 




Scheme 58: Synthesis of 2-(hydroxymethyl)-6-methylphenol (149) from 2-hydroxy-3-methylbenzoic acid 
(147) 
 
With all of the methylated salicyl alcohols in hand, the next step was to synthesise the 
corresponding methylated (bis)epoxide intermediates using sodium periodate in water, following 
the previously published synthesis by Adler and Holmberg.117 The methylated alcohols were mixed 
with the oxidant, sodium periodate, in water at room temperature for 10 mins before being placed 
in the refrigerator (ca. 4 oC) overnight. Following work-up, the crude products were purified via 
recrystallization. This process produced 3 of the 4 methylated (bis)epoxides in varying yields 
however one compound, 2-(hydroxymethyl)-3-methylphenol, did not undergo the dimerisation 
process and remained as an unstable methylated epoxy-dienone (150). 
 
It is thought that having the methyl group adjacent to the primary alcohol in 2-(hydroxymethyl)-3-
methylphenol (141) created a steric clash which prevented the [4+2] Diels-Alder dimerisation 
process from occurring. The resulting epoxy-dienone (150) produced was very unstable and readily 
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decomposed upon purification and also upon storage. We were, therefore, unable to isolate the 














Scheme 59: Synthesis of methylated (bis)epoxide compounds ((±)-151-153) from their corresponding 
methylated salicyl alcohols 
 
We were able to confirm the identity of each methylated (bis)epoxide analogue utilising NMR 
spectroscopy, referencing the previous data from Adler and Holmberg,117 however we were also 










Figure 58: ORTEP representation of the structure of 153, as determined by x-ray crystallography. Ellipsoids 
are at 50% probability; H atoms are shown as spheres of arbitrary radius, plus line representation 
We then took the three successfully synthesised methylated (bis)epoxides and attempted to 
convert them into methylated analogues of compound 104 with the hope that it may cast some 







Scheme 60: Synthesis of compound (±)-154 utilising boron trifluoride diethyl etherate 
Starting with compound 154, we treated methylated (bis)epoxide 151 with boron trifluoride diethyl 
etherate in dichloromethane at reflux (ca. 40 oC) for 22 hours. Following work-up and purification 
via column chromatography, we were able to isolate successfully the corresponding methylated 
analogue of compound 104 in 17% yield. This yield was analogous to the one recorded for the 
parent compound and therefore it appears that having a methyl group at that position within the 
molecule has no effect on the mechanism of formation. 
This reaction, again, produced a structurally complex, novel compound with unusual 3D 
architecture and could form the beginnings of a structural library of compounds based upon the 
core structure of compound 104. 
Following the successful synthesis of the first methylated analogue of compound 104, we turned 
our attention to the other two methylated (bis)epoxide compounds, 152 and 153. We carried out 
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a similar process on both of these compounds, reacting them with boron trifluoride diethyl etherate 










Scheme 61: Synthesis of compounds (±)-155 & (±)-156 from their corresponding methylated (bis)epoxide pre-
cursors 
 
Compound 155 was produced in a 16% yield which, again, was very similar to that of the parent 
compound, 104, however compound 156 was produced in a much improved yield of 50%. This is a 
significant improvement on both that of the parent compound and also the other methylated 
analogues synthesised thus far. This was an unexpected, however, very interesting result. The aim 
of the analogue synthesis programme was the inverse of this result. We were hoping to identify 
methylated (bis)epoxide pre-cursors which decreased the yield or inhibited the formation of the 
desired product. We could, therefore, extrapolate from such a result that the carbon of the core 
scaffold, upon to which the methyl group was attached, was involved in the mechanism of 
formation of compound 104. Alternatively, the methyl group being at that position could cause a 
steric clash to adjacent positions and also decrease the yield.  
This result, however, implies that having a methyl group at the positions of those in compound 153, 
increases the conversion rate by somehow lowering the activation energy barrier and therefore 
allowing more molecules to react in the desired manner. Much more work needs to be carried out 
in order to understand this result, however one explanation could be that a carbocation is formed 
on one of the carbons upon which the methyl group is attached. This, therefore, converts the 
carbocation into a more substituted, and therefore more stable, ion which could in turn lower the 
activation energy barrier and therefore explain the increased yield of this compound. This in turn 
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would imply that those positions within compound 153 would be involved in the formation 
mechanism and therefore could lead further optimisation or computational work in this area. 
We were also able to gain an x-ray single crystal structure of compound 156 which confirmed the 










Figure 59: ORTEP representation of the structure of (±)-156, as determined by x-ray crystallography. Ellipsoids 
are at 50% probability; H atoms are shown as spheres of arbitrary radius, plus line representation 
 
3.4: Mechanism of formation 
We have also been working with a computational chemistry expert who has been conducting 
modelling work on our behalf in order to further elucidate a mechanism of formation for compound 
104. At the time of writing this thesis, no firm conclusions from the computational modelling could 
be drawn, however a summary of the work so far will be provided in the conclusion and future work 
section. 
Another potential mechanism, however, could utilise a semi-pinacol-like reaction, similar to that 
found in the synthesis of Ingenol by Tanino et al., as shown in scheme 62 below.118 This could either 
take place via a concerted mechanism, as shown, or step-wise. 
 
Scheme 62: Postulated mechanism of formation of compound (±)-104  
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4.0: Novel, triflate-containing compound 
The final unusual re-arrangement product which was discovered during the course of this project 
was compound 105. This compound was discovered as part of our efforts to optimise the yield of 
formation of compound 104 through experimentation with different Lewis acids. We discovered 
that if we treated the (bis)epoxide containing intermediate (39) with bismuth triflate, instead of 
boron trifluoride diethyl etherate, in dichloromethane at reflux (ca. 40 oC) then we repeatedly 
produced a compound which was easily isolated and stable under most conditions.  
 
4.1: Structural elucidation 
As this, again, turned out to be a novel rearranged compound, we struggled, at first, to identify the 
structure of this reoccurring compound through traditional means. We, again, turned to the NMR 
elucidation software “ACD/Structure Elucidator” from ACD labs which produced a series of 
potential structures with the best fit compound containing an alternative re-arrangement product 
with an interesting structure.  
Initially, we were sceptical of the predicted structure due to it containing an unusual cyclopropane 
ring. In conjunction with our colleagues in the NMR department, we conducted further NMR 
experiments in order to confirm the presence of a cyclopropane ring by analysing the coupling 
constants between the carbon and protons of the suspected cyclopropane. The 1JCH coupling 
constant between carbon and proton in a cyclopropane ring is very distinctive, typically ≈160 Hz, 
which is much greater than for any other ring type or acyclic C-H.119 Utilising this information, we 
set about to conduct an NMR experiment in order to measure the actual coupling constant. 
Unfortunately, we were unable to differentiate conclusively the relevant carbon peaks within the 
1H coupled 13C NMR spectrum due to overlap of the peaks. We, were, however able to measure the 
coupling constant using the “bleed-through” peaks present in the HMBC spectrum, as shown in 
figure 60 below. Utilising this method, we recorded the 1JCH values as 173.6 Hz and 180.0 Hz. 
Although this did not prove the presence of a cyclopropane beyond doubt, it did provide evidence 




Figure 60: HMBC spectra displaying the 1JCH for the cyclopropane ring 
We also conducted a series of heteroatom NMR experiments in order to confirm the presence of 
any other atoms within the molecule which were predicted by the NMR elucidation software. It was 
discovered that the molecule contained a fluorine environment and therefore it was tentatively 
confirmed that the molecule contained a triflate group. This was further confirmed through the use 
of mass spectrometry.  
Having exhausted all possible confirmatory processes utilising NMR spectroscopy, we attempted to 
grow crystals of the new product in order to elucidate unequivocally it’s structure. This was not 
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possible from the original rearranged product, 105, however, upon derivatization with 3,5-
dinitrobenzoic acid to produce compound 157, as shown below, we were able to grow successfully 




Scheme 63: Derivatization of compound (±)-105 with 3,5-dinitrobenzoic acid 
Despite our best efforts, we were never able to fully purify the derivatized product via silica gel 
column chromatography and the crystal which grew, containing the single product, was too small 
in order to gain any NMR data from it. However, we were able to gain our first crystal structure of 
the novel rearranged product, albeit derivatized, shown in figure 61 below. The structure was of 
low quality due to disorder in the region of the triflate group, however we were able to use the 
data to confirm the gross structure of the compound. Interestingly, we were again surprised to 
learn that the initial structure predicted by ACD/Structure Elucidator was indeed correct and the 








Figure 61: ORTEP representation of the structure (±)-157, as determined by x-ray crystallography. Ellipsoids 
are at 50% probability; H atoms are shown as spheres of arbitrary radius, plus line representation 
 
This x-ray structure, however disordered, enabled us to revisit the NMR spectra and assign the 
spectra more accurately. We could easily assign the carbonyl carbons and therefore use them as a 
handle to enable further assignments. The enone carbonyl carbon was assigned at δ 193.6 ppm due 
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to its upfield position in respect to the other carbonyl carbon. The ketone was, therefore, assigned 
at δ 205.1 ppm.  
Utilising these assignment, we were able to identify and assign the two methylene groups within 
the molecule utilising their HMBC interactions to the carbonyl carbons. The protons at H13 displayed 
the distinctive AB system pattern and were also remarkably downfield. They were assigned at δ 
4.84 and 4.99 ppm. The protons of the other AB system, H15, adjacent to the hydroxyl group, were 
assigned at δ 3.68 and 3.78 ppm. The carbons upon which these protons were attached could also 
be assigned from HSQC interactions. C13 was assigned at δ 73.4 ppm and C15 was assigned at δ 58.0 
ppm.  
The alkenic protons were, again, easily assigned due to their distinctive chemical shift and splitting 
pattern. This was confirmed through their HMBC interaction with C8. They were, therefore, assigned 
at δ 5.98 and 6.94 ppm. From splitting patterns, we could assign H9 at δ 5.98 ppm, due to it being a 
doublet, and H10 at δ 6.94 ppm, due to it being a double doublet. We could then extrapolate the 
alkenic carbons from HSQC interactions and they were assigned as C9 at δ 125.7 ppm and C10 at δ 
150.2 ppm.  
The more upfield protons and quaternary carbons were, again, harder to assign, however it was 
possible through analysis of the 2D NMR data. C7 was assigned at δ 73.8 ppm due to an HMBC 
interaction with the previously assigned H13. Although multiple HMBC interactions were present, it 
was possible to assign this carbon due to its signal being small, indicative of a quaternary carbon. 
H5 was assigned at δ 2.83 ppm due to a COSY interaction with the previously assigned C10. C5 could 
then be assigned at δ 41.0 ppm due to an HSQC interaction. H20 was assigned at δ 4.76 ppm due to 
its downfield chemical shift, a results of it being adjacent to an oxygen atom, and an HMBC 
interaction with C7. C20 was then assigned at δ 69.9 ppm due to an HSQC interaction. The other 
quaternary carbon, C2, was assigned at δ 41.9 ppm due to its HMBC interaction with H15 and its 
diminutive size. H4 was assigned at δ 3.06 ppm due to an HMBC interaction with C13 and C4 was 
assigned at δ 30.47 ppm due to an HSQC with the newly assigned H4. H3 could then be assigned at 
δ 2.42 ppm due to a COSY interaction with H4 and C3 was assigned at δ 28.0 ppm due to an HSQC 
interaction. A further COSY interaction between H3 and H19 allowed its assignment at δ 2.71 ppm 
with the corresponding carbon, C19, being assigned at δ 30.53 ppm due to an HSQC interaction. The 
final methine proton, H6, could then be assigned at δ 2.38 ppm due to a COSY interaction with H20, 
due to H19 now being assigned, and C6 could be assigned at δ 43.8 ppm due to an HSQC interaction. 
The carbon of the triflate group was then assigned at δ 119.6 ppm due to it being split into a quartet 








Figure 62: Compound (±)-105 with atom labels 
 
4.2: Reaction optimisation 
Following identification and assignment of the structure, we conducted a series of experiments in 
order to understand the conditions required for its formation. The initial reaction which produced 
compound 105 was an attempted Ritter amidation however this time utilising bismuth triflate as 






Scheme 64: Alternative Ritter amidation conditions utilising bismuth triflate which led to the discovery of 
compound (±)-105 
Interestingly, it was discovered that in the absence of acetonitrile, compound 105 was not produced 
at all. We, therefore, reinstated the acetonitrile into the reaction mixture, however this time, we 
used anhydrous acetonitrile and it was discovered that compound 105 was, again, not produced 
under these conditions. It could therefore be extrapolated that actually what was necessary for the 
formation of compound 105 was the presence of water. We conducted a series of experiments to 









Scheme 65: Synthesis of compound (±)-105 utilising bismuth triflate and water in dichloromethane 
This resulted in the production of the desired compound in roughly equivalent yield whilst 
maintaining all other reaction conditions the same, i.e. time, temperature and solvent. This 
confirmed that acetonitrile was definitely not necessary for production. We then went one step 
further and reduced the equivalents of bismuth triflate to a catalytic amount, i.e. 0.2 equivalents, 
however we discovered that compound 105 was not produced in any quantity. Following further 
experimentation, it was shown that compound 105 was only produced when the Lewis acid was 
used in stoichiometric amounts, i.e. 1 equivalent. 
From the discovery that water was necessary for the formation, we postulated that perhaps the 
water was involved in the hydrolysis of bismuth triflate to produce triflate anions. Although such 
species are not traditionally associated with nucleophilic behaviour, a recent review by Crich et al. 
detailed a number of examples where trifluoromethanesulfonate anions have been shown to act 
as nucleophiles and react with a number of electrophiles.120 In order to test this theory on our 
substrate, we reacted the (bis)epoxide-containing compound with triflic acid in dichloromethane 












4.3: Mechanism of formation 
Following the brief optimisation process, which concluded that only bismuth triflate and water was 
required for production of compound 105, we moved our attention to the mechanism of formation.  
We, therefore, embarked on a similar programme to that which we conducted with compound 104. 
That is to say, we synthesised a series of methylated analogues of compound 105 from their 
corresponding methylated (bis)epoxides (151-153). This was conducted in the hope that should the 
yield increase, decrease or the compound cease to be produced at all, then we could draw 
conclusions from that result. 
Utilising the previously synthesised methylated (bis)epoxides (151-153), we reacted each 
compound with one equivalent of bismuth triflate and one equivalent of water in dichloromethane 
at reflux (ca. 40 oC) for 18 hours. We were pleased to note that all the methylated (bis)epoxide 
compounds produced the desired methylated analogues of compound 105 in varying yields. The 






Scheme 67: Synthesis of compound (±)-158 from methylated (bis)epoxide (±)-151 
Compound 158 was successfully synthesised in 18% yield from the previously synthesised 
methylated (bis)epoxide 151. The yield of this compound was roughly half of that of the parent 
compound and therefore we could extrapolate from this result that having methyl groups at such 
positions was deleterious for the formation of compound 105. This could be due to the steric clash 
caused by the methyl group present on the alkene within the bicycle[2.2.2]octane subunit, shown 
by the use of a red arrow in scheme 68 below, as it is hypothesised that this alkene is involved in 






Scheme 68: Hypothesised mechanism of formation of compound (±)-105 showing the possible steric clash 
caused by the presence of the extra methyl group on the bridge head alkene 
 
Once the first methylated analogue of compound 105 had been successfully synthesised, we moved 












Scheme 70: Synthesis of compound (±)-160 from methylated (bis)epoxide (±)-153 
Both compounds 159 and 160 were successfully synthesised in a 33% yield which is very similar to 






4.4: Computational studies on mechanism of formation 
Again, we have been working with a computational chemist who has been conducting modelling 
work on our behalf in order to further elucidate a mechanism of formation for compound 105. As 
with compound 104, at present, no firm conclusions can be drawn from the computational data, 
however the work conducted so far will be presented in the conclusion and future work section. 
 
This piece of work has culminated in the discovery and synthesis of multiple novel compounds all 
containing unusual 3D structures. It has provided some tentative evidence towards a proposed 
mechanism of formation, plus it has demonstrated the robustness of our synthetic method. We 
were also able to grow crystals of one of the analogues, compound 160, of which our x-ray 
crystallographer was able to gain a high quality structure. This supersedes the previously gained x-
ray crystal structure which was of low quality due to disorder surrounding the triflate group and 









Figure 63: ORTEP representation of the structure (±)-160, as determined by x-ray crystallography. Ellipsoids 
are at 50% probability; H atoms are shown as spheres of arbitrary radius, plus line representation 
 
Further work would need to be conducted in order to describe confidently the mechanism of this 
reaction through, either further experimental work, or computational studies. It is, however, 
postulated that this compound may be an intermediate which is formed in the synthesis of 






4.5: Conclusions and future work 
This piece of work has successfully produced the principal aims which were set at the onset of this 
project, moreover it has also discovered a series of novel compounds with unusual architectures 
and previously unreported syntheses. The principal aims of this project were to produce a series of 
analogues based upon the (+)−grandifloracin (53) scaffold exploring medicinal chemistry principles. 
The analogues were to contain a variety of functional groups whilst maintaining the perceived 
pharmacophore of the molecule, the core fused ring structure. Exploration of a variety of synthetic 
methods to (+)−grandifloracin identified a single route, through which we synthesised a range of 
compounds which altered the steric and electronic parameters of the initial molecule. This allowed 
us to test our pro-drug hypothesis whereby the R-group moieties were hydrolysed in vivo to 







Scheme 71: Hypothesised in vivo metabolism of GF to active “tetra-ol” compound 
We initially focused on modifying the electronic parameters of the ester containing R-group moiety 
of the molecule in order to assess the effect this could have on the hydrolysis of the moiety. 
Therefore, a series of compounds containing either electron-donating or -withdrawing substituents 
on the benzene ring of the ester motif were synthesised. This would in turn affect the polarity of 
the ester carbonyl group and, therefore, the rate of hydrolysis, if indeed this process was occurring 
at all.  
We then broadened our approach in an attempt to test the hypothesis further by exploring 
chemistries which would substitute the traditional ester containing R-group for an amide or 
thioester group. Again, this would affect the rate of hydrolysis of the R-groups and could provide 
evidence towards, or against, our hypothesis. Due to the inherent instability of the thioester-
containing compounds, we were not able to synthesise and purify such molecules. We did, 
however, gain success towards the synthesis of an amide-containing R-group. We were able to 
synthesise an azide-containing R-group compound, from which, one could postulate a short series 
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Scheme 72: Synthesis of amide containing R-group GF analogue 
These compounds were then added to a library of analogues synthesised by other members of the 
Lewis group and, through our collaborator in Japan, the molecules were tested for their anti-
austerity properties against PANC-1 pancreatic cancer cells which had been cultured under nutrient 
deprived conditions. This biological testing identified 5 of the most active analogues, as shown in 
table 11 below, some of which displayed activities greater than (+)-grandifloracin, some an order 
























Table 11: PC50 values of 5 most active racemic analogues of 53 
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As well as identifying the most active GF analogues synthesised by the group, the biological testing 
also allowed us to reject our pro-drug hypothesis as the most active compound 120 didn’t contain 
an ester or amide R-group motif. Therefore, our hydrolysis model, which produced the proposed 
active tetra-ol compound 40, was shown to be incorrect. 
The future work for this arm of the project would be to focus on the two most active analogues, 
compounds 85 and 120. Throughout the course of this project, the syntheses employed have 
resulted in racemic molecules being produced and therefore the activities above are not a true 
reflection of their potential anti-austerity activity. Compounds 85 and 120 should, therefore, be 
synthesised utilising the previously published method by Palframan et al.74 and then their biological 
activities re-assessed. Another future project should focus on developing the two most active 
compounds further through the synthesis of compounds 122 and 123, as second-generation 







Figure 64: Proposed second generation GF analogues 
The second arm of this project focused on the discovery and exploitation of novel methodologies 
and compounds containing unusual 3D architectures. Chapter 4 previously detailed the work 











Figure 65: unusual re-arrangement products synthesised during the course of this work 
Compound 118 was of note due to its potential in the production of differentiated analogues of GF 
which, until now, have been unobtainable. Compounds 104 and 105 were unexpected and 
significant results from this project. They are compounds which contain unique 3D architectures 
and are produced through novel synthetic methodologies. The simple 2 step synthesis and 
unprecedented nature of these compounds make them exciting molecules for further exploitation.  
Computational work in order to elucidate the mechanism of formation for compounds 104 and 105 
has been started, however no firm conclusions can be drawn at this stage. Schemes 73 and 74 below 











































































































Scheme 73 details the proposed mechanism of formation for compound 104 however it requires 
further refinement as, currently, the two energy barriers between TS1, TS2 and TS3 are too high 
for the reaction conditions. Although not complete, this piece of work has already shown promise 
with the identification of a number of intermediates or transition states with unexpected 
architectures. With further work, the computational modelling will, hopefully, conclude a 
mechanism of formation for this unusual compound.  
Scheme 74, again, details the current hypothesised mechanism of formation for compound 105, 
which requires further work due to the transition energy barriers between TS4, TS5 and TS6 being 
too high under the reaction conditions, however it provides an interesting starting point from which 
further refinement can be conducted. For computational methodology, see appendix. 
Future work should include completion of the computational modelling for compounds 104 and 
105 which would provide another key piece of information for these unprecedented compounds. 
Another future step would be to submit both 104 and 105 for biological evaluation in order to 
evaluate whether the compounds have any biological activity, towards pancreatic cancer or 
otherwise. 
In conclusion, this project has made significant progress in the development of (+)−grandifloracin 
(53) as a potential chemotherapeutic for pancreatic cancer. As a result, we have identified a lead 
compound for further optimisation in second generation analogue development and further 
understood (+)-grandifloracin’s structure-activity relationships. Through further work, as 
highlighted above, a lead candidate could be developed which could then be subjected to the next 















Chapter 5: Experimental 
General conditions 
All reactions were carried out under an atmosphere of N2 or argon, through the use of a Schlenk 
line, unless otherwise stated. Anhydrous solvents were either purchased from Fisher Scientific or 
Sigma-Aldrich, or purified through anhydrous alumina columns using an Innovative Technology Inc. 
PS-400-7 solvent purification system. Solvents were deoxygenated either by channelling a stream 
of N2 through the liquid (sparging), or by the freeze-thaw-pump method. Thin layer 
chromatography (TLC) was carried out on aluminium plates coated with silica gel (Alugram®SIL 
G/UV 254 nm), and visualisation was achieved with UV light or KMnO4, ceric ammonium molybdate 
and iodine dips, followed by gentle heating. Solvents were removed using Büchi rotary evaporators 
and with high vacuum on a Schlenk line. Flash column chromatography was carried out using Davisil 
LC 60 Å silica gel (35-70 micron) purchased from Sigma-Aldrich.  
 
NMR spectra were run in CDCl3 unless otherwise stated, on Bruker Avance 250, Bruker Avance 300, 
Bruker Avance 400, Bruker Avance 500 II+ or Agilent A500a instruments. IR spectra were recorded 
on a Perkin-Elmer 1600 FT-IR instrument. Capillary melting points were recorded on a Büchi 535 
melting point apparatus, and are uncorrected. High resolution mass spectrometry (HRMS) was 
carried out using a micrOTOF ESI-TOF spectrometer coupled to an Agilent 1200 LC system for 
autosampling. X-ray crystallography was carried out on a Nonius Kappa CCD diffractometer with 

















To a stirred solution of 2-hydroxybenzyl alcohol (32, 3.75 g, 30.2 mmol, 1 eq.) in dichloromethane 
(100 mL) at 0 oC was added benzoyl chloride (3.51 mL, 30.2 mmol, 1 eq.) followed by the dropwise 
addition of pyridine (2.44 mL, 30.2 mmol, 1 eq.). The resulting solution was then stirred at 0 oC for 
1 h before being allowed to warm to room temperature (ca. 21 oC) and stirred for a further 2 hours. 
The solvent was removed in vacuo and the crude mixture was purified by column chromatography 
(SiO2), eluting with petrol: ethyl acetate (19:1 → 3:1) to give the desired product (33) as a white, 
waxy solid, 3.48 g (68% yield): Rf 0.45 (1:1 petrol: ethyl acetate); 1H NMR (CDCl3, 250 MHz) δ ppm 
8.23 (br s, 1H), 8.12 (d, J = 7.6 Hz, 2H), 7.54-7.34 (m, 5H), 7.12-6.95 (m, 2H), 5.45 (s, 2H); Data in 







To a stirred solution of 2-hydroxybenzyl benzoate (33, 2.04 g, 8.94 mmol, 1 eq.) in anhydrous 
tetrahydrofuran (THF) (24 mL) was added stabilised 2-iodoxybenzoic acid (SIBX) (6.12 g, 9.84 mmol 
of IBX, 1.1 eq.) as a solid in one portion. The resulting suspension was stirred at room temperature 
(ca. 21 oC) for 23 h, after which time trifluoroacetic acid (0.68 mL, 8.94 mmol, 1 eq.) was added and 
stirred for a further 4 hours. The reaction mixture was then diluted with dichloromethane (100 mL) 
and H2O (50 mL). An aqueous solution of NaHCO3 was added slowly, with shaking, until all the acid 
had been neutralised. The aqueous phase was extracted with dichloromethane (2 x 50 mL). The 
combined organic phases were then washed with NaHCO3 (50 mL), H2O (50 mL), brine (50 mL) and 
then vigorously shaken with an aqueous 1M solution of Na2S2O3 (50 mL), washed again with brine 
(50 mL) and dried over MgSO4, filtered and the solvent evaporated in vacuo to give a dark brown 
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oil. The crude mixture was then purified by column chromatography (SiO2), eluting with 
hexanes:acetone (6:1 → 2:1) and then recrystallized from a mixture of dichloromethane and 
hexanes to give the desired product as a white solid, 1.11 g (50% yield) Rf 0.32 (2:1 petrol: ethyl 
acetate); m.p. 175 – 176 oC (lit. m.p. 161 – 163 oC71); 1H NMR (CDCl3, 250 MHz) δ 8.09-8.03 (m, 2H), 
7.96-7.90 (m, 2H), 7.63-7.51 (m, 2H), 7.50-7.38 (m, 4H), 6.59 (dd, J = 10.1, 4.1 Hz, 1H), 6.44 (ddd, J 
= 8.1, 6.6, 1.3 Hz, 1H), 6.21 (dd, J = 10.1, 1.6 Hz, 1H), 6.02 (ddd, J = 8.0, 6.0, 1.6 Hz, 1H), 5.30 (s, 1H), 
4.47 (d, J = 11.9 Hz, 1H), 4.36 (m, 2H), 4.23 (d, J = 11.9 Hz, 1H), 3.68 (dt, J = 6.7, 1.9 Hz, 1H), 3.49-







2-Hydroxybenzyl alcohol (32, 1.99 g, 16.0 mmol, 1 eq.) was dissolved in water (120 mL). A solution 
of sodium periodate (3.76 g, 17.6 mmol, 1.1 eq.) in water (40 mL) was added. The mixture was 
stirred at room temperature (ca. 21 oC) for 10 minutes and then placed in the refrigerator (ca. 4 oC) 
for 24 h. The solid was filtered off and washed with cold water. The filtrate was extracted with ethyl 
acetate (3 x 50 mL). The organic phase was dried over MgSO4 and concentrated to dryness. The 
solids were combined and recrystallised from chloroform to give the desired product as a fine white 
solid,  1.21 g (62% yield): Rf 0.27 (3:1 petrol: ethyl acetate); m.p. 198 – 200 oC; 1H NMR (CDCl3, 500 
MHz) δ ppm 6.68 (dd, J = 10.2, 4.3 Hz, 1H), 6.64 (dddd, J = 8.1, 6.5, 1.4, 0.6 Hz, 1H), 6.22 (dd, J = 
10.2, 1.7 Hz, 1H), 6.15 (dddd, J = 8.1, 6.2, 1.7, 0.6 Hz, 1H), 3.57 (dddd, J = 8.9, 4.2, 2.3, 1.7, 0.6 Hz, 
1H), 3.51 (ddd, J = 6.3, 2.3, 1.4 Hz, 1H), 3.17 (d, J = 6.1 Hz, 1H), 2.96 (d, J = 6.6 Hz, 1H), 2.95-2.92 (m, 









Dispiro[oxirane-2,3'-tricyclo[6.2.2.0²,⁷]dodecane-10',2''-oxirane]-5',11'-diene-4',9'-dione (39, 0.24 
g, 1.00 mmol) was dissolved in water (10 mL) and stirred at 60 OC for 48 h until all the solid had 
reacted. After which time, toluene (2 mL) was added and the combined solvents were removed in 







To a stirred solution of 2-hydroxybenzyl alcohol (32, 0.50 g, 4.03 mmol, 1 eq.) in dichloromethane 
(10 mL) was added 4-(trifluoromethyl)benzoyl chloride (0.61 mL, 4.03 mmol, 1 eq.) followed by the 
dropwise addition of pyridine (0.33 mL, 4.03 mmol, 1 eq.). The resulting solution was then stirred 
at room temperature (ca. 21 oC) for 4 h. The reaction was quenched by the addition of water (6 mL) 
and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate (20 mL) and 
washed with a saturated aqueous solution of NaHCO3 (2 x 20 mL) and brine (20 mL). The organic 
phases were then combined and dried over MgSO4, filtered and the solvent removed in vacuo. The 
crude mixture purified by column chromatography (SiO2), eluting with pentane: ethyl acetate (9:1 
→ 1:1) to give the desired product as a white solid, 0.41 g (35% yield): Rf 0.34 (3:1 pentane: ethyl 
acetate); m.p. 86-89 oC (pentane:ethyl acetate); νmax/cm-1 (ATR) 3343 (bs), 1710 (s); 1H NMR (CDCl3, 
500 MHz) δ ppm 8.17 (d, J = 7.7 Hz, 2H), 7.73 (s, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.39 (dd, J = 7.6, 1.7 
Hz, 1H), 7.30 (ddd, J = 8.1, 7.3, 1.7 Hz, 1H), 6.99-6.96 (m, 2H), 5.44 (s, 2H); NMR (CDCl3, 500 MHz) δ 
ppm 167.4, 155.5, 135.0 (q, J = 32.8 Hz, 1C), 132.1, 131.3, 130.4, 125.6 (q, J = 3.8 Hz, 1C), 122.8 (q, 
J = 272.3 Hz, 1C), 121.6, 120.9, 117.6, 64.2; 19F NMR (CDCl3, 500 MHz) δ ppm -63.2 (s, 1F); ESI-MS 










To the crude 5,9-dihydroxy-5,9-bis(hydroxymethyl)-1,4a,5,8a-tetrahydro-1,4-ethanonaphthalene-
6,10(4H)-dione (40, 0.28 g, 1.00 mmol) in dichloromethane (20 mL) at 0 oC was added 4-
(trifluoromethyl)benzoyl chloride (0.30 mL, 2.00 mmol, 2 eq.), followed by the dropwise addition 
of pyridine (0.32 mL, 4.00 mmol, 4 eq.). The resulting solution was stirred at 0 oC for 1 h before 
being allowed to warm to room temperature (ca. 21 oC) and stirred for a further 4 h. After which 
time, the reaction mixture was washed with a saturated, aqueous solution of NaHCO3 (2 x 20 mL), 
water (20 mL), brine (20 mL), dried over MgSO4, filtered and the solvent was removed in vacuo. The 
crude mixture was then purified by column chromatography (SiO2), eluting with petrol:EtOAc (6:1 
→ 1:1), and then recrystallized from chloroform to give the desired product as a white solid, 60.0 
mg (20% yield): Rf 0.72 (1:1 petrol:ethyl acetate); m.p. 186-188 oC (petrol:EtOAc); νmax/cm-1 (ATR) 
3422 (bs), 1712 (s), 1710 (s); 1H NMR (CDCl3, 500 MHz) δ ppm 8.17 (d, J = 8.1 Hz, 2H), 8.04 (d, J = 
8.2 Hz, 2H), 7.74 (d, J = 8.2 Hz, 2H), 7.69 (d, J = 8.5 Hz, 2H), 6.61 (dd, J = 10.1, 4.3 Hz, 1H), 6.44 (ddd, 
J = 8.1, 6.7, 1.3 Hz, 1H), 6.22 (dd, J = 10.1, 1.6 Hz, 1H), 6.04 (ddd, J = 7.8, 6.1, 1.6 Hz, 1H), 4.50 (d, J 
= 11.9 Hz, 1H), 4.41 (d, J = 1.7 Hz, 2H), 4.33 (s, 1H), 4.26 (d, J = 11.9 Hz, 1H), 3.68 (dt, J = 6.6, 1.9 Hz, 
1H), 3.45 (ddt, J = 8.3, 4.1, 1.8 Hz, 1H), 3.41 (ddd, J = 6.1, 2.3, 1.3 Hz, 1H), 3.36 (dt, J = 8.5, 2.2 Hz, 
1H), 3.15 (s, 1H); 13C NMR (CDCl3, 500 MHz) δ ppm 208.2, 198.0, 165.6, 164.7, 146.9, 135.1 (q, J = 
32.7 Hz, 1C), 135.0 (q, J = 33.1 Hz, 1C) 134.9, 132.7, 132.6, 130.4, 130.3, 128.8, 128.2, 125.73 (q, J = 
3.6 Hz, 1C), 125.70 (q, J = 3.9 Hz, 1C), 123.7 (q, J = 273.0 Hz, 2C) 75.5, 74.5, 72.2, 68.8, 52.3, 41.1, 
40.1, 37.4; 19F NMR (CDCl3, 500 MHz) δ ppm -63.3 (s, 1F), -63.2 9s, 1F); ESI-MS [M + Na]+ m/z 










To a stirred solution of 2-hydroxybenzyl alcohol (32, 0.50 g, 4.03 mmol, 1 eq.) in dichloromethane 
(10 mL) was added 4-fluorobenzoyl chloride (0.48 mL, 4.03 mmol, 1 eq.) followed by the dropwise 
addition of pyridine (0.33 mL, 4.03 mmol, 1 eq.). The resulting solution was then stirred at room 
temperature (ca. 21 oC) for 4 h. The reaction was quenched by the addition of water (6 mL) and the 
solvent was removed in vacuo. The residue was dissolved in ethyl acetate (20 mL) and washed with 
a saturated aqueous solution of NaHCO3 (2 x 20 mL) and brine (20 mL). The organic phases were 
then combined and dried over MgSO4, filtered and the solvent removed in vacuo. The crude mixture 
purified by column chromatography (SiO2), eluting with pentane: ethyl acetate (9:1 → 1:1) to give 
the desired product as a white solid, 246 mg (44% yield): Rf 0.29 (3:1 pentane : ethyl acetate); m.p. 
82-84 oC; νmax/cm-1 (ATR) 3345 (bs), 1699 (s); 1H NMR (CDCl3, 500 MHz) δ ppm 8.08 (m, 2H), 7.98 
(bs, 1H), 7.36 (dd, J = 7.6, 1.8 Hz, 1H), 7.29 (ddd, J = 8.0, 7.3, 1.7 Hz, 1H), 7.11 (m, 2H), 6.95 (m, 2H), 
5.37 (s, 2H); 13C NMR (CDCl3) δ ppm 167.6 (d, J = 83.0 Hz, 1C), 165.3, 155.8, 132.7 (d, J = 9.5 Hz, 1C), 
132.4, 131.1, 125.6 (d, J = 3.2 Hz, 1C), 121.7, 120.8, 118.0, 115.8 (d, J = 22.0 Hz, 1C), 64.0; 19F (CDCl3, 
















To the crude 5,9-dihydroxy-5,9-bis(hydroxymethyl)-1,4a,5,8a-tetrahydro-1,4-ethanonaphthalene-
6,10(4H)-dione (40, 0.28 g, 1.00 mmol, 1 eq.) in dichloromethane (10 mL) at room temperature was 
added 4-fluorobenzoyl chloride (0.26 mL, 2.20 mmol, 2.2 eq.), DMAP (0.01 g, 0.05 mmol, 0.05 eq.) 
and the dropwise addition of triethylamine (0.56 mL, 4.00 mmol, 4 eq.). The resulting solution was 
stirred at room temperature (ca. 21 oC) for 24 h. After which time, the solvent was removed in 
vacuo and the residue partitioned between ethyl acetate (25 mL) and water (25 mL). The organic 
layer was washed with dilute HCl (0.1 M, 25 mL), water (25 mL), brine (25 mL), dried over MgSO4, 
filtered and the solvent removed in vacuo. The crude mixture was then purified by column 
chromatography (SiO2), eluting with petrol:EtOAc (4:1 → 1:1), and then recrystallized from 
chloroform and petrol to give the desired product as a white solid, 0.09 g (40% yield): Rf; 0.33 
(petrol: EtOAc 1:1) m.p. 185-189 oC (petrol:EtOAc); νmax/cm-1 (ATR) 3461 (bs), 1724 (s), 1687 (s); 1H 
NMR (CDCl3, 500 MHz) δ ppm 8.09-8.05 (m, 2H), 7.96-7.93 (m, 2H), 7.15-7.12 (m, 2H), 7.11-7.08 (m, 
2H), 6.59 (dd, J = 10.2, 4.3 Hz, 1H), 6.43 (ddd, J = 8.0, 6.6, 1.3 Hz, 1H), 6.21 (dd, J = 10.1, 1.7 Hz, 1H), 
6.02 (ddd, J = 8.0, 6.1, 1.6 Hz, 1H), 4.45 (d, J = 11.9 Hz, 1H), 4.40 (d, J = 11.2 Hz, 1H), 4.36 (d, J = 11.2 
Hz, 1H) 4.31 (s, 1H), 4.22 (d, J = 11.9 Hz, 1H), 3.66 (dt, J = 6.6, 1.9 Hz, 1H), 3.44 (ddt, J = 8.4, 4.1, 1.9 
Hz, 1H), 3.39 (ddd, J = 6.2, 2.3, 1.3 Hz, 1H), 3.35 (dd, J = 8.5, 2.2 Hz, 1H), 3.21 (s, 1H); 13C NMR (CDCl3, 
500 MHz) δ ppm 208.2, 198.2, 146.8, 135.2, 132.5 (dd, J = 22.3, 9.5 Hz, 1C), 128.4 (d, J = 67.7 Hz, 
1C), 115.9 (dd, J = 22.2, 8.8 Hz, 1C), 75.5, 74.6, 68.5, 52.3, 41.2, 40.1, 37.4; 19F NMR (CDCl3, 500 











To a stirred solution of 2-hydroxybenzyl alcohol (32, 0.50 g, 4.03 mmol, 1 eq.) in dichloromethane 
(20 mL) was added nicotinoyl chloride (0.72 g, 4.03 mmol, 1 eq.) followed by the dropwise addition 
of triethylamine (0.73 mL, 16.1 mmol, 4 eq.). The resulting solution was then stirred at room 
temperature (ca. 21 oC) for 4 h. The reaction was quenched by the addition of water (6 mL) and the 
solvent was removed in vacuo. The residue was dissolved in ethyl acetate (20 mL) and washed with 
a saturated aqueous solution of NaHCO3 (2 x 20 mL) and brine (20 mL). The organic phases were 
then combined and dried over MgSO4, filtered and the solvent removed in vacuo. The crude mixture 
was purified by column chromatography (SiO2), eluting with pentane: ethyl acetate (1:1) to give the 
desired product as a white solid, 0.36 g (40% yield): Rf  0.31 (petrol:EtOAc 1:1); m.p 216 oC 
(petrol:EtOAc); νmax/cm-1 (ATR) 3460 (s), 1731 (s); 1H NMR (CDCl3, 500 MHz) δ ppm 9.25 (dd, J = 2.2, 
0.9 Hz, 1 H), 8.79 (dd, J = 4.9, 1.8 Hz, 1 H), 8.34 (dt, J = 8.0, 2.0 Hz, 1H), 7.41 (ddd, J = 8.0, 4.9, 1.0 
Hz, 1H) 7.37 (dd, J = 7.6, 1.7 Hz, 1H), 7.29-7.26 (m, 1 H), 6.98-6.92 (m, 2H), 5.43 (s, 2H); 13C NMR 
(CDCl3) δ ppm 167.1, 155.7, 153.8, 151.2, 137.7, 132.3, 131.3, 125.9, 123.6, 121.5 120.7, 117.6, 












To the crude 5,9-dihydroxy-5,9-bis(hydroxymethyl)-1,4a,5,8a-tetrahydro-1,4-ethanonaphthalene-
6,10(4H)-dione (40, 0.28 g, 1.00 mmol, 1 eq.) in dichloromethane (20 mL) at room temperature was 
added nicotinoyl chloride (0.39 mL, 2.20 mmol, 2.2 eq.), DMAP (0.01 g, 0.05 mmol, 0.05 eq.) and 
the dropwise addition of triethylamine (0.56 mL, 4.00 mmol, 4 eq.). The resulting solution was 
stirred at room temperature (ca. 21 oC) for 22 h. After which time, the solvent was removed in 
vacuo and the residue partitioned between ethyl acetate (25 mL) and water (25 mL). The organic 
layer was washed with dilute, aqueous HCl (0.1 M, 25 mL), water (25 mL), brine (25 mL), dried over 
MgSO4, filtered and the solvent removed in vacuo. The crude mixture was then purified by column 
chromatography, eluting with dichloromethane and 1% methanol to give the desired product as a 
cream solid, 0.11 g (29% yield): Rf; 0.56 (CH2Cl2 + 1% MeOH) m.p. 220-224 oC (CH2Cl2:methanol); 
νmax/cm-1 (ATR) 3460 (s), 1731 (s), 1688 (s); 1H NMR (CD2Cl2, 500 MHz) δ ppm 9.07 (dd, J = 2.2, 0.9 
Hz, 1H), 8.76 (dd, J = 4.9, 1.7 Hz, 1H), 8.17 (dt, J = 7.9, 2.0 Hz, 1H), 7.39 (ddd, J = 8.0, 4.9, 0.9 Hz, 1H), 
6.66 (dd, J = 10.3, 4.3 Hz, 1H), 6.43 (ddd, J = 8.2, 6.8, 1.4 Hz, 1H), 6.22 (dd, J = 10.1, 1.8 Hz, 1H), 6.03 
(ddd, J = 8.0, 6.0, 1.5 Hz, 1H), 4.44 (d, J = 11.1 Hz, 1H), 4.39 (d, J = 11.1 Hz, 1H), 4.31 (s, 1H), 3.54.3.52 
(m, 1H), 3.48 (ddd, J = 6.3, 2.5, 1.4 Hz, 1H), 3.14 (dt, J = 6.6, 2.0 Hz, 1H), 3.10 (d, J = 6.2 Hz, 1H), 3.05 
(dd, J = 8.5, 2.1 Hz, 1H), 2.92 (d, J = 6.1 Hz, 1H). 13C NMR (CD2Cl2, 500 MHz) δ ppm 204.2, 198.1, 
165.0, 154.4, 151.4, 147.8, 130.0, 128.5, 125.9, 123.9, 76.0, 72.3, 58.6, 41.5, 40.1, 39.5; ESI-MS [M-















To the crude 5,9-dihydroxy-5,9-bis(hydroxymethyl)-1,4a,5,8a-tetrahydro-1,4-ethanonaphthalene-
6,10(4H)-dione (40, 0.28 g, 1.00 mmol, 1 eq.) in dichloromethane (10 mL) at room temperature was 
added 3,4,5-trimethoxybenzoyl chloride (0.51 g, 2.20 mmol, 2.2 eq.), DMAP (0.01 g, 0.05 mmol, 
0.05 eq.) and the dropwise addition of triethylamine (0.56 mL, 4.00 mmol, 4 eq.). The resulting 
solution was stirred at room temperature (ca. 21 oC) for 22 h. After which time, the solvent was 
removed in vacuo and the residue partitioned between ethyl acetate (25 mL) and water (25 mL). 
The organic layer was washed with dilute HCl (0.1 M, 25 mL), water (25 mL), brine (25 mL), dried 
over MgSO4, filtered and the solvent removed in vacuo. The crude mixture was then purified by 
column chromatography (SiO2), eluting with petrol:EtOAc (2:1 → 1:1) and recrystallized from 
dichloromethane to give the desired product as a white solid, 0.07 g (10% yield): Rf; 0.16 
(petrol:EtOAc 1:1)) m.p. 171-173 oC (dec., dichloromethane); νmax/cm-1 (ATR) 3446 (bs), 1716 (s), 
1588 (s); 1H NMR (CDCl3, 500 MHz) δ ppm 7.30 (s, 2H), 7.18 (s, 2H), 6.60 (dd, J = 10.1, 4.3 Hz, 1H), 
6.43 (ddd, J = 8.1, 6.6, 1.3 Hz, 1H), 6.21 (dd, J = 10.1, 1.6 Hz, 1H), 6.02 (ddd, J = 7.8, 6.0, 1.4 Hz, 1H), 
4.43 (d, J = 11.9 Hz, 1H), 4.38 (d, J = 11.1 Hz, 1H ), 4.32 (d, J = 11.2 Hz, 1H), 4.30 (s, 1H), 4.25 (d, J = 
11.9 Hz, 1H), 3.92 (s, 6H), 3.91 (s, 3H), 3.89 (s, 3H), 3.89 (s, 6H), 3.65 (dt, J = 6.7, 1.9 Hz, 1H), 3.45-
3.43 (m, 1H), 3.40-3.36 (m, 1H), 3.34 (s, 1H); 13C NMR (CDCl3, 500 MHz) δ ppm 208.2, 198.3, 166.6, 
165.5, 153.1, 146.8, 142.7, 135.2, 128.6, 128.2, 124.3, 107.3, 107.1, 75.6, 74.7, 72.0, 68.7, 61.1, 











To the crude 5,9-dihydroxy-5,9-bis(hydroxymethyl)-1,4a,5,8a-tetrahydro-1,4-ethanonaphthalene-
6,10(4H)-dione (40, 0.28 g, 1.00 mmol, 1 eq.) in dichloromethane (10 mL) at room temperature was 
added trimethylacetyl chloride (0.27 mL, 2.20 mmol, 2.2 eq.), DMAP (0.01 g, 0.05 mmol, 0.05 eq.) 
and the dropwise addition of triethylamine (0.56 mL, 4.00 mmol, 4 eq.). The resulting solution was 
stirred at room temperature (ca. 21 oC) for 20 h. After which time, the solvent was removed in 
vacuo and the residue partitioned between ethyl acetate (25 mL) and water (25 mL). The organic 
layer was washed with dilute HCl (0.1 M, 25 mL), water (25 mL), brine (25 mL), dried over MgSO4, 
filtered and the solvent removed in vacuo. The crude mixture was then purified by column 
chromatography (SiO2), eluting with dichloromethane plus 1% methanol to give the desired product 
as a white solid, 0.08 g (19% yield). Rf; 0.23 (CH2Cl2 + 1% MeOH) m.p.158-161 oC (CH2Cl2:MeOH); 
νmax/cm-1 (ATR) 3451 (bs), 1719 (s), 1695 (s); 1H NMR (CDCl3, 500 MHz) δ ppm 6.54 (dd, J = 10.1, 4.3 
Hz, 1H), 6.34 (ddd, J = 8.2, 6.6, 1.3 Hz, 1H), 6.14 (dd, J = 10.1, 1.7 Hz, 1H), 5.96 (ddd, J = 7.9, 6.1, 1.6 
Hz, 1H), 4.25 (d, J = 12.0 Hz, 1H), 4.19 (d, J = 11.2 Hz, 1H), 4.17 (s, 1H), 3.92 (d, J = 12.0 Hz, 1H), 3.36 
(ddt, J = 8.4, 4.2, 2.0 Hz, 1H), 3.50 (dt, J = 6.6, 2.0 Hz, 1H), 3.31 (ddd, J = 6.2, 2.4, 1.4 Hz, 1H), 3.22 
(dd, J = 8.5, 2.1 Hz, 1H), 3.15 (s, 1H), 1.22 (s, 9H), 1.13 (s, 9H); 13C NMR (CDCl3, 500 MHz) δ ppm 
208.2, 198.1, 179.0, 178.0, 146.5, 135.1, 128.6, 128.1, 75.6, 74.6, 71.3, 67.9, 52.3, 41.1, 40.1, 39.1, 











To the crude 5,9-dihydroxy-5,9-bis(hydroxymethyl)-1,4a,5,8a-tetrahydro-1,4-ethanonaphthalene-
6,10(4H)-dione (40, 0.28 g, 1.00 mmol, 1 eq.) in dichloromethane (10 mL) at room temperature was 
added cyclopentane carbonyl chloride (0.27 mL, 2.20 mmol, 2.2 eq.), DMAP (0.01 g, 0.05 mmol, 
0.05 eq.) and the dropwise addition of triethylamine (0.56 mL, 4.00 mmol, 4 eq.). The resulting 
solution was stirred at reflux (40 oC) for 16 h. After which time, the solvent was removed in vacuo 
and the residue partitioned between ethyl acetate (25 mL) and water (25 mL). The organic layer 
was washed with dilute, aqueous HCl (0.1 M, 25 mL), water (25 mL), brine (25 mL), dried over 
MgSO4, filtered and the solvent removed in vacuo. The crude mixture was then purified by column 
chromatography (SiO2), eluting with CH2Cl2:EtOAc (9:1) to give the desired product as a white solid, 
0.09 g (20% yield). Rf; 0.38 (CH2Cl2:EtOAC (9:1)) m.p.149-153 oC; νmax/ cm-1 (ATR) 3435 (bs), 1726 (s), 
1687 (s); 1H NMR (CDCl3, 500 MHz) δ ppm 6.53 (dd, J = 10.1, 4.3 Hz, 1H), 6.33 (ddd, J = 8.0, 6.6, 1.3 
Hz, 1H), 6.14 (dd, J = 10.1, 1.6 Hz, 1H), 5.95 (ddt, J = 7.9, 6.0, 2.8 Hz, 1H), 4.25 (d, J = 11.9 Hz, 1H), 
4.20 (d, J = 11.2 Hz, 1H), 4.17 (s, 1H), 4.08 (d, J = 11.2 Hz, 1H), 3.92 (d, J = 12.0 Hz, 1H), 3.36 (ddt, J 
= 8.4, 4.2, 2.0 Hz, 1H), 3.50 (dt, J = 6.7, 1.9 Hz, 1H), 3.30 (ddd, J = 6.1, 2.3, 1.3 Hz, 1H), 3.21 (d, J = 
3.2 Hz, 1H), 2.77 (q, J = 8.2 Hz, 1H), 2.66 (tt, J = 8.5, 6.8 Hz, 1H), 1.90 (dddd, J = 14.5, 8.7, 7.5, 3.8 Hz, 
1H), 1.84-1.77 (m, 3H), 1.74-1.65 (m, 4H), 1.60-1.55 (m, 2H); 13C NMR (CDCl3, 500 MHz) δ ppm 208.2, 
198.2, 177.2, 176.2, 146.5, 135.1, 128.6, 128.2, 75.6, 74.6, 71.2, 67.7, 52.3, 43.8, 41.1, 40.1, 37.3, 













To a stirred solution of 2-(aminomethyl)phenol (91, 1.00 g, 8.12 mmol, 1 eq.) in dichloromethane 
(20 mL) were added benzoyl chloride (1.89 mL, 16.24 mmol, 2.1 eq.) and triethylamine (2.49 mL, 
17.86 mmol, 2.2 eq.). The resulting solution was stirred at room temperature (ca. 21 oC) for 24 h. 
The reaction mixture was then quenched with a saturated aqueous solution of ammonium chloride 
(20 mL), washed with brine (20 mL), dried over MgSO4, filtered and the solvent removed in vacuo 
to give a light brown oil. The crude mixture was purified by column chromatography (SiO2), eluting 
with petrol:ethyl acetate (6:1 → 1:1) to give the desired product as an off-white solid, 2.02 g (75% 
yield). Rf; 0.33 (Petrol:EtOAc (3:1), m.p. 137 – 139 oC (Lit. 142 – 143 oC121); 1H NMR (CDCl3, 500 MHz) 
δ ppm 8.19 (s, 1H), 7.90-7.86 (m, 1H), 7.76 (d, J = 7.2 Hz, 2H), 7.67 (d, J = 7.6 Hz, 2H), 7.60 (t, J = 7.1 
Hz, 1H), 7.54-7.48 (m, 5H), 7.44-7.38 (m, 2H), 7.25 (t, J = 7.4 Hz, 1H), 4.53 (s, 2H). Data in agreement 







Potassium hydroxide (0.56 g, 9.96 mmol, 2.2 eq.) was dissolved in ethanol (10 mL) and then added 
to 2-(benzamidomethyl)phenyl benzoate (92, 1.50 g, 4.53 mmol, 1 eq.). The resulting suspension 
was stirred for 30 minutes after which time aqueous ammonium chloride solution (5 mL) was added 
dropwise until a neutral pH was achieved. The resulting solution was then extracted with ethyl 
acetate (3 x 20 mL), the combined extracts washed with brine (20 mL), dried over MgSO4, filtered 
and the solvent removed in vacuo. Water (20 mL) was added to the brown oil which precipitated a 
light brown crystalline solid which was filtered off. The mother liquor was further extracted with 
chloroform (3 x 20 mL), the combined extractions washed with brine (20 mL) and then the solvent 
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removed in vacuo. Petrol (10 mL) was then added and the further light brown solid was filtered off. 
The combined solids gave the desired product, 0.11 g (97% yield). Rf; 0.28 (Petrol:EtOAc (1:1), m.p. 
132 – 135 oC (Lit. 143 -144 oC123);  1H NMR (CDCl3, 500 MHz) δ ppm 9.55 (s, 1H), 8.07-8.02 (m, 1H), 
7.77 (d, J = 7.1 Hz, 2H), 7.60-7.33 (m, 3H), 7.23-7.10 (m, 2H), 6.97 (dd, J = 8.1, 1.3 Hz, 1H), 6.83 (td, 









Phthalic anhydride (0.36 g, 2.40 mmol, 1 eq.) was suspended in glacial acetic acid (20 mL) and 2-
(aminomethyl) phenol (91, 0.25 g, 2.00 mL, 1.2 eq.) was added. The mixture was then refluxed (ca. 
120 oC) for 5 h. The hot solution was then poured onto ice, the resulting suspension was filtered 
and the colourless solid was washed with distilled water (30 mL). The solid was dried under vacuum 
and then recrystallized from ethanol to give a brown, crystalline solid, 0.33 g (65% yield). Rf; 0.22 
(Petrol:EtOAC (3:1), m.p. 165 - 166 oC (Lit. 177 oC125)  1H NMR (CDCl3, 500 MHz) δ ppm 7.88-7.84 (m, 
3H), 7.75-7.73 (m, 2H), 7.42 (dd, J = 7.6, 1.7 Hz, 1H), 7.23 (ddd, J = 8.1, 7.3, 1.7 Hz, 1H), 6.97 (dd, J = 













To a stirred solution of 2-(2-hydroxybenzyl)isoindoline-1,3-dione (95, 0.25g, 1.00 mmol, 1 eq.) in 
anhydrous THF (20 mL) was added SIBX (1.29 g, 2.00 mmol, 2 eq.) as a solid in one portion. The 
resulting solution was stirred at room temperature (ca. 21 oC) for 24 h, after which time TFA (0.15 
mL, 2.00 mmol, 2 eq.) was added and the solution stirred for a further 4 h. After which time, the 
solvent was removed in vacuo and then re-hydrated with CH2Cl2 (50 mL) and H2O (50 mL). An 
aqueous solution of NaHCO3 was added slowly, with shaking, until all the acid had been neutralised. 
The aqueous phase was extracted with dichloromethane (2 x 50 mL). The combined organic phases 
were then washed with NaHCO3 (50 mL), H2O (50 mL), brine (50 mL) and then vigorously shaken 
with an aqueous 1M solution of Na2S2O3 (50 mL), washed again with brine (50 mL) and dried over 
MgSO4, filtered and the solvent evaporated in vacuo to give a dark brown oil. The crude product 






A mixture of 2-hydroxybenzyl alcohol (32, 0.62 g, 5.00 mmol, 1 eq.), sodium azide (0.39 g, 6.00 
mmol, 1.2 eq.) and triphenylphosphine (1.31 g, 5.00 mmol, 1 eq.) in a mixture of carbon 
tetrachloride and dimethylformamide (1:4, 12 mL) was heated with stirring at 90 oC for 18 h. The 
resulting mixture was removed from the heat and partitioned between diethyl ether (10 mL) and 
water (10 mL). The ether layer was washed with additional portions of water (2 x 10 mL) and then 
separated. Upon cooling to 0 oC, the triphenylphosphine oxide crystallised and was filtered off. The 
filtrate was then dried over MgSO4, filtered and the solvent removed in vacuo. The crude mixture 
was then purified by column chromatography (SiO2), eluting with petrol:EtOAc (3:1) to give the 
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desired product as a light yellow oil, 0.42 g (56% yield). Rf; 0.81 (Petrol:EtOAc (1:1)),  1H NMR (CDCl3, 
500 MHz) δ ppm 7.27-7.24 (m, 2H), 6.97 (td, J = 7.5, 1.1 Hz, 1H), 6.86 (dd, J = 8.0, 1.0 Hz, 1H), 5.92 







To a stirred solution of 2-(azidomethyl) phenol (106, 0.22 g, 1.49 mmol, 1 eq.) in anhydrous 
tetrahydrofuran (THF) (10 mL) was added stabilised 2-iodoxybenzoic acid (SIBX) (1.85 g, 2.98 mmol 
of IBX, 2 eq.) as a solid in one portion. The resulting suspension was stirred at room temperature 
(ca. 21 oC) for 16 h, after which time trifluoroacetic acid (0.68 mL, 8.94 mmol, 1 eq.) was added and 
stirred for a further 4 h. The reaction mixture was then diluted with dichloromethane (100 mL) and 
H2O (50 mL). An aqueous solution of NaHCO3 was added slowly, with shaking, until all the acid had 
been neutralised. The aqueous phase was extracted with dichloromethane (2 x 20 mL). The 
combined organic phases were then washed with NaHCO3 (20 mL), H2O (20 mL), brine (20 mL) and 
then vigorously shaken with an aqueous 1M solution of Na2S2O3 (20 mL), washed again with brine 
(20 mL) and dried over MgSO4, filtered and the solvent evaporated in vacuo to give a dark brown 
oil. The crude mixture was then purified by column chromatography (SiO2), eluting with 
dichloromethane and 1% methanol to give the desired product as a light brown oil, 0.03 g (12% 
yield). Rf; 0.22 (petrol:EtOAc (1:1)); νmax/ cm-1 (ATR) 3447 (bs), 2100 (s), 1727 (s), 1690 (s); 1H NMR 
(CDCl3, 500 MHz) δ ppm 6.55 (dd, J = 10.1, 4.0 Hz, 1H), 6.34 (ddd, J = 7.9, 6.7, 1.1 Hz, 1H), 6.20 (dd, 
J = 10.1, 1.5 Hz, 1H), 5.95 (ddd, J = 8.2, 6.6, 1.6 Hz, 1H), 4.31 (s, 1H), 3.60 (dt, J = 6.7, 1.9 Hz, 1H), 
3.43 (d, J = 12.5 Hz, 1H), 3.37-3.34 (m, 3H), 3.29-2.26 (m, 2H), 3.20 (d, J = 12.9 Hz, 1H), 2.87 (s, 1H); 
13C NMR (CDCl3, 500 MHz) δ ppm 208.7, 198.4, 146.8, 135.3, 128.8, 128.1, 75.2, 61.4, 57.1, 52.2, 










dione (40, 0.28 g, 1.00 mmol, 1 eq.) was stirred in anhydrous dichloromethane (10 mL) and carbonyl 
diimidazole (0.37 g, 2.30 mmol, 2.3 eq.) was added. The subsequent reaction mixture was stirred 
for 18 h at room temperature (ca. 21 oC). After which time, water (10 mL) was added and the 
extracted with dichloromethane (2 x 10 mL), washed with brine (10 mL), dried over MgSO4, filtered 
and the solvent removed in vacuo. The crude product was purified by column chromatography 
(SiO2), eluting with dichloromethane and 10% methanol to give the desired product as a white 
crystalline solid, 0.13 g (45% yield). Rf; 0.35 (CH2Cl2 + 10% MeOH) m.p. 200-206 oC (CH2Cl2:MeOH); 
νmax/ cm-1 (ATR) 2927 (bs), 1805 (s), 1726 (s); 1H NMR (CD3CN, 500 MHz) δ ppm 6.24 (dddd, J = 8.1, 
6.3, 1.7, 0.8 Hz, 1H), 6.03 (td, J = 7.9, 6.7, 1.2 Hz, 1H), 4.20-4.16 (m, 2H), 4.10 (d, J = 8.8 Hz, 1H), 3.89 
(s, 1H), 3.78 (dd, J = 8.9, 1.1 Hz, 1H), 3.54-3.52 (m, 2H), 3.42 (dt, J = 6.3, 1.6 Hz, 1H), 2.99 (m, 2H), 
2.69 (ddd, J = 19.8, 3.2, 1.2 Hz, 1H), 2.48 (ddd, J = 19.7, 2.1, 1.0 Hz, 1H); 13C NMR (CD3CN, 500 MHz) 
δ ppm 210.7, 202.4, 154.9, 132.1, 131.8, 80.3, 75.0, 72.2, 71.4, 70.7, 48.8, 43.8, 42.3, 41.8, 40.1; 






1’, 4’, 4a’, 8a’-tetrahydro-7’ H-dispiro[oxirane-2,8’-[1, 4]ethanonaphthalene-10’,2”-oxirane]-7’,9’-
dione (39, 0.24 g, 1.00 mmol, 1 eq.) was dissolved in methanol (10 mL) and stirred at 0 oC. Sodium 
methoxide (4.41 mL, 2.20 mmol, 2.2 eq.) was then added dropwise and the reaction mixture 
allowed to stir for 16 h at room temperature (ca. 21 oC). After which time, the reaction mixture was 
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extracted with dichloromethane (3 x 10 mL), washed with a saturated, aqueous solution of NaHCO3 
(10 mL), water (10 mL), brine (10 mL), dried over MgSO4, filtered and the solvent removed in vacuo. 
The crude product was purified by column chromatography (SiO2), eluting with petrol:EtOAc (1:1 
→ 1:2) to give the desired product as a white solid, 0.08 g (41% yield). Rf; 0.47 (petrol:EtOAc (1:1)) 
m.p. 170-174 oC (petrol:EtOAc); νmax/cm-1 (ATR) 3345 (bs), 1731 (s); 1H NMR (CD3CN, 500 MHz) δ 
ppm 7.16 (d, J = 8.1 Hz, 1H), 6.82 (d, J = 2.4 Hz, 1H), 6.79 (ddd, J = 7.8, 6.2, 1.6 Hz, 1H), 6.72 (ddd, J 
= 7.7, 6.0, 1.8 Hz, 1H), 6.67 (dd, J = 8.2, 2.5 Hz, 1H), 4.40 (ddd, J = 6.0, 1.6, 0.5 Hz, 1H), 3.65 (dd, J = 
6.2, 1.8 Hz, 1H), 2.98 (d, J = 6.0 Hz, 1H, 2.98 (d, J = 6.0 Hz, 1H); 13C NMR (CD3CN, 500 MHz) δ ppm 
200.0, 158.5, 142.5, 136.3, 133.3, 127.6, 127.0, 114.6, 113.8, 57.5, 53.4, 48.0; ESI-MS [M+Na]+ m/z 






1’, 4’, 4a’, 8a’-tetrahydro-7’ H-dispiro[oxirane-2,8’-[1, 4]ethanonaphthalene-10’,2”-oxirane]-7’,9’-
dione (39, 0.24 g, 1.00 mmol, 1 eq.) was dissolved in anhydrous THF (12 mL) and DBU (0.30 mL, 2.00 
mmol, 2 eq.) was added dropwise. The resulting mixture was stirred at room temperature (ca. 21 
oC) for 24 h. After which time HCl (10 mL, 1M) was added and then extracted with EtOAc (2 x 20 
mL). The combined organic layers were washed with brine (10 mL), then dried over MgSO4, filtered 
and the solvent removed in vacuo. The crude product was purified by column chromatography 
(SiO2) eluting with petrol:EtOAc (1:1) to give the desired product as a white solid, 0.12 g (51% yield). 
Rf; 0.23 (Petrol:EtOAc (1:1)) m.p. 186-191 oC (petrol:EtOAc); νmax/ cm-1 (ATR) 3445 (bs), 3199 (bs), 
1729; 1H NMR (CD3CN, 500 MHz) δ ppm 7.83 (s, 1H), 7.16 (d, J = 8.0 Hz, 1H), 6.79-6.75 (m, 2H), 6.71 
(d, J = 8.1 Hz, 1H), 4.82 (dd, J = 12.6, 5.2 Hz, 1H), 4.75 (dd, J = 12.6, 5.7 Hz, 1H), 4.43 (dd, J = 5.7, 2.0 
Hz, 1H), 4.09 (dd, J = 6.0, 2.0 Hz, 1H), 3.39 (dd, J = 5.7, 5.2 Hz, 1H), 3.03 (d, J = 5.9 Hz, 1H), 2.97 (d, J 
= 5.9 Hz, 1H); 13C NMR (CD3CN, 500 MHz) δ ppm 199.3, 156.6, 140.5, 136.0, 133.4, 128.3, 126.4, 










1’, 4’, 4a’, 8a’-tetrahydro-7’ H-dispiro[oxirane-2,8’-[1, 4]ethanonaphthalene-10’,2”-oxirane]-7’,9’-
dione (39, 0.15 g, 0.60 mmol, 1 eq.) was dissolved in dichloromethane (12 mL) and BF3.OEt2 (0.09 
mL, 0.72 mmol, 1.2 eq.) was added dropwise. The resulting solution was stirred at reflux (40 oC) for 
18 h. After which time, a saturated, aqueous solution of NaHCO3 (20 mL) was added and the 
aqueous layer extracted with dichloromethane (3 x 10 mL). The combined organic phases were 
washed with brine (10 mL), dried over MgSO4, filtered and the solvent removed in vacuo. The crude 
product was purified by column chromatography (SiO2), eluting with petrol:EtOAc (3:1 → 1:1) to 
give the desired product as a white solid, 0.03 g (16% yield). Rf; 0.58 (Petrol:Diethyl ether (1:1)) m.p. 
171 – 173 oC (petrol:EtOAc); νmax/ cm-1 (ATR) 2944 (bs), 1727 (s), 1677 (s); 1H NMR (CDCl3, 500 MHz) 
δ ppm 7.08 (dd, J = 9.9, 6.3 Hz, 1H, H11), 6.19 (d, J = 1.2 Hz, 1H, H15), 6.02 (dd, J = 9.9, 0.9 Hz, 1H, 
H10), 5.61 (d, J = 1.2 Hz, 1H, H15), 4.57 (td, J = 5.6, 1.0 Hz, 1H, H16), 4.36 (d, J = 5.6 Hz, 1H, H4), 4.08 
(d, J = 9.8 Hz, 1H, H13), 4.03 (d, J = 9.9 Hz, 1H, H13), 3.42 (dq, J = 5.7, 1.4 Hz, 1H, H3), 2.83 (dd, J = 6.3, 
4.1 Hz, 1H, H6), 2.66 (dd, J = 5.5, 4.1 Hz, 1H, H5), 2.61 (dt, J = 5.8, 1.2 Hz, 1H, H7); 13C NMR (CDCl3, 
500 MHz) δ ppm 202.8, 191.7, 162.7, 144.5, 124.3, 121.5, 82.1, 78.7, 74.1, 72.7, 57.6, 52.1, 41.7, 







To a stirred solution of 1’, 4’, 4a’, 8a’-tetrahydro-7’ H-dispiro[oxirane-2,8’-[1, 4]ethanonaphthalene-
10’,2”-oxirane]-7’,9’-dione (39, 0.24 g, 1.00 mmol, 1 eq.) in dichloromethane (12 mL) was added 
bismuth triflate (0.66 g, 1.00 mmol, 1 eq.) and H2O (0.02 mL, 1.00 mmol, 1 eq.). The resulting 
solution was stirred at reflux (40 oC) for 22 h. After which time, the solvent was removed in vacuo 
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and the crude product was purified by column chromatography (SiO2), eluting with petrol:EtOAc 
(2:1 → 1:1) to give the desired product as a white solid, 0.12 g (34% yield). Rf; 0.17 (Petrol:EtOAc 
(1:1)) m.p.155-158 oC (dec., petrol:EtOAc); νmax/ cm-1 (ATR) 3453 (bs), 1728 (s), 1694 (s); 1H NMR 
(CD3CN, 500 MHz) δ ppm 6.94 (ddt, J = 10.1, 6.3, 0.6 Hz, 1H, H10), 5.98 (dt, J = 10.1, 0.6 Hz, 1H, H9), 
4.99 (d, J = 9.6 Hz, 1H, H13), 4.84 (d, J = 9.7 Hz, 1H, H13), 4.76 (ddd, J = 6.0, 4.7, 1.2 Hz, 1H, H20), 3.79 
(d, J = 12.1 Hz, 1H, H15), 3.68 (d, J = 12.2 Hz, 1H, H15), 3.07 (td, J = 5.4, 1.1 Hz, 1H, H4), 2.82 (t, J = 5.4 
Hz, 1H, H5), 2.71 (ddd, J = 7.5, 4.7, 0.6 Hz, 1H, H19), 2.43 (ddd, J = 7.4, 5.7, 1.2 Hz, 1H, H3), 2.39 (ddd, 
J = 6.2, 1.3, 0.7 Hz, 1H, H6); 13C NMR (CD3CN, 500 MHz) δ ppm 205.0, 193.5, 150.5, 125.7, 119.6 (q, 
J = 318.8 Hz, 1C), 73.8, 73.1, 69.9, 57.9, 43.8, 41.9, 41.0, 30.53, 30.47, 28.0; 19F NMR (CD3CN, 500 





Compound 105 (0.12 g, 0.30 mmol, 1 eq.) was dissolved in dichloromethane (12 mL), to which was 
added: 3,5-dinitrobenzoic acid (0.07 g, 0.33 mmol, 1.1 eq.); EDCI.HCl (0.06 g, 0.30 mmol, 1 eq.); 
DMAP (4.00 mg, 0.03 mmol, 0.1 eq.) and triethylamine (0.04 mL, 0.30 mmol, 1 eq.). The mixture 
was then stirred at room temperature (ca. 21 oC) for 18 h. After which time, water (15 mL) was 
added and the mixture extracted with dichloromethane (3 x 15 mL). The combined organic layers 
were washed with brine (15 mL) and dried over MgSO4, filtered and the solvent removed in vacuo. 
The crude product was purified via column chromatography (SiO2), eluting with petrol:ethyl acetate 
(2:1 → 1:1). The product remained impure after purification, therefore only a proton spectrum was 
reported, however an x-ray crystal structure of the product was obtained. Rf; 0.54 (Petrol:EtOAc 
(1:1); 1H NMR (CDCl3, 500 MHz) δ ppm 9.24 (t, J = 1.80 Hz, 1H), 9.15-9.12 (m, 2H), 6.85 (dd, J = 10.1, 
6.3 Hz, 1H), 6.10 (d, J = 10.1 Hz, 1H), 5.02 (d, J = 9.6 Hz, 1H), 4.87 (ddd, J = 6.1, 4.7, 1.2 Hz, 1H), 4.76 
(d, J = 6.4 Hz, 1H), 4.71 (d, J = 7.4 Hz, 1H), 4.67 (d, J = 10.4 Hz, 1H), 3.17 (t, J = 5.4 Hz, 1H), 2.92-2.90 








2-Hydroxy-5-methyl benzaldehyde (142, 1.09 g, 8.00 mmol, 1 eq.) was dissolved in ethanol (40 mL) 
at 0 oC. Sodium borohydride (0.30 g, 8.00 mmol, 1 eq.) was added in portions (ca. 0.1 g) to the 
stirred solution. The reaction mixture was allowed to warm to room temperature (ca. 21 oC) whilst 
stirring for 18 h. After removal of the ethanol under reduced pressure, the resulting solid was 
dissolved in a saturated, aqueous solution of NH4Cl (20 mL). The crude product was extracted with 
diethyl ether (3 x 10 mL). The combined organic phases were then washed with brine (20 mL), dried 
over MgSO4, filtered and the solvent removed in vacuo. The resulting cream coloured solid was 
found to have a very high purity and therefore no further purification was necessary, 1.01 g (91% 
yield) Rf; 0.49 (Petrol:EtOAc (1:1); m.p. 110 – 112 oC (Lit. 104 – 105 oC126); 1H NMR (CDCl3, 500 MHz) 
δ ppm 7.07 (s, 1H), 7.00 (dd, J = 8.2, 2.1 Hz, 1H), 6.84 (s, 1H), 6.78 (d, J = 8.2 Hz, 1H), 4.80 (s, 2H), 






2-(hydroxymethyl)-4-methylphenol (143, 0.26 g, 1.82 mmol, 1 eq.) was dissolved in water (30 mL). 
A solution of sodium periodate (0.43 g, 2.01 mmol, 1.1 eq.) in water (30 mL) was added. The mixture 
was stirred at room temperature (ca. 21 OC) for 10 minutes and then placed in the refrigerator (ca. 
4 OC) for 24 h. The solid was filtered off and dissolved in chloroform. To which, MgSO4 was added, 
filtered and the solvent removed in vacuo to give the desired product as an off-white solid, 0.18 g 
(73% yield). The crude product was deemed of sufficient purity to not require any further 
purification. Rf 0.35 (3:1 petrol: ethyl acetate); 1H NMR (CDCl3, 500 MHz) δ ppm 6.40 (dt, J = 10.2, 
0.6 Hz, 1H), 6.13 (dd, J = 10.3, 0.8 Hz, 1H), 5.75 (dq, J = 6.4, 1.8 Hz, 1H), 3.21 (dd, J = 6.1, 1.0 Hz, 1H), 
3.08 (d, J = 6.4 Hz, 1H), 2.96 (d, J = 6.1 Hz, 1H), 2.91 (dd, J = 6.6, 0.9 Hz, 1H), 2.85 (d, J = 6.5 Hz, 1H), 
2.65 (t, J = 2.3 Hz, 1H), 2.32 (d, J = 2.4 Hz, 1H), 1.90 (dd, J = 1.8, 0.8 Hz, 3H), 1.44 (d, J = 0.7 Hz, 3H). 









oxirane]-7',9'-dione (151, 0.18 g, 0.67 mmol, 1 eq.) was dissolved in dichloromethane (10 mL) and 
BF3.OEt2 (0.10 mL, 0.80 mmol, 1.2 eq.) was added dropwise. The resulting solution was stirred at 
reflux (40 oC) for 22 h. After which time, a saturated, aqueous solution of NaHCO3 (20 mL) was 
added and the aqueous layer extracted with dichloromethane (3 x 10 mL). The combined organic 
phases were washed with brine (10 mL), dried over MgSO4, filtered and the solvent removed in 
vacuo. The crude product was purified by column chromatography (SiO2), eluting with petrol:EtOAc 
(3:1 → 1:1) to give the desired product as a white solid, 0.03 g (17% yield). Rf; 0.43 (Petrol:EtOAc 
(1:1)) m.p. 164-167 oC (petrol:EtOAc); νmax/ cm-1 (ATR) 2965 (bs), 1723 (s), 1687 (s); 1H NMR (CDCl3, 
500 MHz) δ ppm 6.64 (d, J = 9.9 Hz, 1H), 6.23 (s, 1H), 5.94 (d, J = 9.9 Hz, 1H), 5.43 (s, 1H), 4.19 (dd, 
J = 5.3, 1.1 Hz, 1H), 4.11-4.08 (m, 2H), 4.01 (d, J = 10.1 Hz, 1H), 2.57 (d, J = 5.6 Hz, 1H), 2.38 (d, J = 
5.3 Hz, 1H), 1.50-1.09 (m, 5H), 1.36 (s, 3H), 1.15 (s, 3H); 13C NMR (CDCl3, 500 MHz) δ ppm 201.4, 
192.7, 157. 0, 150.8, 124.3, 119.8, 83.9, 78.7, 76.0, 73.0, 51.2, 49.9, 48.7, 34.4, 24.3, 17.8; ESI-MS 








oxirane]-7',9'-dione (151, 0.05 g, 0.18 mmol, 1 eq.) was dissolved in dichloromethane (10 mL) and 
bismuth triflate (0.13 g, 0.20 mmol, 1.1 eq.) was added. H2O (3.00 µL, 0.18 mmol, 1 eq.) was then 
added and the reaction was allowed to stir at reflux (40 oC) for 18 h. After which time the solvent 
was removed under reduced pressure and the crude product was purified by column 
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chromatography (SiO2), eluting with petrol:EtOAc (2:1 → 1:1) to give the desired product as a white 
solid, 0.01 g (18% yield). Rf; 0.34 (Petrol:EtOAc (1:1)) m.p. 151-154 oC (dec., petrol:EtOAc); νmax/cm-
1 (ATR) 3406 (bs), 1718 (s), 1694 (s); 1H NMR (CDCl3, 500 MHz) δ ppm 6.46 (d, J = 10.0 Hz, 1H), 6.00 
(d, J = 10.1 Hz, 1H), 5.00 (d, J = 9.3 Hz, 1H), 4.54 (d, J = 9.3 Hz, 1H), 4.45 (dd, J = 6.0, 1.5 Hz, 1H), 3.94 
(d, J = 12.7 Hz, 1H), 3.86 (d, J = 11.5 Hz, 1H), 2.66 (dd, J = 5.8, 1.4 Hz, 1H), 2.36 (s, 1H), 2.27 (dd, J = 
6.0, 1.4 Hz, 1H), 2.12 (d, J = 5.8 Hz, 1H), 1.56 (s, 3H), 1.14 (s, 3H); 13C NMR (CDCl3, 500 MHz) δ ppm 
203.5, 191.6, 153.7, 123.4, 122.5 (q, J = 320.0, 1C), 74.7, 73.9, 70.2, 58.4, 47.5, 44.3, 40.4, 37.3, 35.3, 
32.2, 22.7, 13.8; 19F NMR (CDCl3, 500 MHz) δ ppm -73.9 (s, 3F); ESI-MS [M+Na]+ m/z C17H17F3NaO7S 






2-Hydroxy-4-methylbenzoic acid (144, 0.61 g, 4.00 mmol, 1 eq.) was dissolved in a mixture of 
concentrated H2SO4 (1.06 mL) and methanol (100 mL) and allowed to stir at reflux (ca. 65 oC) for 20 
h. The reaction was then cooled and quenched with H2O (50 mL) and extracted with diethyl ether 
(3 x 20 mL). The combined organic phases were washed with a saturated, aqueous solution of 
NaHCO3 (20 mL), brine (20 mL), dried over MgSO4, filtered and the solvent removed in vacuo to give 
the desired product as an amorphous white solid, 0.27 g (41% yield). The crude product was 
deemed of very high purity and therefore no further purification was necessary. Rf 0.70 (1:1 petrol: 
ethyl acetate); m.p. 26 – 27 oC (Lit. 27.5 – 28 oC128); 1H NMR (CDCl3, 500 MHz) δ ppm 10.71 (s, 1H), 
7.69 (d, J = 8.1 Hz, 1H), 6.78 (s, 1H), 6.66 (dd, J = 8.0, 1.9 Hz, 1H), 3.90 (s, 3H), 2.32 (s, 3H). Data in 











To a solution of methyl 2-hydroxy-4-methylbenzoate (145, 0.27 g, 1.63 mmol, 1 eq.) in anhydrous 
THF (10 mL) was added dropwise lithium aluminium hydride solution (2.4 M, 0.81 mL, 1.2 eq.) at 0 
oC. The reaction was allowed to warm to room temperature (ca. 21 oC) whilst stirring overnight. 
After which time, the reaction was quenched by the careful addition of a small amount of water. 
The reaction was then acidified with HCl (1 M, 4 mL) until pH 1 was achieved and extracted with 
diethyl ether (3 x 10 mL). The combined organic layers were washed with brine (10 mL), dried over 
MgSO4, filtered and the solvent removed in vacuo to give the desired product as a white solid, 0.18 
g (80% yield). The crude product was deemed of very high purity and therefore no further 
purification was necessary. Rf 0.42 (1:1 petrol: ethyl acetate); m.p. 96 - 100 oC (Lit. 106 – 108 oC130) 
1H NMR (CDCl3, 500 MHz) δ ppm 7.10 (s, 1H), 6.92 (d, J = 7.6 Hz, 1H), 6.72 (s, 1H), 6.67 (d, J = 8.4 Hz, 






2-(hydroxymethyl)-5-methylphenol (146, 0.22 g, 1.62 mmol, 1 eq.) was dissolved in water (30 mL). 
A solution of sodium periodate (0.42 g, 1.95 mmol, 1.2 eq.) in water (10 mL) was added. The mixture 
was stirred at room temperature (ca. 21 oC) for 10 minutes and then placed in the refrigerator (ca. 
4 OC) for 24 h. The solid was filtered off and dissolved in chloroform. To which, MgSO4 was added, 
filtered and the solvent removed in vacuo to give the desired product as a white solid, 0.08 g (35% 
yield). The crude product was deemed of sufficient purity to not require any further purification. Rf 
0.36 (1:1 petrol: ethyl acetate); 1H NMR (CDCl3, 500 MHz) δ ppm 6.20 (dq, J = 6.6, 1.7 Hz, 1H), 6.13 
(s, 1H), 3.45 (t, J = 2.1 Hz, 1H), 3.37 (ddt, J = 9.0, 2.3, 0.8 Hz, 1H), 3.17 (d, J = 6.1 Hz, 1H), 2.91 (dd, J 
= 9.0, 6.3 Hz, 2H), 2.86-2.83 (m, 2H), 2.68 (dd, J = 9.0, 2.3 Hz, 1H), 2.09 (dd, J = 1.4, 0.6 Hz, 3H), 1.75 








oxirane]-7',9'-dione (152, 0.15 g, 0.60 mmol, 1 eq.) was dissolved in dichloromethane (12 mL) and 
BF3.OEt2 (0.09 mL, 0.72 mmol, 1.2 eq.) was added dropwise. The resulting solution was stirred at 
reflux (40 oC) for 18 h. After which time, a saturated, aqueous solution of NaHCO3 (20 mL) was 
added and the aqueous layer extracted with dichloromethane (3 x 10 mL). The combined organic 
phases were washed with brine (10 mL), dried over MgSO4, filtered and the solvent removed in 
vacuo. The crude product was purified by column chromatography (SiO2), eluting with petrol:EtOAc 
(3:1 → 1:1) to give the desired product as a white solid, 0.03 g (16% yield). Rf; 0.58 (petrol:diethyl 
ether (1:1)) m.p. 171 – 173 oC (petrol:diethyl ether); νmax/ cm-1 (ATR) 2944 (bs), 1727 (s), 1677 (s); 
1H NMR (CDCl3, 500 MHz) δ ppm 6.20 (d, J = 1.3 Hz, 1H), 5.86 (d, J = 1.4 Hz, 1H), 5.60 (d, J = 1.2 Hz, 
1H), 4.29 (d, J = 5.5 Hz, 1H), 4.09 (d, J = 10.0 Hz, 1H), 3.98 (d, J = 9.5 Hz, 1H), 3.04 (q, J = 1.5 Hz, 1H), 
2.59 (dd, J = 5.5, 4.0 Hz, 1H), 2.55 (d, J = 4.0 Hz, 1H), 2.10 (d, J = 1.4 Hz, 3H), 1.26 (s, 3H); 13C NMR 
(CDCl3, 500 MHz) δ ppm 202.8, 191.7, 162.7, 144.5, 124.3, 121.5, 82.1, 78.7, 74.1, 72.7, 57.6, 52.1, 







oxirane]-7',9'-dione (152, 0.08 g, 0.29 mmol, 1 eq.) was dissolved in dichloromethane (10 mL) and 
bismuth triflate (0.19 g, 0.29 mmol, 1 eq.) was added. H2O (5.00 µL, 0.29 mmol, 1 eq.) was then 
added and the reaction was allowed to stir at reflux (40 oC) for 22 h. After which time the solvent 
was removed under reduced pressure and the crude product was purified by column 
chromatography (SiO2), eluting with petrol:EtOAc (2:1 → 1:1) to give the desired product as a white 
solid, 0.04 g (33% yield). Rf; 0.14 (Petrol:EtOAc (1:1)) m.p. 152-155 oC (dec., petrol:EtOAc); νmax/ cm-
1 (ATR) 3432 (bs), 1732 (s), 1686 (s); 1H NMR (CDCl3, 500 MHz) δ ppm 5.92 (d, J = 1.6 Hz, 1H), 5.01 
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(d, J = 9.4 Hz, 1H), 4.62 (d, J = 9.4 Hz, 1H), 3.90 (d, J = 12.4 Hz, 1H), 3.83 (d, J = 12.4 Hz, 1H), 2.99 (td, 
J = 5.3, 1.0 Hz, 1H), 2.57 (d, J = 4.9 Hz, 1H), 2.43-2.39 (m, 2H), 2.03-1.98 (m, 2H), 1.96 (d, J = 1.4 Hz, 
3H), 1.38 (s, 3H); 13C NMR (CDCl3, 500 MHz) δ ppm 204.2, 193.1, 162.3, 123.5, 119.6 (q, J = 318.6 
Hz, 1C), 75.7, 74.7, 73.2, 57.9, 50.2, 46.1, 42.2, 35.1, 30.8, 28.8, 24.4, 22.0; 19F NMR (CDCl3, 500 






2-Hydroxy-3-methylbenzoic acid (147, 5.00 g, 32.10 mmol, 1 eq.) was dissolved in a mixture of 
concentrated H2SO4 (3.51 mL) and methanol (20 mL) and allowed to stir at reflux (ca. 65 oC) for 24 
h. The reaction was then cooled and quenched with H2O (120 mL) and extracted with 
dichloromethane (3 x 40 mL). The combined organic phases were washed with a saturated, aqueous 
solution of NaHCO3 (40 mL), brine (20 mL), dried over MgSO4, filtered and the solvent removed in 
vacuo to give the desired product as a colourless oil, 5.02 g (92% yield). The crude product was 
deemed of very high purity and therefore no further purification was necessary. Rf 0.65 (CHCl3); 1H 
NMR (CDCl3, 500 MHz) δ ppm 7.70 (d, J = 7.3 Hz, 1H), 7.32 (dd, J = 7.5, 6.8 Hz, 1H), 6.77 (d, J = 7.8 













To a solution of methyl 2-hydroxy-3-methylbenzoate (148, 5.16 g, 30.11 mmol, 1 eq.) in anhydrous 
THF (50 mL) was added dropwise lithium borohydride solution (4.0 M, 15.0 mL, 1.2 eq.) at 0 oC. The 
reaction was allowed to warm to room temperature (ca. 21 oC) whilst stirring overnight. After which 
time, the reaction was quenched by the careful addition of ethyl acetate (80 mL) and then water 
(80 mL). The reaction mixture was extracted with ethyl acetate (3 x 25 mL) and the combined 
organic phases were washed with brine (20 mL), dried over MgSO4, filtered and the solvent 
removed in vacuo. The crude product was purified by column chromatography (SiO2), eluting with 
chloroform plus 2% methanol to give the desired product as a crystalline white solid, 4.16 g (63% 
yield). Rf 0.14 (1:1 petrol: ethyl acetate); m.p. 45 – 46 oC (Lit. 36 – 38 oC126); 1H NMR (CDCl3, 500 
MHz) δ ppm 7.43 (s, 1H), 7.10 (d, J = 7.5 Hz, 1H), 6.86 (d, J = 7.5 Hz, 1H), 6.76 (t, J = 7.5 Hz, 1H), 4.82 






2-(Hydroxymethyl)-6-methylphenol (149, 2.02 g, 14.50 mmol, 1 eq.) was dissolved in water (30 mL). 
A solution of sodium periodate (3.41 g, 14.95 mmol, 1 eq.) in water (20 mL) was added. The mixture 
was stirred at room temperature (ca. 21 oC) for 10 minutes and then placed in the refrigerator (ca. 
4 OC) for 24 h. The solid was filtered off and dissolved in chloroform. To which, MgSO4 was added, 
filtered and the solvent removed in vacuo. The crude product was then purified via recrystallization 
from chloroform to give the desired product as a yellow, crystalline solid, 0.83 g (42% yield). Rf 0.40 
(1:1 petrol: ethyl acetate); 1H NMR (CDCl3, 500 MHz) δ ppm 6.58 (dd, J = 8.2, 6.6 Hz, 1H), 6.53 (dd, 
J = 4.7, 1.6 Hz, 1H), 5.77 (dd, J = 8.2, 1.6 Hz, 1H), 3.15 (d, J = 6.2 Hz, 1H), 3.13-3.09 (m, 1H), 2.92 (d, 
J = 6.1 Hz, 1H), 2.88 (d, J = 6.5 Hz, 2H), 2.82 (d, J = 6.5 Hz, 1H), 2.80 (dd, J = 9.1, 2.3 Hz, 1H), 1.86 (t, 









oxirane]-7',9'-dione (153, 0.70 g, 2.57 mmol, 1 eq.) was dissolved in dichloromethane (40 mL) and 
BF3.OEt2 (0.38 mL, 3.09 mmol) was added dropwise. The resulting solution was stirred at reflux 
(40 oC) for 24 h. After which time, a saturated, aqueous solution of NaHCO3 (30 mL) was added 
and the aqueous layer extracted with dichloromethane (3 x 15 mL). The combined organic phases 
were washed with brine (10 mL), dried over MgSO4, filtered and the solvent removed in vacuo. 
The crude product was purified by column chromatography (SiO2), eluting with petrol:EtOAc (3:1 
→ 1:1) to give the desired product as a yellow solid, 0.35 g (50% yield). Rf; 0.46 (Petrol:EtOAc 
(1:1)) m.p 167-170 oC. (petrol:EtOAc); νmax/cm-1 (ATR) 2951 (bs), 2011 (s), 1920 (s), 1878 (s), 1721 
(s), 1675; 1H NMR (CDCl3, 500 MHz) δ ppm 6.73 (dt, J = 6.4, 1.6 Hz, 1H), 6.20 (d, J = 1.2 Hz, 1H), 
5.59 (s, 1H), 4.31-4.28 (m, 1H), 4.10 (d, J = 9.8 Hz, 1H), 4.06 (dd, J = 5.7, 1.0 Hz, 1H), 4.01 (d, J = 9.8 
Hz, 1H), 3.38 (dd, J = 5.8 Hz, 1.3 Hz, 1H), 2.67 (q, J = 4.1 Hz, 1H), 2.65 (q, J = 5.7 Hz, 1H), 1.89 (s, 
3H), 1.21 (s, 3H); 13C NMR (CDCl3, 500 MHz) δ ppm 206.1, 191.9, 144.7, 143.6, 134.8, 121.2, 82.1, 
78.7, 76.3, 72.7, 51.4, 47.1, 43.1, 34.6, 15.9, 15.4; ; ESI-MS [M+Na]+ m/z C16H16O4 requires 







oxirane]-7',9'-dione (153, 0.188 g, 0.600 mmol, 1 eq.) was dissolved in dichloromethane (15 mL) 
and bismuth triflate (0.39 g, 0.60 mmol, 1 eq.) was added. H2O (0.01 mL, 0.29 mmol, 1 eq.) was then 
added and the reaction was allowed to stir at reflux (40 oC) for 18 h. After which time the solvent 
was removed under reduced pressure and the crude product was purified by column 
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chromatography (SiO2), eluting with petrol:EtOAc (2:1 → 1:1) to give the desired product as a white 
solid, 0.04 g (33% yield). Rf; 0.31 (petrol:diethyl ether (1:1)) m.p. 155-158 oC (dec., petrol:diethyl 
ether); νmax/ cm-1 (ATR) 2933 (bs), 1731 (s), 1687 (s); 1H NMR (CDCl3, 500 MHz) δ ppm 6.49 (dd, J = 
6.7, 1.6 Hz, 1H), 5.05 (d, J = 9.4 Hz, 1H), 4.69 (d, J = 9.4 Hz, 1H), 4.29 (dd, J = 4.7, 1.2 Hz, 1H), 3.93 (d, 
J = 12.4 Hz, 1H), 3.83 (d, J = 12.5 Hz, 1H), 3.06 (t, J = 5.3 Hz, 1H), 2.63-2.59 (m, 2H), 2.39 (ddd, J = 
7.3, 5.7, 1.2 Hz, 1H), 1.86 (s, 3H), 1.11 (s, 3H); 13C NMR (CDCl3, 500 MHz) δ ppm 206.9, 191.1, 141.3, 
134.2, 118.7 (q, J = 319.6 Hz, 1C), 76.2, 72.7, 71.1, 59.2, 45.3, 43.1, 40.7, 30.8, 29.0, 27.5, 15.8, 12.4; 
19F NMR (CDCl3, 500 MHz) δ ppm -74.0 (s, 3F); ; ESI-MS [M+H]+ m/z C17H18F3O7S requires 423.0720, 






2-Hydroxy-6-methylbenzoic acid (139, 0.50 g, 3.29 mmol, 1 eq.) was dissolved in a mixture of 
concentrated H2SO4 (1.06 mL) and methanol (80 mL) and allowed to stir at reflux (ca. 65 oC) for 24 
h. The reaction was then cooled and quenched with H2O (50 mL) and extracted with diethyl ether 
(3 x 10 mL). The combined organic phases were washed with a saturated, aqueous solution of 
NaHCO3 (10 mL), brine (10 mL), dried over MgSO4, filtered and the solvent removed in vacuo to give 
the desired product as a colourless liquid, 0.25 g (47% yield). The crude product was deemed of 
very high purity and therefore no further purification was necessary. Rf 0.45 (5% ethyl acetate in 
petrol); 1H NMR (CDCl3, 500 MHz) δ ppm 11.28 (s, 1H), 7.26 (dd, J = 8.3, 7.5 Hz, 1H), 6.83 (ddd, J = 
8.4, 1.4, 0.6 Hz, 1H), 6.70 (dt, J = 7.5, 1.0 Hz, 3H), 3.95 (s, 3H), 2.53 (d, J = 0.8 Hz, 1H). Data in 











To a solution of methyl 2-hydroxy-6-methylbenzoate (140, 0.25 g, 1.51 mmol, 1 eq.) in anhydrous 
THF (10 mL) was added dropwise lithium aluminium hydride solution (2.4 M, 0.81 mL, 1.2 eq.) at 0 
oC. The reaction was allowed to warm to room temperature (ca. 21 oC) whilst stirring overnight. 
After which time, the reaction was quenched by the careful addition of a small amount of water. 
The reaction was then acidified with HCl (1 M, 4 mL) until pH 1 was achieved and extracted with 
diethyl ether (3 x 10 mL). The combined organic layers were washed with brine (10 mL), dried over 
MgSO4, filtered and the solvent removed in vacuo to give the desired product as a crystalline white 
solid, 0.17 g (84% yield). The crude product was deemed of very high purity and therefore no further 
purification was necessary. Rf 0.40 (1:1 petrol: ethyl acetate); m.p. 100 – 101 oC (Lit. 105.6 – 106.6 
oC134); 1H NMR (CDCl3, 500 MHz) δ ppm 7.79 (s, 1H), 7.07 (t, J = 7.8 Hz, 1H), 6.73-6.69 (m, 2H), 4.91 







To a solution of benzaldehyde dimethyl acetal (0.75 mL, 5.00 mmol, 1.2 eq.) and 2-
(hydroxymethyl)phenol (32, 0.48 g, 3.85 mmol, 1 eq.) in acetonitrile (12 mL) was added 
camphorsulfonic acid (0.01 g, 0.05 mmol, 0.05 eq.). The reaction was stirred at room temperature 
(ca. 21 oC) for 3 hours and was then diluted with dichloromethane (50 mL) and washed with a 
saturated, aqueous solution of NaHCO3 (2 x 10 mL). The combined aqueous phases were washed 
with dichloromethane (2 x 10 mL) and the combined organic phases were dried over MgSO4, filtered 
and the solvent removed in vacuo. The crude product was purified via column chromatography 
(SiO2), eluting with heptane:toluene (1:3) to give the desired product as a white solid, 0.515 g (65% 
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yield). Rf 0.50 (heptane:toluene (1:3)); m.p. 40 – 43 oC (Lit. 54 oC135); 1H NMR (CDCl3, 500 MHz) δ 
ppm 7.64-7.61 (m, 2H), 7.46-7.40 (m, 3H), 7.21 (dddd, J = 7.7, 5.6, 2.1, 1.1 Hz, 1H), 7.03-6.98 (m, 3 







To a solution of 2-phenyl-4H-benzo[d][1,3]dioxine (124, 0.51 g, 2.43 mmol, 1 eq.) and borane 
trimethyl amine complex (1.03 g, 14.09 mmol, 5.8 eq.) in anhydrous THF (30 mL) was added AlCl3 
(2.14 g, 16.04 mmol, 6.6 eq.) dissolved in anhydrous THF (10 mL) dropwise at 0 oC. The reaction was 
allowed to stir at that temperature for 18 hours. After which time, a saturated, aqueous solution of 
NaHCO3 (10 mL) was added dropwise and the aqueous phase extracted with diethyl ether (3 x 10 
mL). The combined organic phases were washed with brine (10 mL), were dried over MgSO4, filtered 
and the solvent removed in vacuo. The crude product was purified via column chromatography 
(SiO2), eluting with petrol:EtOAc (8:1) to give the desired product as a colourless oil, 0.16 g (31% 
yield). Rf 0.73 (petrol:EtOAc (1:1)); 1H NMR (CDCl3, 500 MHz) δ ppm 7.42-7.39 (m, 1H), 7.31-7.21 
(m, 4H), 7.15-7.10 (m, 1H), 6.92 (dt, J = 7.5, 1.9 Hz, 1H), 6.82 (d, J = 8.2 Hz, 1H), 6.76 (t, J = 6.8 Hz, 






4-Fluoro-2-hydroxybenzoic acid (129, 0.62 g, 4.00 mmol, 1 eq.) was dissolved in a mixture of 
concentrated H2SO4 (1.20 mL) and methanol (80 mL) and allowed to stir at reflux (ca. 65 oC) for 18 
h. The reaction was then cooled and quenched with H2O (50 mL) and extracted with diethyl ether 
(3 x 10 mL). The combined organic phases were washed with a saturated, aqueous solution of 
NaHCO3 (10 mL), brine (10 mL), dried over MgSO4, filtered and the solvent removed in vacuo to give 
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the desired product as a pale yellow solid, 0.37 g (55% yield). The crude product was deemed of 
very high purity and therefore no further purification was necessary. Rf 0.79 (1:4 ethyl 
acetate:petrol); m.p. 48 – 50 oC (Lit. 39 – 40 oC137); 1H NMR (CDCl3, 500 MHz) δ ppm 10.99 (d, J = 1.6 
Hz, 1H), 7.84 (dd, J = 8.9, 6.6 Hz, 1H), 6.67 (dd, J = 10.3, 2.5 Hz, 1H), 6.60 (ddd, J = 8.8, 8.1, 2.5 Hz, 





To a solution of methyl 4-fluoro-2-hydroxybenzoate (130, 0.37 g, 2.20 mmol, 1 eq.) in anhydrous 
THF (10 mL) was added dropwise lithium aluminium hydride solution (2.4 M, 1.08 mL, 1.2 eq.) at 0 
oC. The reaction was allowed to warm to room temperature (ca. 21 oC) whilst stirring overnight. 
After which time, the reaction was quenched by the careful addition of a small amount of water. 
The reaction was then acidified with HCl (1 M, 4 mL) until pH 1 was achieved and extracted with 
diethyl ether (3 x 10 mL). The combined organic layers were washed with brine (10 mL), dried over 
MgSO4, filtered and the solvent removed in vacuo to give the desired product as a white solid, 0.29 
g (93% yield). The crude product was deemed of very high purity and therefore no further 
purification was necessary. Rf 0.55 (1:1 petrol: ethyl acetate); m.p. 118 – 121 oC); 1H NMR (MeOD, 
300 MHz) δ ppm 7.23 (dd, 3JHH = 7.5 Hz, 4JHF = 7.5 Hz, 1H), 6.55-6.45 (m, 2H), 4.59 (s, 2H). Data in 
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